EP2583098B1 - Biomarkers for the treatment of psoriasis - Google Patents
Biomarkers for the treatment of psoriasis Download PDFInfo
- Publication number
- EP2583098B1 EP2583098B1 EP11726315.2A EP11726315A EP2583098B1 EP 2583098 B1 EP2583098 B1 EP 2583098B1 EP 11726315 A EP11726315 A EP 11726315A EP 2583098 B1 EP2583098 B1 EP 2583098B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- level
- mrna
- alkyl
- carbon atoms
- monitored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims description 171
- 201000004681 Psoriasis Diseases 0.000 title claims description 78
- 239000000090 biomarker Substances 0.000 title description 93
- 108020004999 messenger RNA Proteins 0.000 claims description 186
- 150000001875 compounds Chemical class 0.000 claims description 161
- 210000003491 skin Anatomy 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 78
- 230000007423 decrease Effects 0.000 claims description 72
- 230000014509 gene expression Effects 0.000 claims description 54
- 102100028681 C-type lectin domain family 4 member K Human genes 0.000 claims description 38
- 101710183165 C-type lectin domain family 4 member K Proteins 0.000 claims description 38
- 210000002615 epidermis Anatomy 0.000 claims description 38
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 34
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 34
- 230000004044 response Effects 0.000 claims description 32
- 210000004207 dermis Anatomy 0.000 claims description 31
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 claims description 30
- 108050003558 Interleukin-17 Proteins 0.000 claims description 29
- 102000013691 Interleukin-17 Human genes 0.000 claims description 29
- 108010065805 Interleukin-12 Proteins 0.000 claims description 28
- 102000013462 Interleukin-12 Human genes 0.000 claims description 28
- 230000003247 decreasing effect Effects 0.000 claims description 28
- 102000004890 Interleukin-8 Human genes 0.000 claims description 27
- 108090001007 Interleukin-8 Proteins 0.000 claims description 27
- 102100026886 Beta-defensin 104 Human genes 0.000 claims description 26
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims description 26
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 108010074328 Interferon-gamma Proteins 0.000 claims description 24
- 108010066364 Keratin-16 Proteins 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 24
- 102000003814 Interleukin-10 Human genes 0.000 claims description 23
- 108090000174 Interleukin-10 Proteins 0.000 claims description 23
- 102100030703 Interleukin-22 Human genes 0.000 claims description 23
- 108010074109 interleukin-22 Proteins 0.000 claims description 23
- 102100037850 Interferon gamma Human genes 0.000 claims description 22
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims description 21
- 239000002771 cell marker Substances 0.000 claims description 21
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 19
- 238000012544 monitoring process Methods 0.000 claims description 19
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims description 18
- 102000011718 Interleukin-23 Subunit p19 Human genes 0.000 claims description 18
- QDZOBXFRIVOQBR-LJQANCHMSA-N n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-LJQANCHMSA-N 0.000 claims description 15
- 102000013264 Interleukin-23 Human genes 0.000 claims description 12
- 108010065637 Interleukin-23 Proteins 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 280
- -1 e.g. Chemical group 0.000 description 197
- 125000000217 alkyl group Chemical group 0.000 description 180
- 239000000523 sample Substances 0.000 description 134
- 125000004093 cyano group Chemical group *C#N 0.000 description 89
- 125000003545 alkoxy group Chemical group 0.000 description 86
- 210000004027 cell Anatomy 0.000 description 76
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 75
- 229910052739 hydrogen Inorganic materials 0.000 description 74
- 239000001257 hydrogen Chemical group 0.000 description 73
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 73
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 72
- 125000005843 halogen group Chemical group 0.000 description 70
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 68
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 61
- 125000001424 substituent group Chemical group 0.000 description 52
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 38
- 230000009467 reduction Effects 0.000 description 37
- 125000000753 cycloalkyl group Chemical group 0.000 description 34
- 230000008859 change Effects 0.000 description 32
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 31
- 102100022297 Integrin alpha-X Human genes 0.000 description 30
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 29
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 29
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 28
- 108020004707 nucleic acids Proteins 0.000 description 27
- 238000001574 biopsy Methods 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 238000007390 skin biopsy Methods 0.000 description 23
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 238000009396 hybridization Methods 0.000 description 21
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 19
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 19
- 239000012472 biological sample Substances 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 17
- 210000004443 dendritic cell Anatomy 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 108091033319 polynucleotide Proteins 0.000 description 15
- 239000002157 polynucleotide Substances 0.000 description 15
- 102000040430 polynucleotide Human genes 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 14
- 125000003282 alkyl amino group Chemical group 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000012453 solvate Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000000975 dye Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 125000004076 pyridyl group Chemical group 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 11
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 11
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 11
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 125000000000 cycloalkoxy group Chemical group 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 10
- 150000002367 halogens Chemical class 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 125000001624 naphthyl group Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 229930192474 thiophene Natural products 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 9
- 210000001821 langerhans cell Anatomy 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 8
- 239000005977 Ethylene Substances 0.000 description 8
- 125000004442 acylamino group Chemical group 0.000 description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 125000004663 dialkyl amino group Chemical group 0.000 description 7
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 7
- 206010040882 skin lesion Diseases 0.000 description 7
- 231100000444 skin lesion Toxicity 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 102000006354 HLA-DR Antigens Human genes 0.000 description 6
- 108010058597 HLA-DR Antigens Proteins 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- IMOZEMNVLZVGJZ-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 125000001118 alkylidene group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 150000001602 bicycloalkyls Chemical group 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 125000005678 ethenylene group Chemical class [H]C([*:1])=C([H])[*:2] 0.000 description 5
- 150000003949 imides Chemical class 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- QDZOBXFRIVOQBR-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-UHFFFAOYSA-N 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 4
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 125000005592 polycycloalkyl group Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- OXYAFFHMEHZDGM-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-dinitroisoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C(=CC=C3C2=O)[N+]([O-])=O)[N+]([O-])=O)=O)=C1 OXYAFFHMEHZDGM-UHFFFAOYSA-N 0.000 description 3
- YYQGUWHFXVXQOO-GFCCVEGCSA-N 2-chloro-4-[[3-[(2R)-2-hydroxybutyl]-1-methyl-2-oxobenzimidazol-5-yl]amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC2=C(N(C(N2C[C@@H](CC)O)=O)C)C=C1 YYQGUWHFXVXQOO-GFCCVEGCSA-N 0.000 description 3
- DHKAFTYWTCIWJX-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=CC=CC=C2C1 DHKAFTYWTCIWJX-UHFFFAOYSA-N 0.000 description 3
- 0 C*C(*)N(C*)C(C)=O Chemical compound C*C(*)N(C*)C(C)=O 0.000 description 3
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 3
- 101150015280 Cel gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000000541 Defensins Human genes 0.000 description 3
- 108010002069 Defensins Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000005605 benzo group Chemical group 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000003950 cyclic amides Chemical class 0.000 description 3
- VBQUDDWATQWCPP-UHFFFAOYSA-N ethylsulfonylbenzene Chemical class CCS(=O)(=O)C1=CC=CC=C1 VBQUDDWATQWCPP-UHFFFAOYSA-N 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical class C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 2
- 150000005072 1,3,4-oxadiazoles Chemical class 0.000 description 2
- NTWLARBDJFXJNZ-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-3-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(CCO)N1C(=O)C2=CC=CC=C2C1=O NTWLARBDJFXJNZ-UHFFFAOYSA-N 0.000 description 2
- GODXRDNLVMRFSG-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)propan-2-yl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)N1C(=O)C2=CC=CC=C2C1=O GODXRDNLVMRFSG-UHFFFAOYSA-N 0.000 description 2
- YEALSVAJNLBPLB-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-5-methylisoindole-1,3-dione Chemical compound COC1=CC=C(C(CC=2OC=NN=2)N2C(C3=CC(C)=CC=C3C2=O)=O)C=C1OC1CCCC1 YEALSVAJNLBPLB-UHFFFAOYSA-N 0.000 description 2
- DZMANEJEPAEVPF-UHFFFAOYSA-N 3,3-bis(3,4-dimethoxyphenyl)prop-2-enenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(=CC#N)C1=CC=C(OC)C(OC)=C1 DZMANEJEPAEVPF-UHFFFAOYSA-N 0.000 description 2
- XTNHNNYYNNRZIV-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-n-hydroxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1 XTNHNNYYNNRZIV-UHFFFAOYSA-N 0.000 description 2
- HRYCWEZIWMFEDD-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(4-nitro-1,3-dioxoisoindol-2-yl)-n-phenylmethoxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOCC=2C=CC=CC=2)N2C(C3=C(C=CC=C3C2=O)[N+]([O-])=O)=O)=C1 HRYCWEZIWMFEDD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 229910003844 NSO2 Inorganic materials 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- RKUKMEJKLRORIR-UHFFFAOYSA-N [[3-(1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoyl]amino] propanoate Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOC(=O)CC)N2C(C3=CC=CC=C3C2=O)=O)=C1 RKUKMEJKLRORIR-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000011256 aggressive treatment Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004702 alkoxy alkyl carbonyl group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000005293 bicycloalkoxy group Chemical group 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000036566 epidermal hyperplasia Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical group C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000003914 myeloid leukocyte Anatomy 0.000 description 2
- QDZOBXFRIVOQBR-IBGZPJMESA-N n-[2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 QDZOBXFRIVOQBR-IBGZPJMESA-N 0.000 description 2
- YENYTUWIKANDNM-UHFFFAOYSA-N n-[3-amino-3-(3,4-dimethoxyphenyl)propanoyl]benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(N)CC(=O)NC(=O)C1=CC=CC=C1 YENYTUWIKANDNM-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 229940095574 propionic acid Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- BFESEYUXGQAUDS-LJQANCHMSA-N (3r)-3-(4-acetamido-3-oxo-1h-isoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(=O)N(C)C)N2C(C3=C(NC(C)=O)C=CC=C3C2)=O)=C1 BFESEYUXGQAUDS-LJQANCHMSA-N 0.000 description 1
- LLYCQFTTYQQHMI-GOSISDBHSA-N (3r)-3-[4-[(2-chloroacetyl)amino]-3-oxo-1h-isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(=O)N(C)C)N2C(C3=C(NC(=O)CCl)C=CC=C3C2)=O)=C1 LLYCQFTTYQQHMI-GOSISDBHSA-N 0.000 description 1
- VAZPGDVTTOAULR-LJQANCHMSA-N (3r)-3-[4-[[2-(dimethylamino)acetyl]amino]-1,3-dioxoisoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(=O)N(C)C)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 VAZPGDVTTOAULR-LJQANCHMSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
- LHMYYQCQGPBDIH-UHFFFAOYSA-N 2-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanamide Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)N)CC1=CC=CC=C1 LHMYYQCQGPBDIH-UHFFFAOYSA-N 0.000 description 1
- FZEBPJBRDFXKIH-UHFFFAOYSA-N 2-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(C(=O)O)CC1=CC=CC=C1 FZEBPJBRDFXKIH-UHFFFAOYSA-N 0.000 description 1
- FACSMBGYDORUJJ-SFHVURJKSA-N 2-(dimethylamino)-n-[2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC([C@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 FACSMBGYDORUJJ-SFHVURJKSA-N 0.000 description 1
- ZTBBGZCPPYWHIZ-LJQANCHMSA-N 2-(dimethylamino)-n-[2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)=O)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 ZTBBGZCPPYWHIZ-LJQANCHMSA-N 0.000 description 1
- FACSMBGYDORUJJ-GOSISDBHSA-N 2-(dimethylamino)-n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 FACSMBGYDORUJJ-GOSISDBHSA-N 0.000 description 1
- RJNHBBSGPDOAND-UHFFFAOYSA-N 2-(dimethylamino)-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C(C)N(C)C)C=CC=C3C2=O)=O)=C1 RJNHBBSGPDOAND-UHFFFAOYSA-N 0.000 description 1
- VYOZUXZBZYTKOW-UHFFFAOYSA-N 2-(dimethylamino)-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-oxo-1h-isoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2)=O)=C1 VYOZUXZBZYTKOW-UHFFFAOYSA-N 0.000 description 1
- ZTBBGZCPPYWHIZ-UHFFFAOYSA-N 2-(dimethylamino)-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)=O)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 ZTBBGZCPPYWHIZ-UHFFFAOYSA-N 0.000 description 1
- HHZHPBGFUBYKRN-UHFFFAOYSA-N 2-(dimethylamino)-n-[[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CNC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 HHZHPBGFUBYKRN-UHFFFAOYSA-N 0.000 description 1
- ISPUPFYJUWLMEH-CAWMZFRYSA-N 2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-4-(1h-pyrrol-2-ylmethyl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)O)N2C(C3=C(CC=4NC=CC=4)C=CC=C3C2=O)=O)=C1 ISPUPFYJUWLMEH-CAWMZFRYSA-N 0.000 description 1
- NAKSEFFBNWKUJH-OAQYLSRUSA-N 2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-4-(1h-pyrrol-2-ylmethyl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)=O)N2C(C3=C(CC=4NC=CC=4)C=CC=C3C2=O)=O)=C1 NAKSEFFBNWKUJH-OAQYLSRUSA-N 0.000 description 1
- AUVWUWFCGQNERQ-UHFFFAOYSA-N 2-[1-(3,4-dimethoxyphenyl)-2-methylsulfonylethyl]-4-(1h-pyrrol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(CS(C)(=O)=O)N1C(=O)C2=C(C=3NC=CC=3)C=CC=C2C1=O AUVWUWFCGQNERQ-UHFFFAOYSA-N 0.000 description 1
- HGWJEAFEEZXCPG-UHFFFAOYSA-N 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-oxobutyl]-4-(1h-pyrrol-2-yl)isoindole-1,3-dione Chemical compound COC1=CC=C(C(CC(C)=O)N2C(C3=C(C=4NC=CC=4)C=CC=C3C2=O)=O)C=C1OC1CCCC1 HGWJEAFEEZXCPG-UHFFFAOYSA-N 0.000 description 1
- ZOMMYBFPBGWUAT-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(1h-imidazol-2-ylmethyl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CC=4NC=CN=4)C=CC=C3C2=O)=O)=C1 ZOMMYBFPBGWUAT-UHFFFAOYSA-N 0.000 description 1
- LXFIMHZDTHLHOA-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(1h-pyrrol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C=4NC=CC=4)C=CC=C3C2=O)=O)=C1 LXFIMHZDTHLHOA-UHFFFAOYSA-N 0.000 description 1
- HPNGOUOSHMENJP-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(1h-pyrrol-2-ylmethyl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CC=4NC=CC=4)C=CC=C3C2=O)=O)=C1 HPNGOUOSHMENJP-UHFFFAOYSA-N 0.000 description 1
- KYBGGKMHMYDTDS-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(5-methyl-1,3,4-oxadiazol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C=4OC(C)=NN=4)C=CC=C3C2=O)=O)=C1 KYBGGKMHMYDTDS-UHFFFAOYSA-N 0.000 description 1
- AUYSFUSWFJUKMJ-UHFFFAOYSA-N 2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-4-(1h-pyrrol-2-yl)isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)=O)N2C(C3=C(C=4NC=CC=4)C=CC=C3C2=O)=O)=C1 AUYSFUSWFJUKMJ-UHFFFAOYSA-N 0.000 description 1
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
- FFOXNTUNASQTMG-UHFFFAOYSA-N 2-amino-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)CN)C=CC=C3C2=O)=O)=C1 FFOXNTUNASQTMG-UHFFFAOYSA-N 0.000 description 1
- KVBKXXOHQDLRLG-UHFFFAOYSA-N 2-chloro-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)CCl)C=CC=C3C2=O)=O)=C1 KVBKXXOHQDLRLG-UHFFFAOYSA-N 0.000 description 1
- RREPAJHHRAPCQP-UHFFFAOYSA-N 2-chloro-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)=O)N2C(C3=C(NC(=O)CCl)C=CC=C3C2=O)=O)=C1 RREPAJHHRAPCQP-UHFFFAOYSA-N 0.000 description 1
- ISODCLUTRNLGQU-UHFFFAOYSA-N 2-chloro-n-[[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CNC(=O)CCl)C=CC=C3C2=O)=O)=C1 ISODCLUTRNLGQU-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- JIMIQGNFLBAYNO-UHFFFAOYSA-N 3-(1,3-dioxobenzo[f]isoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC4=CC=CC=C4C=C3C2=O)=O)=C1 JIMIQGNFLBAYNO-UHFFFAOYSA-N 0.000 description 1
- UFZWIEHRDSAKPV-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC=CC=C3C2=O)=O)=C1 UFZWIEHRDSAKPV-UHFFFAOYSA-N 0.000 description 1
- GSCRRCMZMKJZFP-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-phenylmethoxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOCC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2=O)=O)=C1 GSCRRCMZMKJZFP-UHFFFAOYSA-N 0.000 description 1
- QONJXSUGPNCIKG-UHFFFAOYSA-N 3-(1,3-dioxoisoindol-2-yl)-n-hydroxy-3-(4-methoxy-3-propan-2-yloxyphenyl)propanamide Chemical compound C1=C(OC(C)C)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1=O QONJXSUGPNCIKG-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- OUDWSJIHPUWLQE-UHFFFAOYSA-N 3-(3,4-diethoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C(CC(O)=O)N1C(=O)C2=CC=CC=C2C1 OUDWSJIHPUWLQE-UHFFFAOYSA-N 0.000 description 1
- OQYFIVKWHLAOKT-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(=O)NO)N1C(=O)C2=CC=CC=C2C1=O OQYFIVKWHLAOKT-UHFFFAOYSA-N 0.000 description 1
- BIPSRNADJRZGBV-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-3-(5,7-dioxopyrrolo[3,4-b]pyridin-6-yl)propanamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(N)=O)N1C(=O)C2=NC=CC=C2C1=O BIPSRNADJRZGBV-UHFFFAOYSA-N 0.000 description 1
- HHRBRFMDLUNNSX-UHFFFAOYSA-N 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(N)=O)N2C(C3=CC=CC=C3C2)=O)=C1 HHRBRFMDLUNNSX-UHFFFAOYSA-N 0.000 description 1
- AAGICWVGIIDLTO-UHFFFAOYSA-N 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 AAGICWVGIIDLTO-UHFFFAOYSA-N 0.000 description 1
- DJGWCAKHYFQWHI-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxobenzo[f]isoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(N)=O)N2C(C3=CC4=CC=CC=C4C=C3C2=O)=O)C=C1OC1CCCC1 DJGWCAKHYFQWHI-UHFFFAOYSA-N 0.000 description 1
- HHVLVKOMFOFNPK-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxypropanamide Chemical compound COC1=CC=C(C(CC(=O)NO)N2C(C3=CC=CC=C3C2=O)=O)C=C1OC1CCCC1 HHVLVKOMFOFNPK-UHFFFAOYSA-N 0.000 description 1
- XHDUFCCOLBQWDW-UHFFFAOYSA-N 3-(3-cyclopentyloxy-4-methoxyphenyl)-n-hydroxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound COC1=CC=C(C(CC(=O)NO)N2C(C3=CC=CC=C3C2)=O)C=C1OC1CCCC1 XHDUFCCOLBQWDW-UHFFFAOYSA-N 0.000 description 1
- FYNUUEVQBYCTHI-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)-n-phenylmethoxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOCC=2C=CC=CC=2)N2C(C3=CC=CC=C3C2)=O)=C1 FYNUUEVQBYCTHI-UHFFFAOYSA-N 0.000 description 1
- QYOSHOBNEQEKHZ-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 QYOSHOBNEQEKHZ-UHFFFAOYSA-N 0.000 description 1
- GGNUZNOYDSSADP-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-hydroxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC=CC=C3C2)=O)=C1 GGNUZNOYDSSADP-UHFFFAOYSA-N 0.000 description 1
- UWQLHYJEPXAAIF-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-hydroxy-3-(4-nitro-1,3-dioxoisoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(C=CC=C3C2=O)[N+]([O-])=O)=O)=C1 UWQLHYJEPXAAIF-UHFFFAOYSA-N 0.000 description 1
- YSFZDWMJUFEYIP-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-hydroxy-3-(5-methyl-1,3-dioxoisoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC(C)=CC=C3C2=O)=O)=C1 YSFZDWMJUFEYIP-UHFFFAOYSA-N 0.000 description 1
- JBOBZXFXFVDGNO-UHFFFAOYSA-N 3-(3-ethoxy-4-methoxyphenyl)-n-methoxy-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NOC)N2C(C3=CC=CC=C3C2)=O)=C1 JBOBZXFXFVDGNO-UHFFFAOYSA-N 0.000 description 1
- CMBFWNFHRMUSLM-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanamide Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC(=O)N)C1=CC=CC=C1 CMBFWNFHRMUSLM-UHFFFAOYSA-N 0.000 description 1
- MQSVZMUVVKVXTQ-UHFFFAOYSA-N 3-(3-oxo-1h-isoindol-2-yl)-3-phenylpropanoic acid Chemical compound C1C2=CC=CC=C2C(=O)N1C(CC(=O)O)C1=CC=CC=C1 MQSVZMUVVKVXTQ-UHFFFAOYSA-N 0.000 description 1
- XAWOJFZKIJHZEW-UHFFFAOYSA-N 3-(4,7-difluoro-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(C(=CC=C3F)F)C2=O)=O)=C1 XAWOJFZKIJHZEW-UHFFFAOYSA-N 0.000 description 1
- HQUCDINVZJIZIL-UHFFFAOYSA-N 3-(4-acetamido-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 HQUCDINVZJIZIL-UHFFFAOYSA-N 0.000 description 1
- LVGHSBVWSORFEX-UHFFFAOYSA-N 3-(4-amino-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 LVGHSBVWSORFEX-UHFFFAOYSA-N 0.000 description 1
- XTEVFIVUZLSJHJ-UHFFFAOYSA-N 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanamide Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(N)=O)N2C(C3=CC=CC=C3C2)=O)=C1 XTEVFIVUZLSJHJ-UHFFFAOYSA-N 0.000 description 1
- AIZIZEHVOQPQPO-UHFFFAOYSA-N 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoic acid Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(O)=O)N2C(C3=CC=CC=C3C2)=O)=C1 AIZIZEHVOQPQPO-UHFFFAOYSA-N 0.000 description 1
- ASXKYGLTYKLCLZ-UHFFFAOYSA-N 3-(5-amino-1,3-dioxoisoindol-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-n-hydroxypropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)NO)N2C(C3=CC(N)=CC=C3C2=O)=O)=C1 ASXKYGLTYKLCLZ-UHFFFAOYSA-N 0.000 description 1
- SMBSZJBWYCGCJP-UHFFFAOYSA-N 3-(diethylamino)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(N(CC)CC)=CC2=C1 SMBSZJBWYCGCJP-UHFFFAOYSA-N 0.000 description 1
- RKODPUVUBAWGBM-UHFFFAOYSA-N 3-(dimethylamino)-n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]propanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)CCN(C)C)C=CC=C3C2=O)=O)=C1 RKODPUVUBAWGBM-UHFFFAOYSA-N 0.000 description 1
- VEXOSRQHSWXFDL-UHFFFAOYSA-N 3-[1,3-dioxo-4-(1h-pyrrol-2-yl)isoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)N(C)C)N2C(C3=C(C=4NC=CC=4)C=CC=C3C2=O)=O)=C1 VEXOSRQHSWXFDL-UHFFFAOYSA-N 0.000 description 1
- VAZPGDVTTOAULR-UHFFFAOYSA-N 3-[4-[[2-(dimethylamino)acetyl]amino]-1,3-dioxoisoindol-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)N(C)C)N2C(C3=C(NC(=O)CN(C)C)C=CC=C3C2=O)=O)=C1 VAZPGDVTTOAULR-UHFFFAOYSA-N 0.000 description 1
- QKHSAVPFILQVGW-UHFFFAOYSA-N 4,5-diamino-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(N)C(N)=CC=C3C2=O)=O)=C1 QKHSAVPFILQVGW-UHFFFAOYSA-N 0.000 description 1
- CEUCTMSNRQZUSX-UHFFFAOYSA-N 4-(aminomethyl)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CN)C=CC=C3C2=O)=O)=C1 CEUCTMSNRQZUSX-UHFFFAOYSA-N 0.000 description 1
- JSLPDEPKIWZVKP-UHFFFAOYSA-N 4-[3-[(dimethylamino)methyl]-1h-pyrrol-2-yl]-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(C4=C(C=CN4)CN(C)C)C=CC=C3C2=O)=O)=C1 JSLPDEPKIWZVKP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- IOIBFPBEUNZCMX-PVQCJRHBSA-N 4-amino-2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)O)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 IOIBFPBEUNZCMX-PVQCJRHBSA-N 0.000 description 1
- HEWRXBRDIAUSKW-MRXNPFEDSA-N 4-amino-2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)=O)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 HEWRXBRDIAUSKW-MRXNPFEDSA-N 0.000 description 1
- HEWRXBRDIAUSKW-UHFFFAOYSA-N 4-amino-2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]isoindole-1,3-dione Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)=O)N2C(C3=C(N)C=CC=C3C2=O)=O)=C1 HEWRXBRDIAUSKW-UHFFFAOYSA-N 0.000 description 1
- IDLISIVVYLGCKO-UHFFFAOYSA-N 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein Chemical compound O1C(=O)C2=CC=C(C(O)=O)C=C2C21C1=CC(OC)=C(O)C(Cl)=C1OC1=C2C=C(OC)C(O)=C1Cl IDLISIVVYLGCKO-UHFFFAOYSA-N 0.000 description 1
- WQZIDRAQTRIQDX-UHFFFAOYSA-N 6-carboxy-x-rhodamine Chemical compound OC(=O)C1=CC=C(C([O-])=O)C=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 WQZIDRAQTRIQDX-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- VWOLRKMFAJUZGM-UHFFFAOYSA-N 6-carboxyrhodamine 6G Chemical compound [Cl-].C=12C=C(C)C(NCC)=CC2=[O+]C=2C=C(NCC)C(C)=CC=2C=1C1=CC(C(O)=O)=CC=C1C(=O)OCC VWOLRKMFAJUZGM-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- AUYSFUSWFJUKMJ-HXUWFJFHSA-N C(C)OC=1C=C(C=CC=1OC)[C@@H](CC(C)=O)N1C(C2=CC=CC(=C2C1=O)C=1NC=CC=1)=O Chemical compound C(C)OC=1C=C(C=CC=1OC)[C@@H](CC(C)=O)N1C(C2=CC=CC(=C2C1=O)C=1NC=CC=1)=O AUYSFUSWFJUKMJ-HXUWFJFHSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- XVVPUIFFCFFMBS-UHFFFAOYSA-N C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CONC=O)C=CC=C3C2=O)=O)=C1 Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CONC=O)C=CC=C3C2=O)=O)=C1 XVVPUIFFCFFMBS-UHFFFAOYSA-N 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 108010014231 Chemokine CXCL9 Proteins 0.000 description 1
- 102000016937 Chemokine CXCL9 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 1
- 101710183400 Keratin, type I cytoskeletal 16 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- PAOZAMACNXMCIB-UHFFFAOYSA-N N-[2-[1-(3,4-dimethoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CS(C)(=O)=O)N1C(=O)C2=C(NC(=O)C3CC3)C=CC=C2C1=O PAOZAMACNXMCIB-UHFFFAOYSA-N 0.000 description 1
- GFUVTYHCYYMDMO-UHFFFAOYSA-N N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]cyclopentanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CCCC4)C=CC=C3C2=O)=O)=C1 GFUVTYHCYYMDMO-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 102000012265 beta-defensin Human genes 0.000 description 1
- 108050002883 beta-defensin Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical group 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VYXSBFYARXAAKO-UHFFFAOYSA-N ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate;hydron;chloride Chemical compound [Cl-].C1=2C=C(C)C(NCC)=CC=2OC2=CC(=[NH+]CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000001998 leucyl group Chemical group 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000002073 methionyl group Chemical group 0.000 description 1
- BPBRDDCTMUGRTO-UHFFFAOYSA-N methyl 3-(3-butoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCCCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 BPBRDDCTMUGRTO-UHFFFAOYSA-N 0.000 description 1
- MBRFGSOSVRLYHU-UHFFFAOYSA-N methyl 3-(3-ethoxy-4-methoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 MBRFGSOSVRLYHU-UHFFFAOYSA-N 0.000 description 1
- OWDLKUNGWLGJFD-UHFFFAOYSA-N methyl 3-(4-methoxy-3-propoxyphenyl)-3-(3-oxo-1h-isoindol-2-yl)propanoate Chemical compound C1=C(OC)C(OCCC)=CC(C(CC(=O)OC)N2C(C3=CC=CC=C3C2)=O)=C1 OWDLKUNGWLGJFD-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- MQRUNQYIJQXVLP-PQJIZZRHSA-N n-[2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 MQRUNQYIJQXVLP-PQJIZZRHSA-N 0.000 description 1
- HHSCRXUCPLPVQX-GOSISDBHSA-N n-[2-[(1r)-1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(C)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 HHSCRXUCPLPVQX-GOSISDBHSA-N 0.000 description 1
- XCCGODHJXOPFSU-HXUWFJFHSA-N n-[2-[(1r)-3-(dimethylamino)-1-(3-ethoxy-4-methoxyphenyl)-3-oxopropyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CC(=O)N(C)C)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 XCCGODHJXOPFSU-HXUWFJFHSA-N 0.000 description 1
- CZVNIGALSIBARE-GOSISDBHSA-N n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2=O)=O)=C1 CZVNIGALSIBARE-GOSISDBHSA-N 0.000 description 1
- JKJDMNWLHGJEDK-UHFFFAOYSA-N n-[2-[1-(3,4-dimethoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]-2-(dimethylamino)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CS(C)(=O)=O)N1C(=O)C2=C(NC(=O)CN(C)C)C=CC=C2C1=O JKJDMNWLHGJEDK-UHFFFAOYSA-N 0.000 description 1
- REHJAEDOIKWMDG-UHFFFAOYSA-N n-[2-[1-(3,4-dimethoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]-n-methylsulfonylmethanesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1C(CC(C)=O)N1C(=O)C2=C(N(S(C)(=O)=O)S(C)(=O)=O)C=CC=C2C1=O REHJAEDOIKWMDG-UHFFFAOYSA-N 0.000 description 1
- MVFSISZBKOLEKN-UHFFFAOYSA-N n-[2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound COC1=CC=C(C(CC(C)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)C=C1OC1CCCC1 MVFSISZBKOLEKN-UHFFFAOYSA-N 0.000 description 1
- SMAINSPNWIAUNS-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-(1,3,4-oxadiazol-2-yl)ethyl]-3-oxo-1h-isoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC=2OC=NN=2)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2)=O)=C1 SMAINSPNWIAUNS-UHFFFAOYSA-N 0.000 description 1
- HTMFPTFPZHDRKM-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C(F)(F)F)C=CC=C3C2=O)=O)=C1 HTMFPTFPZHDRKM-UHFFFAOYSA-N 0.000 description 1
- YERMOCFDEPTPGV-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]-n-methylsulfonylmethanesulfonamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(N(S(C)(=O)=O)S(C)(=O)=O)C=CC=C3C2=O)=O)=C1 YERMOCFDEPTPGV-UHFFFAOYSA-N 0.000 description 1
- CZVNIGALSIBARE-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]cyclopropanecarboxamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NC(=O)C4CC4)C=CC=C3C2=O)=O)=C1 CZVNIGALSIBARE-UHFFFAOYSA-N 0.000 description 1
- UXIXMIGOPYWHCQ-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]methanesulfonamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(NS(C)(=O)=O)C=CC=C3C2=O)=O)=C1 UXIXMIGOPYWHCQ-UHFFFAOYSA-N 0.000 description 1
- MQRUNQYIJQXVLP-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 MQRUNQYIJQXVLP-UHFFFAOYSA-N 0.000 description 1
- KIRMTFBOUGUJOQ-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxypentyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(O)CC)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 KIRMTFBOUGUJOQ-UHFFFAOYSA-N 0.000 description 1
- HHSCRXUCPLPVQX-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(C)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 HHSCRXUCPLPVQX-UHFFFAOYSA-N 0.000 description 1
- JGGSUUSWFUVOKY-UHFFFAOYSA-N n-[2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxopentyl]-1,3-dioxoisoindol-4-yl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CC(=O)CC)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 JGGSUUSWFUVOKY-UHFFFAOYSA-N 0.000 description 1
- GNDMDNGVKFJTQD-UHFFFAOYSA-N n-[[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindol-4-yl]methyl]acetamide Chemical compound C1=C(OC)C(OCC)=CC(C(CS(C)(=O)=O)N2C(C3=C(CNC(C)=O)C=CC=C3C2=O)=O)=C1 GNDMDNGVKFJTQD-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009745 pathological pathway Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000004647 pro-inflammatory pathway Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000001022 rhodamine dye Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003291 riboses Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 125000001239 threonyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002233 tyrosyl group Chemical group 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000001018 xanthene dye Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- monitoring of specific biomarkers in samples obtained from skin biopsies before and during therapy for psoriasis is also provided herein. Also provided herein is monitoring of expression of one or more specific genes or proteins before and during the therapy.
- Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by epidermal hyperproliferation of keratinocytes and endothelial cells, and inflammatory cell accumulation (e.g., activated T cells).
- Griffiths CE J. Eur. Acad. Dermatol. Venereol. 2003, 17 Suppl 2:1-5 ; Creamer JD, et al., Clin. Exp. Dermatol. 1995, 20(1):6-9 .
- NK natural killer
- NK T cells interferon-gamma
- Proinflammatory mediators shown to be elevated in the psoriasis skin lesions include, tumor necrosis factor-alpha (TNF- ⁇ ), interleukin-6 (IL-6), IL-8, IL-12, IFN- ⁇ , and inducible nitric oxide synthase (iNOS).
- TNF- ⁇ tumor necrosis factor-alpha
- IL-6 interleukin-6
- IL-8 interleukin-8
- IL-12 interleukin-12
- IFN- ⁇ inducible nitric oxide synthase
- iNOS inducible nitric oxide synthase
- PDE4 inhibitors may provide therapeutic benefits in the treatment of psoriasis.
- US 2008/234359 describes solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and methods of using the same for treating or preventing diseases ameliorated by PDE4 inhibition. Also certain biomarkers including CD11c, ICAM-1, HLA-DR, iNOS and K16 are described.
- CD11c+ cells are a major cell type in psoriasis skin lesions, discussing expression of CD11c and iNOS at different time points of psoriasis treatment.
- US 2009/239926 describes methods for treating psoriasis and psoriatic arthritis involving administration of cyclopropyl-N- ⁇ 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl ⁇ carboxamide as well as pharmaceutical compositions and single unit dose forms.
- biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis are biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis.
- provided herein is a method of predicting or monitoring the efficacy of a psoriasis treatment by measuring the level of one or more specific biomarkers in cells obtained from patients before or during the treatment.
- the cells are obtained by skin biopsies.
- the biomarkers include, CD11c, CD3, CD56, Langerin, and/or Foxp3.
- the treatment is administration of a PDE4 modulator provided herein elsewhere.
- mRNA levels of Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN- ⁇ and/or CXCL9 can be used to predict whether a treatment is likely to be successful in treating psoriasis. Further, the expression of these genes can be used to monitor efficacy/progress of the treatment once the treatment begins. In one embodiment, the treatment is administration of a PDE4 modulator provided herein elsewhere.
- a method for monitoring patient compliance with a drug treatment protocol comprises measuring the expression level of at least one biomarker provided herein in a sample from the patient, and determining if the expression level is increased or decreased in the patient sample compared to the expression level in a control untreated sample, wherein an increased or decreased expression indicates patient compliance with the drug treatment protocol.
- the kit comprises a solid support, nucleic acids contacting the support, where the nucleic acids are complementary to at least 20, 50, 100, 200, 350, or more bases of an mRNA biomarker provided herein, and a means for detecting the expression of the mRNA in a biological sample.
- kit can employ, for example a dipstick, a membrane, a chip, a disk, a test strip, a filter, a microsphere, a slide, a multiwell plate, or an optical fiber.
- the solid support of the kit can be, for example, a plastic, silicon, a metal, a resin, glass, a membrane, a particle, a precipitate, a gel, a polymer, a sheet, a sphere, a polysaccharide, a capillary, a film, a plate, or a slide.
- the biological sample can be, for example, a cell culture, a cell line, a tissue, an oral tissue, gastrointestinal tissue, an organ, an organelle, a biological fluid, a blood sample, a urine sample, or a skin sample.
- the biological sample can be, for example, a skin biopsy.
- biomarkers can be utilized as biomarkers to indicate the effectiveness or progress of a treatment for psoriasis.
- these biomarkers can be used to predict, assess and track the effectiveness of patient treatment or to monitor the patient's compliance to the treatment regimen.
- treat refers to an action that occurs while a patient is suffering from psoriasis, which reduces the severity of psoriasis, or retards or slows the progression of the cancer.
- sensitivity and "sensitive” when made in reference to treatment is a relative term which refers to the degree of effectiveness of a treatment compound in lessening or decreasing the symptoms of the disease being treated.
- increased sensitivity when used in reference to treatment of a cell or patient refers to an increase of, at least a 5%, or more, in the effectiveness in lessening or decreasing the symptoms of psoriasis when measured using any methods well-accepted in the art.
- the term "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of psoriasis, or to delay or minimize one or more symptoms associated with psoriasis.
- a therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of psoriasis.
- the term "therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of psoriasis, or enhances the therapeutic efficacy of another therapeutic agent.
- an "effective patient response” refers to any increase in the therapeutic benefit to the patient.
- An “effective patient tumor response” can be, for example, a 5%, 10%, 25%, 50%, or 100% decrease in the physical symptoms of psoriasis.
- predict generally means to determine or tell in advance.
- predict can mean that the likelihood of the outcome of the treatment can be determined at the outset, before the treatment has begun, or before the treatment period has progressed substantially.
- monitoring generally refers to the overseeing, supervision, regulation, watching, tracking, or surveillance of an activity.
- monitoring the efficacy of a treatment for psoriasis refers to tracking the effectiveness in treating psoriasis in a patient or in a cell, usually obtained from a patient.
- monitoring when used in connection with patient compliance, either individually, or in a clinical trial, refers to the tracking or confirming that the patient is actually following the treatment regimen being tested as prescribed.
- polypeptide and “protein” as used interchangeably herein, refer to a polymer of amino acids of three or more amino acids in a serial array, linked through peptide bonds.
- polypeptide includes proteins, protein fragments, protein analogues, oligopeptides and the like.
- polypeptide as used herein can also refer to a peptide.
- the amino acids making up the polypeptide may be naturally derived, or may be synthetic.
- the polypeptide can be purified from a biological sample.
- antibody is used herein in the broadest sense and covers fully assembled antibodies, antibody fragments which retain the ability to specifically bind to the antigen (e.g ., Fab, F(ab')2, Fv, and other fragments), single chain antibodies, diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, humanized antibodies, and the like.
- antibody covers both polyclonal and monoclonal antibodies.
- expressed or expression refers to the transcription from a gene to give an RNA nucleic acid molecule at least complementary in part to a region of one of the two nucleic acid strands of the gene.
- expressed or expression as used herein also refers to the translation from the RNA molecule to give a protein, a polypeptide or a portion thereof.
- An mRNA that is “upregulated” is generally “increased” upon a given treatment or condition.
- An mRNA that is “downregulated” generally refers to a "decrease” in the level of expression of the mRNA in response to a given treatment or condition. In some situations, the mRNA level can remain unchanged upon a given treatment or condition.
- An mRNA from a patient sample can be "upregulated,” i.e., the level of mRNA can be increased, for example, by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 500%, 1,000%, 5,000% or more of the comparative control mRNA level.
- an mRNA can be "downregulated," i.e., the level of mRNA level can be decreased, for example, by about 99%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 1% or less of the comparative control mRNA level.
- the level of a polypeptide or protein biomarker from a patient sample can be increased as compared to a non-treated control. This increase can be about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 500%, 1,000%, 5,000% or more of the comparative control protein level.
- the level of a protein biomarker can be decreased. This decrease can be, for example, present at a level of about 99%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 1% or less of the comparative control protein level.
- PDE4 modulators refers to a molecule or compound that inhibits PDE4.
- the PDE4 modulators can be those available from Celgene Corporation (provided herein elsewhere), which potently inhibit TNF- ⁇ production, but exhibit modest inhibitory effects on LPS induced IL-1 ⁇ and IL-12, and do not inhibit IL-6 even at high drug concentrations.
- PDE4 inhibitors tend to produce a modest IL-10 stimulation. L.G. Corral, et al., Ann. Rheum. Dis., 58:(Suppl I) 1107-1113 (1999 ).
- determining generally refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assessing may be relative or absolute. “Assessing the presence of' can include determining the amount of something present, as well as determining whether it is present or absent.
- nucleic acid and “polynucleotide” are used interchangeably herein to describe a polymer of any length composed of nucleotides, e.g., deoxyribonucleotides or ribonucleotides, or compounds produced synthetically, which can hybridize with naturally occurring nucleic acids in a sequence specific manner analogous to that of two naturally occurring nucleic acids, e.g., can participate in Watson-Crick base pairing interactions.
- bases are synonymous with “nucleotides” (or “nucleotide”), i.e., the monomer subunit of a polynucleotide.
- nucleoside and nucleotide are intended to include those moieties that contain not only the known purine and pyrimidine bases, but also other heterocyclic bases that have been modified. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, alkylated riboses or other heterocycles.
- nucleoside and nucleotide include those moieties that contain not only conventional ribose and deoxyribose sugars, but other sugars as well. Modified nucleosides or nucleotides also include modifications on the sugar moiety, e.g., wherein one or more of the hydroxyl groups are replaced with halogen atoms or aliphatic groups, or are functionalized as ethers, amines, or the like.
- Analogues refer to molecules having structural features that are recognized in the literature as being mimetics, derivatives, having analogous structures, or other like terms, and include, for example, polynucleotides incorporating non-natural nucleotides, nucleotide mimetics such as 2'-modified nucleosides, peptide nucleic acids, oligomeric nucleoside phosphonates, and any polynucleotide that has added substituent groups, such as protecting groups or linking moieties.
- first polynucleotide and a second polynucleotide are complementary if they bind to each other in a hybridization assay under stringent conditions, e.g. if they produce a given or detectable level of signal in a hybridization assay.
- Portions of polynucleotides are complementary to each other if they follow conventional base-pairing rules, e.g. A pairs with T (or U) and G pairs with C, although small regions ( e.g. less than about 3 bases) of mismatch, insertion, or deleted sequence may be present.
- Sequence identity or “identity” in the context of two nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window, and can take into consideration additions, deletions and substitutions.
- substantially identical in their various grammatical forms in the context of polynucleotides generally means that a polynucleotide comprises a sequence that has a desired identity, for example, at least 60% identity, preferably at least 70% sequence identity, more preferably at least 80%, still more preferably at least 90% and even more preferably at least 95%, compared to a reference sequence.
- a desired identity for example, at least 60% identity, preferably at least 70% sequence identity, more preferably at least 80%, still more preferably at least 90% and even more preferably at least 95%.
- bound can be used herein to indicate direct or indirect attachment.
- bound (or “bonded”) may refer to the existence of a chemical bond directly joining two moieties or indirectly joining two moieties ( e.g., via a linking group or any other intervening portion of the molecule).
- the chemical bond may be a covalent bond, an ionic bond, a coordination complex, hydrogen bonding, van der Waals interactions, or hydrophobic stacking, or may exhibit characteristics of multiple types of chemical bonds.
- “bound” includes embodiments where the attachment is direct and also embodiments where the attachment is indirect.
- isolated and purified refer to isolation of a substance (such as mRNA or protein) such that the substance comprises a substantial portion of the sample in which it resides, i.e., greater than the substance is typically found in its natural or un-isolated state.
- a substantial portion of the sample comprises, e.g., greater than 1%, greater than 2%, greater than 5%, greater than 10%, greater than 20%, greater than 50%, or more, usually up to about 90%-100% of the sample.
- a sample of isolated mRNA can typically comprise at least about 1% total mRNA.
- Techniques for purifying polynucleotides are well known in the art and include, for example, gel electrophoresis, ion-exchange chromatography, affinity chromatography, flow sorting, and sedimentation according to density.
- sample as used herein relates to a material or mixture of materials, typically, although not necessarily, in fluid form, containing one or more components of interest.
- Bio sample refers to a sample obtained from a biological subject, including sample of biological tissue or fluid origin, obtained, reached, or collected in vivo or in situ.
- a biological sample also includes samples from a region of a biological subject containing precancerous or cancer cells or tissues. Such samples can be, but are not limited to, organs, tissues, fractions and cells isolated from a mammal.
- Exemplary biological samples include but are not limited to cell lysate, a cell culture, a cell line, a tissue, oral tissue, gastrointestinal tissue, an organ, an organelle, a biological fluid, a blood sample, a urine sample, a skin sample, and the like.
- Preferred biological samples include but are not limited to whole blood, partially purified blood, PBMCs, tissue biopsies, and the like.
- analyte refers to a known or unknown component of a sample.
- capture agent refers to an agent that binds an mRNA or protein through an interaction that is sufficient to permit the agent to bind and concentrate the mRNA or protein from a homogeneous mixture.
- probe refers to a capture agent that is directed to a specific target mRNA biomarker sequence. Accordingly, each probe of a probe set has a respective target mRNA biomarker.
- a probe/target mRNA duplex is a structure formed by hybridizing a probe to its target mRNA biomarker.
- nucleic acid or “oligonucleotide probe” refers to a nucleic acid capable of binding to a target nucleic acid of complementary sequence, such as the mRNA biomarkers provided herein, through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation.
- a probe may include natural (e.g., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.).
- the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization.
- probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions.
- the probes are preferably directly labeled with isotopes, for example, chromophores, lumiphores, chromogens, or indirectly labeled with biotin to which a streptavidin complex may later bind.
- isotopes for example, chromophores, lumiphores, chromogens, or indirectly labeled with biotin to which a streptavidin complex may later bind.
- stringent assay conditions refers to conditions that are compatible to produce binding pairs of nucleic acids, e.g., probes and target mRNAs, of sufficient complementarity to provide for the desired level of specificity in the assay while being generally incompatible to the formation of binding pairs between binding members of insufficient complementarity to provide for the desired specificity.
- stringent assay conditions generally refers to the combination of hybridization and wash conditions.
- a “label” or a “detectable moiety” in reference to a nucleic acid refers to a composition that, when linked with a nucleic acid, renders the nucleic acid detectable, for example, by spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
- Exemplary labels include, but are not limited to, radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, enzymes, biotin, digoxigenin, haptens, and the like.
- a "labeled nucleic acid or oligonucleotide probe” is generally one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic bonds, van der Waals forces, electrostatic attractions, hydrophobic interactions, or hydrogen bonds, to a label such that the presence of the nucleic acid or probe can be detected by detecting the presence of the label bound to the nucleic acid or probe.
- PCR polymerase chain reaction
- sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified.
- the 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material.
- PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51: 263 (1987 ); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989 ).
- cycle number refers to the PCR cycle number at which the fluorescence level passes a given set threshold level.
- the CT measurement can be used, for example, to approximate levels of mRNA in an original sample.
- the CT measurement is often used in terms of "dCT” or the “difference in the CT” score, when the CT of one nucleic acid is subtracted from the CT of another nucleic acid.
- optically pure means a composition that comprises one optical isomer of a compound and is substantially free of other isomers of that compound.
- an optically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
- An optically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound.
- a typical optically pure compound comprises greater than about 80% by weight of one enantiomer of the compound and less than about 20% by weight of other enantiomers of the compound, more preferably greater than about 90% by weight of one enantiomer of the compound and less than about 10% by weight of the other enantiomers of the compound, even more preferably greater than about 95% by weight of one enantiomer of the compound and less than about 5% by weight of the other enantiomers of the compound, more preferably greater than about 97% by weight of one enantiomer of the compound and less than about 3% by weight of the other enantiomers of the compound, and most preferably greater than about 99% by weight of one enantiomer of the compound and less than about 1% by weight of the other enantiomers of the compound.
- Cell markers or mRNA levels can be used to determine whether a treatment is likely to be successful in cell models of disease.
- a biological marker or "biomarker” is a substance whose detection indicates a particular biological state, such as, for example, the progress of psoriasis.
- biomarkers can either be determined individually, or several biomarkers can be measured simultaneously.
- a “biomarker” indicates a change in the level of nucleic acid expression that may correlate with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment.
- the biomarker is a mRNA or cDNA.
- a "biomarker” indicates a change in the level of certain cell markers that may correlate with the risk, susceptibility to treatment, or progression of a disease.
- the relative level of specific cell markers can be determined by methods known in the art. For example, antibody based methods, such as an immunoblot, enzyme-linked immunosorbent assay (ELISA), or other methods can be used.
- the levels of these cell markers may be used as a biomarker for predicting the sensitivity of a potential psoriasis treatment.
- the cell markers include CD3, CD56, Langerin and Foxp3. Each of these biomarkers may be monitored separately, or two or more of the biomarkers may be simultaneously monitored.
- these biomarkers can be used to predict the effectiveness of a psoriasis treatment in a patient.
- the level of the biomarker is measured in a biological sample obtained from a potential patient.
- the cell markers can also be used as a biomarker for an in vitro assay to predict the success of a psoriasis treatment, by taking a sample of cells from the patient, culturing them in the presence or absence of the treatment compound, and testing the cells for an increase or decrease in the levels of the biomarkers.
- a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- the progress of a psoriasis treatment can be followed by monitoring the levels of the cell markers described above.
- a method of assessing or monitoring the effectiveness of a psoriasis treatment in a patient is provided.
- a sample is obtained from the patient, and the levels of one or more of the above-described biomarkers are measured to determine whether their levels are increased or decreased compared to the levels prior to the initiation of the treatment.
- the biomarkers can also be used to track and adjust individual patient treatment effectiveness.
- the biomarkers can be used to gather information needed to make adjustments in a patient's treatment, increasing or decreasing the dose of an agent as needed. For example, a patient receiving a treatment compound can be tested using a biomarker to see if the dosage is becoming effective, or if a more aggressive treatment plan may be needed.
- a method of monitoring patient response to a psoriasis treatment comprising:
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one embodiment, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- the level of CD11c obtained from the dermis region is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of CD11c in the first biological sample.
- the level of CD11c obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD11c in the first biological sample.
- the level of CD3 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD3 in the first skin sample. In another embodiment, the level of CD3 obtained from the epidermis region is monitored, and the decrease is about 25%, 30%, 35%, or 40% or more as compared to the level of CD3 in the first skin sample.
- the level of CD56 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD56 in the first skin sample. In another embodiment, the level of CD56 obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD56 in the first skin sample.
- the level of Langerin obtained from the dermis region is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of Langerin in the first skin sample.
- the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- the treatment compound is a provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- a method of to a psoriasis treatment comprising:
- the decrease in the level of Langerin is amount 5%, 10%, 15%, or 20% as compared to the level of Langerin in the first skin sample.
- patients can submit the cell sample by any desired means, such as, for example, a skin biopsy.
- Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment.
- the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- the sample cells from patient are obtained using a skin biopsy.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- these biomarkers can additionally be used to track or perform quality control on human research trials or to monitor the patient compliance to a drug regimen by providing a means to confirm that the patient is receiving specific drug treatments.
- These biomarkers can be used in connection with, for example, the management of patient treatment, clinical trials, and cell-based research.
- these biomarkers can be used to track patient compliance during individual treatment regimes, or during clinical trials.
- the levels of biomarkers can be followed at set intervals during a clinical trial to ensure that the patients included in the trial are taking the drugs as instructed.
- the treatment of individual patients can also be followed using the procedure. For example, when the level of a particular biomarker is measured, an altered level of the biomarker compared to that of an untreated control indicates at least partial patient compliance with the drug treatment protocol. An altered level of the biomarker that is at a similar quantity to that of a positive control indicates the likelihood of full compliance with the treatment protocol.
- a method for assessing patient compliance with a drug treatment protocol is provided.
- a biological sample is obtained from the patient, and the levels of the biomarkers are measured and compared to that of a control untreated sample.
- An altered levels of biomarkers compared to those of an untreated control sample indicates compliance with the protocol.
- a method for monitoring patient compliance with a drug treatment protocol for psoriasis comprising:
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. By following the levels of these biomarkers, the patient compliance can be monitored over time.
- the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- the level of CD11c obtained from the dermis region is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of CD11c in the first biological sample. In another described aspect, the level of CD11c obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD11c in the first biological sample.
- the level of CD3 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD3 in the first skin sample. In another embodiment, the level of CD3 obtained from the epidermis region is monitored, and the decrease is about 25%, 30%, 35%, or 40% or more as compared to the level of CD3 in the first skin sample.
- the level of CD56 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD56 in the first skin sample. In another embodiment, the level of CD56 obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD56 in the first skin sample.
- the level of Langerin obtained from the dermis region is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of Langerin in the first skin sample.
- the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- a method for with a drug treatment protocol for psoriasis comprising:
- the decrease in the level of Langerin is amount 5%, 10%, 15%, or 20% as compared to the level of Langerin in the first skin sample.
- patients can submit the cell sample by any desired means, such as, for example, a skin biopsy.
- Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment.
- the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- the sample cells from patient are obtained using a skin biopsy.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- the levels of these mRNAs may be used as a biomarker for predicting the sensitivity of a potential psoriasis treatment.
- the mRNAs include, but are not limited to, mRNAs for Keratin 16, iNOS, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN- ⁇ and/or CXCL9. Each of these biomarkers may be monitored separately, or two or more of the biomarkers may be simultaneously monitored.
- these biomarkers can be used to predict the effectiveness of a psoriasis treatment in a patient.
- the level of the biomarker is measured in a biological sample obtained from a potential patient.
- the cell markers can also be used as a biomarker for an in vitro assay to predict the success of a psoriasis treatment, by taking a sample of cells from the patient, culturing them in the presence or absence of the treatment compound, and testing the cells for an increase or decrease in the levels of the biomarkers.
- a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- the level of only one of the mRNA is monitored. In another embodiment, the levels of two or more of the mRNAs are monitored simultaneously.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- the progress of a psoriasis treatment can be followed by monitoring the levels of the mRNAs described above.
- a method of assessing or monitoring the effectiveness of a psoriasis treatment in a patient is provided.
- a sample is obtained from the patient, and the levels of one or more of the above-described mRNAs are measured to determine whether their levels are increased or decreased compared to the levels prior to the initiation of the treatment.
- the biomarkers can also be used to track and adjust individual patient treatment effectiveness.
- the biomarkers can be used to gather information needed to make adjustments in a patient's treatment, increasing or decreasing the dose of an agent as needed. For example, a patient receiving a treatment compound can be tested using a biomarker to see if the dosage is becoming effective, or if a more aggressive treatment plan may be needed.
- a method of monitoring patient response to a psoriasis treatment comprising:
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one embodiment, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- the level of only one of the mRNA is monitored. In another embodiment, the levels of two or more of the mRNAs are monitored simultaneously.
- the level of IL-12/IL-13 p40 mRNA is monitored, and the decrease is about 80%, 85% 90%, or 95% or more as compared to the level of IL-12/IL-13 p40 mRNA in the first skin sample.
- the level of iNOS mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of iNOS mRNA in the first biological sample.
- the level of IL-22 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-22 mRNA in the first skin sample.
- the level of IL-8 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-8 mRNA in the first skin sample.
- the level of DEFB4 mRNA is monitored, and the decrease is about 45%, 50%, 55%, or 60% or more as compared to the level of DEFB4 mRNA in the first skin sample.
- the level of MX-1 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of MX-1 mRNA in the first skin sample.
- the level of Keratin 16 mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of Keratin 16 mRNA in the first skin sample.
- the level of IL-17A mRNA is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of IL-17A mRNA in the first skin sample.
- the level of IL-23 p19 mRNA is monitored, and the decrease is about 40% 45%, 50%, or 55% or more as compared to the level of IL-23 p19 mRNA in the first skin sample.
- the level of IL-10 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-10 mRNA in the first skin sample.
- the level of IFN- ⁇ mRNA is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of IFN- ⁇ mRNA in the first skin sample.
- the level of CXCL9 mRNA is monitored, and the decrease is about 20%, 25%, 30%, or 35% or more as compared to the level of CXCL9 mRNA in the first skin sample.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- these biomarkers can additionally be used to track or perform quality control on human research trials or to monitor the patient compliance to a drug regimen by providing a means to confirm that the patient is receiving specific drug treatments.
- These biomarkers can be used in connection with, for example, the management of patient treatment, clinical trials, and cell-based research.
- these biomarkers can be used to track patient compliance during individual treatment regimes, or during clinical trials.
- the levels of biomarkers can be followed at set intervals during a clinical trial to ensure that the patients included in the trial are taking the drugs as instructed.
- the treatment of individual patients can also be followed using the procedure. For example, when the level of a particular biomarker is measured, an altered level of the biomarker compared to that of an untreated control indicates at least partial patient compliance with the drug treatment protocol. An altered level of the biomarker that is at a similar quantity to that of a positive control indicates the likelihood of full compliance with the treatment protocol.
- a method for assessing patient compliance with a drug treatment protocol is provided.
- a biological sample is obtained from the patient, and the levels of the biomarkers are measured and compared to that of a control untreated sample.
- An altered levels of biomarkers compared to those of an untreated control sample indicates compliance with the protocol.
- a method for with a drug treatment protocol for psoriasis comprising:
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. By following the levels of these biomarkers, the patient compliance can be monitored over time.
- the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- the level of IL-12/IL-13 p40 mRNA is monitored, and the decrease is about 80%, 85% 90%, or 95% or more as compared to the level of IL-12/IL-13 p40 mRNA in the first skin sample.
- the level of iNOS mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of iNOS mRNA in the first biological sample.
- the level of IL-22 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-22 mRNA in the first skin sample.
- the level of IL-8 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-8 mRNA in the first skin sample.
- the level of DEFB4 mRNA is monitored, and the decrease is about 45%, 50%, 55%, or 60% or more as compared to the level of DEFB4 mRNA in the first skin sample.
- the level of MX-1 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of MX-1 mRNA in the first skin sample.
- the level of Keratin 16 mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of Keratin 16 mRNA in the first skin sample.
- the level of IL-17A mRNA is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of IL-17A mRNA in the first skin sample.
- the level of IL-23 p19 mRNA is monitored, and the decrease is about 40% 45%, 50%, or 55% or more as compared to the level of IL-23 p19 mRNA in the first skin sample.
- the level of IL-10 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-10 mRNA in the first skin sample.
- the level of IFN- ⁇ mRNA is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of IFN- ⁇ mRNA in the first skin sample.
- the level of CXCL9 mRNA is monitored, and the decrease is about 20%, 25%, 30%, or 35% or more as compared to the level of CXCL9 mRNA in the first skin sample.
- the treatment compound is a PDE4 inhibitor provided herein elsewhere.
- the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide.
- the treatment compound is cyclopropanecarboxylic acid ⁇ 2-[( 1S )-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H- isoindol-4-yl ⁇ -amide.
- the biomarkers provided herein may be used to predict or monitor the efficacy of treatment for psoriasis by a PDE4 modulator.
- PDE4 modulators described herein include racemic, stereomerically pure and stereomerically enriched PDE4 modulators, stereomerically and enantiomerically pure compounds that have selective cytokine inhibitory activities, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs thereof. Certain compounds described herein are known PDE4 modulators of Celgene Corporation, NJ.
- PDE 4 modulators encompasses small molecule drugs, e.g., small organic molecules which are not peptides, proteins, nucleic acids, oligosaccharides or other macromolecules. Preferred compounds inhibit TNF- ⁇ production. Compounds may also have a modest inhibitory effect on LPS induced IL1 ⁇ and IL12. More preferably, the compounds provided herein are potent PDE 4 inhibitors.
- PDE 4 modulators include, but are not limited to, the cyclic imides disclosed in U.S. patent nos. 5,605,914 and 5,463,063 ; the cycloalkyl amides and cycloalkyl nitriles of U.S. patent nos. 5,728,844 , 5,728,845 , 5,968,945 , 6,180,644 and 6,518,281 ; the aryl amides (for example N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)-propanamide) of U.S. patent nos.
- 6,667,316 for example, cyclopropyl-N- ⁇ 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl ⁇ carboxamide, cyclopropyl-N- ⁇ 2-[1(S)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl ⁇ carboxamide, and cyclopropyl-N- ⁇ 2-[1(R)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl ⁇ carboxamide; and imido and amido substituted acylhydroxamic acids (for example, (3-(1,3-dioxoisoindoline-2-yl)-3-o
- PDE 4 modulators include diphenylethylene compounds disclosed in U.S. patent publication no. 2005/0014727 .
- Other PDE 4 modulators include isoindoline compounds disclosed in U.S. patent publication nos. 2006/0025457 and 2006/0084815 .
- Other specific PDE 4 modulators include 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, and stereoisomers thereof.
- (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione was disclosed in WO 03/080049 .
- Additional PDE 4 modulators belong to a family of synthesized chemical compounds of which typical examples include 3-(1,3-dioxobenzo-[f]isoindol-2-yl)-3-(3-cyclopentyloxy-4-methoxyphenyl)propionamide and 3-(1,3-dioxo-4-azaisoindol-2-yl)-3-(3,4-dimethoxyphenyl)-propionamide.
- PDE4 modulators described herein contain one or more chiral centers, and can exist as racemic mixtures of enantiomers or mixtures of diastereomers.
- the methods and compositions herein encompass the use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms.
- mixtures comprising unequal amounts of the enantiomers of a particular PDE4 modulator may be used in methods and compositions provided herein.
- These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents.
- optically pure means a composition that comprises one optical isomer of a compound and is substantially free of other isomers of that compound.
- an optically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound.
- An optically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound.
- a typical optically pure compound comprises greater than about 80% by weight of one enantiomer of the compound and less than about 20% by weight of other enantiomers of the compound, greater than about 90% by weight of one enantiomer of the compound and less than about 10% by weight of the other enantiomers of the compound, greater than about 95% by weight of one enantiomer of the compound and less than about 5% by weight of the other enantiomers of the compound, greater than about 97% by weight of one enantiomer of the compound and less than about 3% by weight of the other enantiomers of the compound or greater than about 99% by weight of one enantiomer of the compound and less than about 1% by weight of the other enantiomers of the compound.
- Certain specific PDE4 modulators belong to a class of non-polypeptide cyclic amides disclosed in U.S. patent nos. 5,698,579 , 5,877,200 , 6,075,041 and 6,200,987 , and WO 95/01348 .
- Representative cyclic amides include compounds of the formula:
- PDE4 modulators include compounds of the formula: in which Z is: in which:
- PDE4 modulators include the imido and amido substituted alkanohydroxamic acids disclosed in WO 99/06041 and U.S. patent no. 6,214,857 . Examples of such compound include, but are not limited to: wherein:
- Additional specific PDE4 modulators provided herein include, but are not limited to:
- Additional PDE 4 modulators include the phenethylsulfones substituted on the phenethyl group with a oxoisoindoline group.
- Examples of such compounds include, but are not limited to, those disclosed in U.S. patent no. 6,020,358 , which include the following: wherein the carbon atom designated * constitutes a center of chirality;
- a further specific group of such compounds are those in which each of R 1 , R 2 , R 3 , and R 4 independently of the others, is hydrogen, halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or -NR 8 R 9 in which each of R 8 and R 9 taken independently of the other is hydrogen or methyl or one of R 8 and R 9 is hydrogen and the other is -COCH 3 .
- Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is -NH 2 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
- Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is-NHCOCH 3 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
- Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is-N(CH 3 ) 2 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
- a further preferred group of such compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is methyl and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
- Particular compounds are those in which one of R 1 , R 2 , R 3 , and R 4 is fluoro and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen.
- each of R 5 and R 6 independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.
- Particular compounds are those in which R 5 is methoxy and R 6 is monocycloalkoxy, polycycloalkoxy, and benzocycloalkoxy.
- Particular compounds are those in which R 5 is methoxy and R 6 is ethoxy.
- R 7 is hydroxy, methyl, ethyl, phenyl, benzyl, or NR 8' R 9' in which each of R 8' and R 9' taken independently of the other is hydrogen or methyl.
- R 7 is methyl, ethyl, phenyl, benzyl or NR 8' R 9' in which each of R 8' and R 9' taken independently of the other is hydrogen or methyl.
- Particular compounds are those in which R 7 is methyl.
- R 7 is NR 8' R 9' in which each of R 8' and R 9' taken independently of the other is hydrogen or methyl.
- Additional PDE4 modulators include fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds disclosed in U.S. patent publication no. 2004/0204448 .
- Representative compounds are of formula: wherein:
- Additional PDE4 modulators include the enantiomerically pure compounds disclosed in U.S. patent publication nos. 2003/0187052 , 2004/0167199 , and 2005/0014727 and international patent publication nos. WO 2003/080048 and WO 2003.080049 .
- the compound is an enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and an enantiomer of 3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide.
- PDE4 modulator is cyclopropanecarboxylic acid ⁇ 2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 H -isoindol-4-yl ⁇ -amide, available from Celgene Corp., Warren, NJ. 3-(3,4-Dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide has the following chemical structure:
- PDE4 modulators include, but are not limited to, the cycloalkyl amides and cycloalkyl nitriles disclosed in U.S. patent nos. 5,728,844 , 5,728,845 , 5,968,945 , 6,180,644 and 6,518,281 , and WO 97/08143 and WO 97/23457 .
- Representative compounds are of the formula: wherein:
- one of R 1 and R 2 is R 3 -X- and the other is hydrogen, nitro, cyano, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo, or R3-X-;
- R 3 is monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms;
- X is -CH 2 -, or -O-;
- R 5 is (i) the vicinally divalent residue of pyridine, pyrrolidine, imidazole, naphthalene, or thiophene, wherein the two bonds of the divalent residue are on vicinal ring carbon atoms;
- one of R 1 and R 2 is R 3 -X- and the other is hydrogen, nitro, cyano, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo, HF 2 CO, F 3 CO, or R 3 -X-;
- R 3 is monocycloalkyl, bicycloalkyl, benzocyclo alkyl of up to 18 carbon atoms, tetrahydropyran, or tetrahydrofuran;
- R 5 is (i) o-phenylene, unsubstituted or substituted with 1 to 3 substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbo(lower)alkoxy, acetyl, or carbam
- the PDE 4 modulators are of formula: wherein:
- PDE 4 modulators include, but are not limited to, the aryl amides (for example, an example being N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)-propanamide) disclosed in U.S. patent nos. 5,801,195 , 5,736,570 , 6,046,221 and 6,284,780 .
- Representative compounds are of formula: wherein:
- PDE 4 modulators include, but are not limited to, the imide/amide ethers and alcohols (for example, 3-phthalimido-3-(3',4'-dimethoxyphenyl) propan-1-ol) disclosed in U.S. patent no. 5,703,098 .
- Representative compounds have the formula: wherein:
- PDE 4 modulators include, but are not limited to, the succinimides and maleimides (for example methyl 3-(3',4',5'6'-petrahydrophthalimdo)-3-(3",4"-dimethoxyphenyl)propionate) disclosed in U.S. patent no. 5,658,940 .
- Representative compounds are of formula: wherein:
- PDE 4 modulators include, but are not limited to, substituted imides (for example, 2-phthalimido-3-(3',4'-dimethoxyphenyl) propane) disclosed in U.S. patent no. 6,429,221 .
- Representative compounds have the formula: wherein:
- PDE4 modulators include, but are not limited to, substituted 1,3,4-oxadiazoles (for example, 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazole-2-yl)ethyl]-5-methylisoindoline-1,3-dione) disclosed in U.S. patent no. 6,326,388 .
- Representative compounds are of formula: wherein:
- the PDE4 modulators are of formula: wherein:
- PDE4 modulators include, but are not limited to, cyano and carboxy derivatives of substituted styrenes (for example, 3,3-bis-(3,4-dimethoxyphenyl) acrylonitrile) disclosed in U.S. patent nos. 5,929,117 , 6,130,226 , 6,262,101 and 6,479,551 .
- Representative compounds are of formula: wherein:
- the PDE4 modulators are of formula: wherein:
- the PDE4 modulators are nitriles of the formula: wherein:
- PDE4 modulators include, but are not limited to, isoindoline-1-one and isoindoline-1,3-dione substituted in the 2-position with an ⁇ -(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group disclosed in WO 01/34606 and U.S. patent no. 6,667,316 .
- Representative compounds are of formula: or a pharmaceutically acceptable salt and stereoisomer thereof, wherein:
- z is not 0 when (i) R 3 is -SO 2 -Y, -COZ, or -CN and (ii) one of R 4 or R 5 is hydrogen.
- R 4 and R 5 are both structures of formula (A).
- Exemplary compounds are of formula: and the enantiomers thereof. Further exemplary compounds are of formulas: and
- Further examples include, but are not limited to: 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-dinitroisoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-diaminoisoindoline-1,3-dione; 7-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3 -pyrrolino [3,4-e]benzimidazole-6,8-dione; 7-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]hydro-3-pyrrolino[3,4-e]benzimidazole-2,6,8-trione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-
- Still other PDE 4 modulators include, but are not limited to, imido and amido substituted acylhydroxamic acids (for example, (3-(1,3-dioxoisoindoline-2-yl)-3-(3-ethoxy-4-methoxyphenyl) propanoylamino) propanoate disclosed in WO 01/45702 and U.S. patent no. 6,699,899 .
- Representative compounds are of formula: wherein:
- PDE 4 modulators include, but are not limited to, 7-amido-isoindolyl compounds disclosed in U.S. patent publication no. 2004/0254214 .
- Representative compounds are of formula: wherein:
- W is
- representative compounds are of formula: wherein: R 1 , R 2 and R 3 are independently H or C 1-8 -alkyl, with the proviso that at least one of R 1 , R 2 and R 3 is not H; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
- PDE 4 modulators include, but are not limited to, isoindoline compounds disclosed in U.S. patent publication no. 2006/0025457 . Representative compounds are listed in Table 1 below, for which pharmaceutically acceptable prodrugs, salts, solvates, and stereoisomers thereof are also encompassed: Table 1. No. Structure No. Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
- PDE 4 modulators include, but are not limited to, isoindoline compounds disclosed in U.S. patent publication no. 2006/0084815 .
- Representative compounds are cyclopropanecarboxylic acid ⁇ 2-[1-(3-ethoxy-4-methoxy-phenyl)-2-[1,3,4]oxadiazol-2-yl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl ⁇ -amide, which has the following chemical structure, and pharmaceutically acceptable salts, solvates, prodrugs, and stereoisomers thereof:
- PDE 4 modulators include, but are not limited to, N-alkyl-hydroxamic acid-isoindolyl compounds disclosed in U.S. patent publication no. 2004/0259873 .
- Representative compounds are of formula: wherein:
- PDE 4 modulators include, but are not limited to, diphenylethylene compounds disclosed in U.S. patent publication no. 2005/0014727 .
- Representative compounds are of formula: or a pharmaceutically acceptable salt, solvate, or hydrates thereof, wherein:
- representative compounds are of formula: or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein:
- compounds provided herein are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and cyclopropyl-N- ⁇ 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl ⁇ carboxamide, which respectively have the following structures: or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- stereoisomers of these compounds are also encompassed.
- optically pure compounds can be asymmetrically synthesized or resolved using known resolving agents or chiral columns as well as other standard synthetic organic chemistry techniques.
- Compounds used herein may be small organic molecules having a molecular weight less than about 1,000 g/mol, and are not proteins, peptides, oligonucleotides, oligosaccharides or other macromolecules.
- the PDE4 modulator is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide: or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
- the PDE4 modulator is cyclopropanecarboxylic acid ⁇ 2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl ⁇ -amide: or a pharmaceutically acceptable salt or solvate thereof.
- the biomarker to be detected is an mRNA molecule.
- the method of measuring gene or protein expression can involve methods such as cDNA hybridization, flow cytometry, immunofluorescence, immunoblots, ELISAs or microspotted-antibody immunofluorescence assays, an antibody-based dipstick assay, cytometric bead arrays, or other common mRNA or protein detecting methods.
- mRNA sequence can be used to prepare a probe that is at least partially complementary.
- the probe can then be used to detect the mRNA sequence in a sample, using any suitable assay, such as PCR-based methods, Northern blotting, a dipstick assay, and the like.
- a nucleic acid assay for testing for immunomodulatory activity in a biological sample can be prepared.
- An assay typically contains a solid support and at least one nucleic acid contacting the support, where the nucleic acid corresponds to at least a portion of an mRNA that has altered expression during an immunomodulatory treatment in a patient.
- the assay can also have a means for detecting the altered expression of the mRNA in the sample.
- the assay method can be varied depending on the type of mRNA information desired.
- Exemplary methods include but are not limited to Northern blots and PCR-based methods (e.g. , qRT-PCR). Methods such as qRT-PCR can also accurately quantitate the amount of the mRNA in a sample.
- an assay may be in the form of a dipstick, a membrane, a chip, a disk, a test strip, a filter, a microsphere, a slide, a multiwell plate, or an optical fiber.
- An assay system may have a solid support on which a nucleic acid corresponding to the mRNA is attached.
- the solid support may comprise, for example, a plastic, silicon, a metal, a resin, glass, a membrane, a particle, a precipitate, a gel, a polymer, a sheet, a sphere, a polysaccharide, a capillary, a film a plate, or a slide.
- the assay components can be prepared and packaged together as a kit for detecting an mRNA.
- the nucleic acid can be labeled, if desired, to make a population of labeled mRNAs.
- a sample can be labeled using methods that are well known in the art (e.g ., using DNA ligase, terminal transferase, or by labeling the RNA backbone, etc.; see, e.g., Ausubel, et al., Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons 1995 and Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, 2001 Cold Spring Harbor, N.Y .).
- the sample is labeled with fluorescent label.
- Exemplary fluorescent dyes include but are not limited to xanthene dyes, fluorescein dyes, rhodamine dyes, fluorescein isothiocyanate (FITC), 6 carboxyfluorescein (FAM), 6 carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6 carboxy 4', 5' dichloro 2', 7' dimethoxyfluorescein (JOE or J), N,N,N',N' tetramethyl 6 carboxyrhodamine (TAMRA or T), 6 carboxy X rhodamine (ROX or R), 5 carboxyrhodamine 6G (R6G5 or G5), 6 carboxyrhodamine 6G (R6G6 or G6), and rhodamine 110; cyanine dyes, e.g.
- Cy3, Cy5 and Cy7 dyes include Alexa dyes, e.g. Alexa-fluor-555; coumarin, Diethylaminocoumarin, umbelliferone; benzimide dyes, e.g. Hoechst 33258; phenanthridine dyes, e.g.
- Texas Red ethidium dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethine dyes, BODIPY dyes, quinoline dyes, Pyrene, Fluorescein Chlorotriazinyl, R110, Eosin, JOE, R6G, Tetramethylrhodamine, Lissamine, ROX, Napthofluorescein, and the like.
- the nucleic acids may be present in specific, addressable locations on a solid support; each corresponding to at least a portion of mRNA sequences that are differentially expressed upon treatment of an immunomodulatory compound in a cell or a patient.
- a typical mRNA assay method can contain the steps of 1) obtaining surface-bound subject probes; 2) hybridization of a population of mRNAs to the surface-bound probes under conditions sufficient to provide for specific binding (3) post-hybridization washes to remove nucleic acids not bound in the hybridization; and (4) detection of the hybridized mRNAs.
- the reagents used in each of these steps and their conditions for use may vary depending on the particular application.
- Hybridization can be carried out under suitable hybridization conditions, which may vary in stringency as desired. Typical conditions are sufficient to produce probe/target complexes on a solid surface between complementary binding members, i.e., between surface-bound subject probes and complementary mRNAs in a sample. In certain embodiments, stringent hybridization conditions may be employed.
- Hybridization is typically performed under stringent hybridization conditions.
- Standard hybridization techniques e.g. under conditions sufficient to provide for specific binding of target mRNAs in the sample to the probes
- Kallioniemi et al. Science 258:818-821 (1992 ) and WO 93/18186 .
- Several guides to general techniques are available, e.g., Tijssen, Hybridization with Nucleic Acid Probes, Parts I and II (Elsevier, Amsterdam 1993 ).
- For descriptions of techniques suitable for in situ hybridizations see Gall et al. Meth. Enzymol., 21:470-480 (1981 ); and Angerer et al.
- the surface bound polynucleotides are typically washed to remove unbound nucleic acids. Washing may be performed using any convenient washing protocol, where the washing conditions are typically stringent, as described above. The hybridization of the target mRNAs to the probes is then detected using standard techniques.
- PCR-based methods can also be used to follow the expression of the mRNA biomarkers.
- PCR methods can be found in the literature.
- examples of PCR assays can be found in U.S. Patent No. 6,927,024 .
- RT-PCR methods can be found in U.S. Patent No. 7,122,799 .
- a method of fluorescent in situ PCR is described in U.S. Patent No. 7,186,507 .
- qRT-PCR Real-Time Reverse Transcription-PCR
- RNA targets Bustin, et al., 2005, Clin. Sci., 109:365-379 .
- Quantitative results obtained by qRT-PCR are generally more informative than qualitative data.
- qRT-PCR-based assays can be useful to measure mRNA levels during cell-based assays.
- the qRT-PCR method is also useful to monitor patient therapy. Examples of qRT-PCR-based methods can be found, for example, in U.S. Patent No. 7,101,663 .
- real-time PCR In contrast to regular reverse transcriptase-PCR and analysis by agarose gels, real-time PCR gives quantitative results.
- An additional advantage of real-time PCR is the relative ease and convenience of use.
- Instruments for real-time PCR such as the Applied Biosystems 7500, are available commercially, as are the reagents, such as TaqMan Sequence Detection chemistry.
- TaqMan® Gene Expression Assays can be used, following the manufacturer's instructions.
- kits are pre-formulated gene expression assays for rapid, reliable detection and quantification of human, mouse and rat mRNA transcripts.
- An exemplary PCR program for example, is 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, then 60°C for 1 minute.
- the data can be analyzed, for example, using a 7500 Real-Time PCR System Sequence Detection software v1.3 using the comparative CT relative quantification calculation method. Using this method, the output is expressed as a fold-change of expression levels.
- the threshold level can be selected to be automatically determined by the software. In some embodiments, the threshold level is set to be above the baseline but sufficiently low to be within the exponential growth region of an amplification curve.
- biomarker is a protein
- protein detection and quantitation methods can be used to measure the presence of the biomarker. Any suitable protein quantitation method can be used.
- antibody-based methods are used. Exemplary methods that can be used include but are not limited to immunoblotting (western blot), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, cytometric bead array, mass spectroscopy, and the like.
- ELISA enzyme-linked immunosorbent assay
- Several types of ELISA are commonly used, including direct ELISA, indirect ELISA, and sandwich ELISA.
- kits for detecting the mRNA biomarkers can be prepared.
- the kits can include, for example, a probe or probe set comprising oligonucleotides that can bind to the mRNA biomarker(s) of interest for psoriasis. Washing solutions, reagents for performing a hybridization assay, mRNA isolation or purification means, detection means, as well as positive and negative controls can also be included.
- the kit can also include instructions for using the components of the kit.
- the kit can be tailored for in-home use, clinical use, or research use.
- kits for detecting protein levels can be prepared.
- the kits can include, for example, a dipstick coated with an antibody that recognizes the protein, washing solutions, reagents for performing the assay, protein isolation or purification means, detection means, as well as positive and negative controls.
- the kit can also include instructions for using the components of the kit.
- the kit can be tailored for in-home use, clinical use, or research use.
- Skin biopsies were evaluated on 20 patients in a clinical trial, where 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide was administered b.i.d. to patients with psoriasis. Skin biopsies were done 4 weeks and 12 weeks post-treatment.
- the biopsies were subjected to a histological analysis in which response was assessed in H&E stained sections of skin biopsies and after staining frozen sections of skin biopsies with antibodies to keratin 16, CD3, CD11c, ICAM-1, Langerin, CD56, Foxp3, and HLA-DR.
- This analysis thus included an assessment of epidermal growth/differentiation, skin infiltration by T-cells and DC subsets, presence of regulatory T-cells, and presence of inflammation-regulating molecules in skin lesions.
- Epidermal CD11c+ infiltrates were even more strongly reduced (73-84%) at weeks 4 and 12, respectively. Both sets of reductions were highly significant (0.001 or better). This may indicate that the treatment compound has stronger suppressive effects on myeloid leukocytes, compared to effects on T-cells.
- CD56+ cells NK cells or NK-T-cells
- NK cells or NK-T-cells were minimally altered during treatment, i.e., between week 4 and week 12.
- a small increase in epidermal Langerhan's cells was noted in day 85 biopsies, consistent with normalization of this cell population with effective therapy.
- ICAM-1 and HLA-DR inflammation-associated molecules
- ICAM-1 and HLA-DR were qualitative markers of inflammation, so the change has not been quantified and subjected to statistical analysis.
- mRNA abundance for a variety of inflammatory molecules was measured by real-time RT-PCR and expression was normalized to the house-keeping gene HARP (human acidic ribosomal protein).
- Inflammatory markers assessed by mRNA levels included the chemokine CXCL9, beta-defensin (DEFB4), interferon-gamma, IL-10, IL-17a, IL-22, IL-8, keratin 16, MX-1, IL-12/23 p40, IL-23 p19, iNOS and TNF. These are inflammatory molecules produced by activated DC populations, Th1, Th17, Th22 T-cells, and response genes to interferon (MX-1, CXCL9) or IL-17 (defensin). Keratin 16 was also measured by mRNA levels to assess the epidermal response by an alternate means.
- CD11c+ myeloid leukocytes showed more consistent reductions than T-cells in lesions.
- TNF-induced gene in CD11c+ DCs is the IL-12/23 p40 gene.
- Skin biopsies were evaluated on 20 patients in this trial.
- the biopsies were analyzed by immunohistochemistry for a set of cellular markers (keratin 16, CD3, CD11c, ICAM-1, Langerin, CD56, Foxp3, and HLA-DR) to assess epidermal growth/differentiation, skin infiltration by T-cells and dendritic cells (DC), presence of regulatory T-cells, and the presence of inflammation-regulating molecules in skin lesions.
- RT-PCR real-time polymerase chain reaction
- DEFB4 a defensin induced in keratinocytes by IL-17, was reduced by 55% in week 4 biopsies and by 82% in week 12 biopsies.
- IL-8 which is induced in keratinocytes by IL-17, was reduced by 76% in week 4 biopsies and by 66% in week 12 biopsies.
- the analysis may be set to designate PASI-75 response to be change in IFN ⁇ expression between -60% and -100%.
- the prediction accuracies were about 75% for PASI-75 response and 80% for non PASI-75 response, respectively. Therefore, monitoring a subject for a decrease in IFN- ⁇ expression in the skin or peripheral blood may provide a method of early prediction for eventual attainment of a beneficial clinical response.
- Another useful predictive marker may be the reduction in the amount of Langerin (a marker of Langerhans cells, or LC) in the dermis at week 4. Similar to the IFN ⁇ analysis, if the Langerin staining in the dermis is decreased by -70% to -100% at Week 4, it was predicted that the subject will have PASI-75 response; otherwise non PASI-75 response. As shown in FIG. 8 , among four subjects who had PASI-75 response at week 12, three showed Langerin change between -70% to -100% at week 4, indicating a 75% accuracy in this prediction model. In addition, nine out of the ten subjects who had non PASI-75 response at week 12 showed Langerin change less than 70% decrease, indicating a 90% accuracy.
- Langerin a marker of Langerhans cells, or LC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
- Provided herein is monitoring of specific biomarkers in samples obtained from skin biopsies before and during therapy for psoriasis. Also provided herein is monitoring of expression of one or more specific genes or proteins before and during the therapy.
- Psoriasis is a chronic autoimmune inflammatory skin disorder characterized by epidermal hyperproliferation of keratinocytes and endothelial cells, and inflammatory cell accumulation (e.g., activated T cells). Griffiths CE, J. Eur. Acad. Dermatol. Venereol. 2003, 17 Suppl 2:1-5; Creamer JD, et al., Clin. Exp. Dermatol. 1995, 20(1):6-9. Also, recent evidence suggests the involvement of natural killer (NK) and NK T cells in the pathogenesis of psoriasis as these cells produce interferon-gamma (IFN-γ) which has been shown to play a role in psoriasis keratinocyte proliferation. Bos JD, et al., Br. J. Dermatol. 2005, 152(6):1098-107.
- Clinically the main symptoms of psoriasis are gray or silvery flaky patches on the skin that are red and inflamed underneath. Central to the proposed pathogenic pathway are cytokines, chemokines and other inflammatory mediators produced by activated keratinocytes, dendritic cells, neutrophils, and NK T cells which are believed to induce both keratinocytes proliferation and lymphocyte migration. Creamer JD, et al., Clin. Exp. Dermatol. 1995, 20(1):6-9; Bos JD, et al., Br. J. Dermatol. 2005, 152(6):1098-107; Bowcock et al., Nat. Rev. Immunol. 2005, 5(9):699-71. Proinflammatory mediators shown to be elevated in the psoriasis skin lesions include, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-8, IL-12, IFN-γ, and inducible nitric oxide synthase (iNOS). LaDuca JR, et al., Dermatol. Clin. 2001, 19(4):617-35; Duan H, et al., J. Dermatol. Sci. 2001, 26(2):119-24; Gottlieb et al., J. Immunol. 2005, 175(4):2721-9. Furthermore, low expression levels of the anti-inflammatory cytokine IL-10 were observed in psoriasis lesions. Asadullah K, et al., Curr. Drug Targets Inflamm. Allergy. 2004, 3(2):185-92.
- Since the pathogenesis of psoriasis is reported to involve upregulation of at least TNF-α, IFN-γ, IL-6, IL-8 and IL-12 in addition to reductions in IL-10, it is thought that PDE4 inhibitors may provide therapeutic benefits in the treatment of psoriasis. A need exists for reliable biomarkers for psoriasis that can provide accurate assessment with regard to prognosis and efficacy of a particular treatment.
-
US 2008/234359 describes solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and methods of using the same for treating or preventing diseases ameliorated by PDE4 inhibition. Also certain biomarkers including CD11c, ICAM-1, HLA-DR, iNOS and K16 are described. - M.A. Lowes, Proceedings of the national academy of sciences, vol. 102, no.52, 27 December 2005, pages 19057-19062, describes that CD11c+ cells are a major cell type in psoriasis skin lesions, discussing expression of CD11c and iNOS at different time points of psoriasis treatment.
- Malaviya R. et al., Journal of the American academy of dermatology, vol. 55, , describes the efficacy of Etanercept in psoriasis treatment, including CD11c as a cell marker.
- De Meijere A., Angewandte Chemie, vol. 18, no. 11, November 1979, pages 809-826, is a text book excerpt describing the bonding properties of cyclopropane and their chemical consequences.
- Anand B S et al., Current eye research, IRL Press, Oxford GB, vol. 26, no. 3-04, 1 March 2003, pages 151-163 concerns an analysis of dipeptide prodrugs in antiviral treatment.
-
US 2009/239926 describes methods for treating psoriasis and psoriatic arthritis involving administration of cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide as well as pharmaceutical compositions and single unit dose forms. - Described herein are biomarkers for predicting or monitoring the efficacy of a treatment for psoriasis.
- In one embodiment, provided herein is a method of predicting or monitoring the efficacy of a psoriasis treatment by measuring the level of one or more specific biomarkers in cells obtained from patients before or during the treatment. In one embodiment, the cells are obtained by skin biopsies. In another embodiment, the biomarkers include, CD11c, CD3, CD56, Langerin, and/or Foxp3. In one embodiment, the treatment is administration of a PDE4 modulator provided herein elsewhere.
- In another embodiment, provided herein is the use of specific mRNAs as biomarkers to predict or ascertain the efficacy and progress of a treatment for psoriasis. In one embodiment, the mRNA levels of Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ and/or CXCL9 can be used to predict whether a treatment is likely to be successful in treating psoriasis. Further, the expression of these genes can be used to monitor efficacy/progress of the treatment once the treatment begins. In one embodiment, the treatment is administration of a PDE4 modulator provided herein elsewhere.
- In yet another embodiment, a method for monitoring patient compliance with a drug treatment protocol is provided. The method comprises measuring the expression level of at least one biomarker provided herein in a sample from the patient, and determining if the expression level is increased or decreased in the patient sample compared to the expression level in a control untreated sample, wherein an increased or decreased expression indicates patient compliance with the drug treatment protocol.
- Also described is a useful for predicting the likelihood of an effective treatment of psoriasis. The kit comprises a solid support, nucleic acids contacting the support, where the nucleic acids are complementary to at least 20, 50, 100, 200, 350, or more bases of an mRNA biomarker provided herein, and a means for detecting the expression of the mRNA in a biological sample.
- Such a kit can employ, for example a dipstick, a membrane, a chip, a disk, a test strip, a filter, a microsphere, a slide, a multiwell plate, or an optical fiber. The solid support of the kit can be, for example, a plastic, silicon, a metal, a resin, glass, a membrane, a particle, a precipitate, a gel, a polymer, a sheet, a sphere, a polysaccharide, a capillary, a film, a plate, or a slide. The biological sample can be, for example, a cell culture, a cell line, a tissue, an oral tissue, gastrointestinal tissue, an organ, an organelle, a biological fluid, a blood sample, a urine sample, or a skin sample. The biological sample can be, for example, a skin biopsy.
- The methods provided herein are based, in part, on the discovery that the presence and level of certain molecules or mRNAs in cell samples can be utilized as biomarkers to indicate the effectiveness or progress of a treatment for psoriasis. In particular, these biomarkers can be used to predict, assess and track the effectiveness of patient treatment or to monitor the patient's compliance to the treatment regimen.
-
-
FIG. 1 illustrates change in epidermal cells (CD11+ dendritic cells; CD3+ T cells; CD56+ NK cells; and Langerhans cells) at 4 weeks and 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.). -
FIG. 2 illustrates change in epidermal cells (CD11+ dendritic cells; CD3+ T cells; CD56+ NK cells; and Langerhans cells) at 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.) in responders and non-responders. -
FIG. 3 illustrates change in dermal cells (CD11+ dendritic cells; CD3+ T cells; CD56+ NK cells; and Langerhans cells) at 4 weeks and 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.). -
FIG. 4 illustrates change in dermal cells (CD11+ dendritic cells; CD3+ T cells; CD56+ NK cells; and Langerhans cells) at 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.) in responders and non-responders. -
FIG. 5 illustrates change in gene expression proinflammatory gene products associated with pathogenesis of psoriasis (IL-12/23 p40; iNOS; IL-22; IL-8; DEFB4; MX1; Keratin 16; IL-17A; IL-23 p19; IL-10; IFNγ; MIG; TNFα; and IL-2) at 4 weeks and 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.). -
FIG. 6 illustrates change in gene expression proinflammatory gene products associated with pathogenesis of psoriasis (IL-12/23 p40; iNOS; IL-22; IL-8; DEFB4; MX1; Keratin 16; IL-17A; IL-23 p19; IL-10; IFNγ; MIG; TNFα; and IL-2) at 12 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.) in responders and non-responders. -
FIG. 7 illustrates the correlation between change in IFNγ gene expression in psoriasis lesional skin at 4 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.) and PASI score at 12 weeks after the administration of 20 mg of the same compound twice daily (b.i.d.). -
FIG. 8 illustrates the correlation between change in Langerin staining in psoriasis lesional skin at 4 weeks after the administration of 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide twice daily (b.i.d.) and PASI score at 12 weeks after the administration of 20 mg of the same compound twice daily (b.i.d.). - As used herein, and unless otherwise specified, the terms "treat," "treating" and "treatment" refer to an action that occurs while a patient is suffering from psoriasis, which reduces the severity of psoriasis, or retards or slows the progression of the cancer.
- The term "sensitivity" and "sensitive" when made in reference to treatment is a relative term which refers to the degree of effectiveness of a treatment compound in lessening or decreasing the symptoms of the disease being treated. For example, the term "increased sensitivity" when used in reference to treatment of a cell or patient refers to an increase of, at least a 5%, or more, in the effectiveness in lessening or decreasing the symptoms of psoriasis when measured using any methods well-accepted in the art.
- As used herein, and unless otherwise specified, the term "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of psoriasis, or to delay or minimize one or more symptoms associated with psoriasis. A therapeutically effective amount of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of psoriasis. The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of psoriasis, or enhances the therapeutic efficacy of another therapeutic agent.
- As used herein, an "effective patient response" refers to any increase in the therapeutic benefit to the patient. An "effective patient tumor response" can be, for example, a 5%, 10%, 25%, 50%, or 100% decrease in the physical symptoms of psoriasis.
- The term "likelihood" generally refers to an increase in the probability of an event. The term "likelihood" when used in reference to the effectiveness of a patient response generally contemplates an increased probability that the symptoms of psoriasis will be lessened or decreased.
- The term "predict" generally means to determine or tell in advance. When used to "predict" the effectiveness of a psoriasis treatment, for example, the term "predict" can mean that the likelihood of the outcome of the treatment can be determined at the outset, before the treatment has begun, or before the treatment period has progressed substantially.
- The term "monitor," as used herein, generally refers to the overseeing, supervision, regulation, watching, tracking, or surveillance of an activity. For example, the term "monitoring the efficacy of a treatment for psoriasis" refers to tracking the effectiveness in treating psoriasis in a patient or in a cell, usually obtained from a patient. Similarly, the term "monitoring," when used in connection with patient compliance, either individually, or in a clinical trial, refers to the tracking or confirming that the patient is actually following the treatment regimen being tested as prescribed.
- As used herein the terms "polypeptide" and "protein" as used interchangeably herein, refer to a polymer of amino acids of three or more amino acids in a serial array, linked through peptide bonds. The term "polypeptide" includes proteins, protein fragments, protein analogues, oligopeptides and the like. The term polypeptide as used herein can also refer to a peptide. The amino acids making up the polypeptide may be naturally derived, or may be synthetic. The polypeptide can be purified from a biological sample.
- The term "antibody" is used herein in the broadest sense and covers fully assembled antibodies, antibody fragments which retain the ability to specifically bind to the antigen (e.g., Fab, F(ab')2, Fv, and other fragments), single chain antibodies, diabodies, antibody chimeras, hybrid antibodies, bispecific antibodies, humanized antibodies, and the like. The term "antibody" covers both polyclonal and monoclonal antibodies.
- The term "expressed" or "expression" as used herein refers to the transcription from a gene to give an RNA nucleic acid molecule at least complementary in part to a region of one of the two nucleic acid strands of the gene. The term "expressed" or "expression" as used herein also refers to the translation from the RNA molecule to give a protein, a polypeptide or a portion thereof.
- An mRNA that is "upregulated" is generally "increased" upon a given treatment or condition. An mRNA that is "downregulated" generally refers to a "decrease" in the level of expression of the mRNA in response to a given treatment or condition. In some situations, the mRNA level can remain unchanged upon a given treatment or condition. An mRNA from a patient sample can be "upregulated," i.e., the level of mRNA can be increased, for example, by about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 500%, 1,000%, 5,000% or more of the comparative control mRNA level. Alternatively, an mRNA can be "downregulated," i.e., the level of mRNA level can be decreased, for example, by about 99%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 1% or less of the comparative control mRNA level.
- Similarly, the level of a polypeptide or protein biomarker from a patient sample can be increased as compared to a non-treated control. This increase can be about 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 90%, 100%, 200%, 300%, 500%, 1,000%, 5,000% or more of the comparative control protein level. Alternatively, the level of a protein biomarker can be decreased. This decrease can be, for example, present at a level of about 99%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 1% or less of the comparative control protein level.
- The term "PDE4 modulators" refers to a molecule or compound that inhibits PDE4. In one embodiment, the PDE4 modulators can be those available from Celgene Corporation (provided herein elsewhere), which potently inhibit TNF-α production, but exhibit modest inhibitory effects on LPS induced IL-1β and IL-12, and do not inhibit IL-6 even at high drug concentrations. In addition, PDE4 inhibitors tend to produce a modest IL-10 stimulation. L.G. Corral, et al., Ann. Rheum. Dis., 58:(Suppl I) 1107-1113 (1999).
- The terms "determining", "measuring", "evaluating", "assessing" and "assaying" as used herein generally refer to any form of measurement, and include determining if an element is present or not. These terms include both quantitative and/or qualitative determinations. Assessing may be relative or absolute. "Assessing the presence of' can include determining the amount of something present, as well as determining whether it is present or absent.
- The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to describe a polymer of any length composed of nucleotides, e.g., deoxyribonucleotides or ribonucleotides, or compounds produced synthetically, which can hybridize with naturally occurring nucleic acids in a sequence specific manner analogous to that of two naturally occurring nucleic acids, e.g., can participate in Watson-Crick base pairing interactions. As used herein in the context of a polynucleotide sequence, the term "bases" (or "base") is synonymous with "nucleotides" (or "nucleotide"), i.e., the monomer subunit of a polynucleotide. The terms "nucleoside" and "nucleotide" are intended to include those moieties that contain not only the known purine and pyrimidine bases, but also other heterocyclic bases that have been modified. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, alkylated riboses or other heterocycles. In addition, the terms "nucleoside" and "nucleotide" include those moieties that contain not only conventional ribose and deoxyribose sugars, but other sugars as well. Modified nucleosides or nucleotides also include modifications on the sugar moiety, e.g., wherein one or more of the hydroxyl groups are replaced with halogen atoms or aliphatic groups, or are functionalized as ethers, amines, or the like. "Analogues" refer to molecules having structural features that are recognized in the literature as being mimetics, derivatives, having analogous structures, or other like terms, and include, for example, polynucleotides incorporating non-natural nucleotides, nucleotide mimetics such as 2'-modified nucleosides, peptide nucleic acids, oligomeric nucleoside phosphonates, and any polynucleotide that has added substituent groups, such as protecting groups or linking moieties.
- The term "complementary" refers to specific binding between polynucleotides based on the sequences of the polynucleotides. As used herein, a first polynucleotide and a second polynucleotide are complementary if they bind to each other in a hybridization assay under stringent conditions, e.g. if they produce a given or detectable level of signal in a hybridization assay. Portions of polynucleotides are complementary to each other if they follow conventional base-pairing rules, e.g. A pairs with T (or U) and G pairs with C, although small regions (e.g. less than about 3 bases) of mismatch, insertion, or deleted sequence may be present.
- "Sequence identity" or "identity" in the context of two nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence over a specified comparison window, and can take into consideration additions, deletions and substitutions.
- The term "substantial identity" or "homologous" in their various grammatical forms in the context of polynucleotides generally means that a polynucleotide comprises a sequence that has a desired identity, for example, at least 60% identity, preferably at least 70% sequence identity, more preferably at least 80%, still more preferably at least 90% and even more preferably at least 95%, compared to a reference sequence. Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions.
- As used herein, the term "bound" can be used herein to indicate direct or indirect attachment. In the context of chemical structures, "bound" (or "bonded") may refer to the existence of a chemical bond directly joining two moieties or indirectly joining two moieties (e.g., via a linking group or any other intervening portion of the molecule). The chemical bond may be a covalent bond, an ionic bond, a coordination complex, hydrogen bonding, van der Waals interactions, or hydrophobic stacking, or may exhibit characteristics of multiple types of chemical bonds. In certain instances, "bound" includes embodiments where the attachment is direct and also embodiments where the attachment is indirect.
- The terms "isolated" and "purified" refer to isolation of a substance (such as mRNA or protein) such that the substance comprises a substantial portion of the sample in which it resides, i.e., greater than the substance is typically found in its natural or un-isolated state. Typically, a substantial portion of the sample comprises, e.g., greater than 1%, greater than 2%, greater than 5%, greater than 10%, greater than 20%, greater than 50%, or more, usually up to about 90%-100% of the sample. For example, a sample of isolated mRNA can typically comprise at least about 1% total mRNA. Techniques for purifying polynucleotides are well known in the art and include, for example, gel electrophoresis, ion-exchange chromatography, affinity chromatography, flow sorting, and sedimentation according to density.
- The term "sample" as used herein relates to a material or mixture of materials, typically, although not necessarily, in fluid form, containing one or more components of interest.
- "Biological sample" as used herein refers to a sample obtained from a biological subject, including sample of biological tissue or fluid origin, obtained, reached, or collected in vivo or in situ. A biological sample also includes samples from a region of a biological subject containing precancerous or cancer cells or tissues. Such samples can be, but are not limited to, organs, tissues, fractions and cells isolated from a mammal. Exemplary biological samples include but are not limited to cell lysate, a cell culture, a cell line, a tissue, oral tissue, gastrointestinal tissue, an organ, an organelle, a biological fluid, a blood sample, a urine sample, a skin sample, and the like. Preferred biological samples include but are not limited to whole blood, partially purified blood, PBMCs, tissue biopsies, and the like.
- The term "analyte" as used herein, refers to a known or unknown component of a sample.
- The term "capture agent," as used herein, refers to an agent that binds an mRNA or protein through an interaction that is sufficient to permit the agent to bind and concentrate the mRNA or protein from a homogeneous mixture.
- The term "probe" as used herein, refers to a capture agent that is directed to a specific target mRNA biomarker sequence. Accordingly, each probe of a probe set has a respective target mRNA biomarker. A probe/target mRNA duplex is a structure formed by hybridizing a probe to its target mRNA biomarker.
- The term "nucleic acid" or "oligonucleotide probe" refers to a nucleic acid capable of binding to a target nucleic acid of complementary sequence, such as the mRNA biomarkers provided herein, through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (e.g., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. It will be understood by one of skill in the art that probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled with isotopes, for example, chromophores, lumiphores, chromogens, or indirectly labeled with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of a target mRNA biomarker of interest.
- The term "stringent assay conditions" refers to conditions that are compatible to produce binding pairs of nucleic acids, e.g., probes and target mRNAs, of sufficient complementarity to provide for the desired level of specificity in the assay while being generally incompatible to the formation of binding pairs between binding members of insufficient complementarity to provide for the desired specificity. The term "stringent assay conditions"generally refers to the combination of hybridization and wash conditions.
- A "label" or a "detectable moiety" in reference to a nucleic acid, refers to a composition that, when linked with a nucleic acid, renders the nucleic acid detectable, for example, by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. Exemplary labels include, but are not limited to, radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, enzymes, biotin, digoxigenin, haptens, and the like. A "labeled nucleic acid or oligonucleotide probe" is generally one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic bonds, van der Waals forces, electrostatic attractions, hydrophobic interactions, or hydrogen bonds, to a label such that the presence of the nucleic acid or probe can be detected by detecting the presence of the label bound to the nucleic acid or probe.
- The terms "polymerase chain reaction," or "PCR," as used herein generally refers to a procedure wherein small amounts of a nucleic acid, RNA and/or DNA, are amplified as described, for example, in
U.S. Pat. No. 4,683,195 to Mullis . Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51: 263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). - The term "cycle number" or "CT" when used herein in reference to PCR methods, refers to the PCR cycle number at which the fluorescence level passes a given set threshold level. The CT measurement can be used, for example, to approximate levels of mRNA in an original sample. The CT measurement is often used in terms of "dCT" or the "difference in the CT" score, when the CT of one nucleic acid is subtracted from the CT of another nucleic acid.
- As used herein, and unless otherwise indicated, the term "optically pure" means a composition that comprises one optical isomer of a compound and is substantially free of other isomers of that compound. For example, an optically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound. An optically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical optically pure compound comprises greater than about 80% by weight of one enantiomer of the compound and less than about 20% by weight of other enantiomers of the compound, more preferably greater than about 90% by weight of one enantiomer of the compound and less than about 10% by weight of the other enantiomers of the compound, even more preferably greater than about 95% by weight of one enantiomer of the compound and less than about 5% by weight of the other enantiomers of the compound, more preferably greater than about 97% by weight of one enantiomer of the compound and less than about 3% by weight of the other enantiomers of the compound, and most preferably greater than about 99% by weight of one enantiomer of the compound and less than about 1% by weight of the other enantiomers of the compound.
- The practice of the embodiments provided herein will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, and immunology, which are within the skill of those working in the art. Such techniques are explained fully in the literature. Examples of particularly suitable texts for consultation include the following: Sambrook et al. (1989) Molecular Cloning; A Laboratory Manual (2d ed.); D.N Glover, ed. (1985) DNA Cloning, Volumes I and II; M.J. Gait, ed. (1984) Oligonucleotide Synthesis ; B.D. Hames & SJ. Higgins, eds. (1984) Nucleic Acid Hybridization; B.D. Hames & S.J. Higgins, eds. (1984) Transcription and Translation ; R.I. Freshney, ed. (1986) Animal Cell Culture; Immobilized Cells and Enzymes (IRL Press, 1986); Immunochemical Methods in Cell and Molecular Biology (Academic Press, London); Scopes (1987) Protein Purification: Principles and Practice (2d ed.; Springer Verlag, N.Y.); and D.M. Weir and C. C. Blackwell, eds. (1986) Handbook of Experimental Immunology, Volumes I-IV.
- Provided herein are methods relating to the use of cell marker molecules and mRNAs as biomarkers to predict or ascertain the efficacy of a treatment for psoriasis. Cell markers or mRNA levels can be used to determine whether a treatment is likely to be successful in cell models of disease.
- A biological marker or "biomarker" is a substance whose detection indicates a particular biological state, such as, for example, the progress of psoriasis. In some embodiments, biomarkers can either be determined individually, or several biomarkers can be measured simultaneously.
- In some embodiments, a "biomarker" indicates a change in the level of nucleic acid expression that may correlate with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment. In some embodiments, the biomarker is a mRNA or cDNA.
- In additional embodiments, a "biomarker" indicates a change in the level of certain cell markers that may correlate with the risk, susceptibility to treatment, or progression of a disease. The relative level of specific cell markers can be determined by methods known in the art. For example, antibody based methods, such as an immunoblot, enzyme-linked immunosorbent assay (ELISA), or other methods can be used.
- Based, in part, on the finding that detectable increase or decrease in certain cell markers are observed during the psoriasis treatment, the levels of these cell markers may be used as a biomarker for predicting the sensitivity of a potential psoriasis treatment. The cell markers include CD3, CD56, Langerin and Foxp3. Each of these biomarkers may be monitored separately, or two or more of the biomarkers may be simultaneously monitored.
- In some embodiments, these biomarkers can be used to predict the effectiveness of a psoriasis treatment in a patient. In one embodiment, the level of the biomarker is measured in a biological sample obtained from a potential patient. Alternatively, the cell markers can also be used as a biomarker for an in vitro assay to predict the success of a psoriasis treatment, by taking a sample of cells from the patient, culturing them in the presence or absence of the treatment compound, and testing the cells for an increase or decrease in the levels of the biomarkers.
- Thus, in one embodiment, provided herein is a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- culturing cells from a skin sample of the patient in the presence or absence of the treatment compound;
- measuring the level of a cell marker selected from CD3, CD56, Foxp3 and a combination thereof; and
- comparing the level of the cell marker in the cells cultured in the presence of the treatment compound to that in cells cultured in the absence of the treatment compound;
- In one embodiment, the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- In one described aspect, the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- In one embodiment, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.
- In another aspect, described herein is a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- culturing the cells from the epidermis region of the patient the presence or absence of the treatment compound;
- measuring the level of Langerin in the cells; and
- comparing the level of Langerin in the cells cultured in the presence of the treatment compound to that in cells cultured in the absence of the treatment compound;
- In one described aspect, the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In addition to the initial prediction of the likelihood of treatment effectiveness in a patient with psoriasis, the progress of a psoriasis treatment can be followed by monitoring the levels of the cell markers described above. Thus, in some embodiments, a method of assessing or monitoring the effectiveness of a psoriasis treatment in a patient is provided. A sample is obtained from the patient, and the levels of one or more of the above-described biomarkers are measured to determine whether their levels are increased or decreased compared to the levels prior to the initiation of the treatment.
- The biomarkers can also be used to track and adjust individual patient treatment effectiveness. The biomarkers can be used to gather information needed to make adjustments in a patient's treatment, increasing or decreasing the dose of an agent as needed. For example, a patient receiving a treatment compound can be tested using a biomarker to see if the dosage is becoming effective, or if a more aggressive treatment plan may be needed.
- In one embodiment, provided herein is a method of monitoring patient response to a psoriasis treatment comprising:
- measuring the level of a cell marker selected from CD3, CD56, Foxp3, Langerin and a combination thereof, in a first skin sample from the patient,
- measuring the level of a cell marker selected from CD3, CD56, Foxp3, Langerin and a combination thereof, in a second skin sample obtained after administering a treatment compound to the patient; and
- comparing the levels of the cell marker obtained from first and second skin samples;
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one embodiment, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- In one embodiment, the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- In one described aspect, the level of CD11c obtained from the dermis region is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of CD11c in the first biological sample. In another described aspect the level of CD11c obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD11c in the first biological sample.
- In one embodiment, the level of CD3 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD3 in the first skin sample. In another embodiment, the level of CD3 obtained from the epidermis region is monitored, and the decrease is about 25%, 30%, 35%, or 40% or more as compared to the level of CD3 in the first skin sample.
- In one embodiment, the level of CD56 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD56 in the first skin sample. In another embodiment, the level of CD56 obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD56 in the first skin sample.
- In one embodiment, the level of Langerin obtained from the dermis region is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of Langerin in the first skin sample.
- In one described aspect, the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- In one described aspect, the treatment compound is a provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In another embodiment, provided herein is a method of to a psoriasis treatment comprising:
- measuring the level of Langerin in a first skin sample from the epidermis region of the patient,
- measuring the level of Langerin in a second skin sample obtained from the epidermis region of the patient after administering a treatment compound to the patient, and
- comparing the levels of Langerin obtained from first and second skin samples;
- In one embodiment, the decrease in the level of Langerin is amount 5%, 10%, 15%, or 20% as compared to the level of Langerin in the first skin sample.
- Again, patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one embodiment, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time. In one embodiment, the sample cells from patient are obtained using a skin biopsy.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In other embodiments, these biomarkers can additionally be used to track or perform quality control on human research trials or to monitor the patient compliance to a drug regimen by providing a means to confirm that the patient is receiving specific drug treatments. These biomarkers can be used in connection with, for example, the management of patient treatment, clinical trials, and cell-based research.
- In one embodiment, these biomarkers can be used to track patient compliance during individual treatment regimes, or during clinical trials. For example, the levels of biomarkers can be followed at set intervals during a clinical trial to ensure that the patients included in the trial are taking the drugs as instructed. The treatment of individual patients can also be followed using the procedure. For example, when the level of a particular biomarker is measured, an altered level of the biomarker compared to that of an untreated control indicates at least partial patient compliance with the drug treatment protocol. An altered level of the biomarker that is at a similar quantity to that of a positive control indicates the likelihood of full compliance with the treatment protocol.
- Thus, in some embodiments, a method for assessing patient compliance with a drug treatment protocol is provided. A biological sample is obtained from the patient, and the levels of the biomarkers are measured and compared to that of a control untreated sample. An altered levels of biomarkers compared to those of an untreated control sample indicates compliance with the protocol.
- In one embodiment, provided herein is a method for monitoring patient compliance with a drug treatment protocol for psoriasis, comprising:
- measuring the level of a cell marker selected from CD3, CD56, Foxp3, Langerin and a combination thereof, in a skin sample from the patient, and
- determining if the expression level is decreased in the skin sample compared to the expression level in a control untreated sample;
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. By following the levels of these biomarkers, the patient compliance can be monitored over time.
- In one embodiment, the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- In one described aspect, the level of CD11c obtained from the dermis region is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of CD11c in the first biological sample. In another described aspect, the level of CD11c obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD11c in the first biological sample.
- In one embodiment, the level of CD3 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD3 in the first skin sample. In another embodiment, the level of CD3 obtained from the epidermis region is monitored, and the decrease is about 25%, 30%, 35%, or 40% or more as compared to the level of CD3 in the first skin sample.
- In one embodiment, the level of CD56 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD56 in the first skin sample. In another embodiment, the level of CD56 obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD56 in the first skin sample.
- In one embodiment, the level of Langerin obtained from the dermis region is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of Langerin in the first skin sample.
- In one described aspect, the sample cells from patient are obtained using a skin biopsy. In one described aspect, the sample cells from patient are obtained from the dermis region of the patient. In another described aspect, the sample cells from patient are obtained from the epidermis region of the patient.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In another embodiment, provided herein is a method for with a drug treatment protocol for psoriasis, comprising:
- measuring the level of Langerin in a skin sample from the epidermis region of said patient, and
- determining if the expression level is decreased in the skin sample compared to the expression level in a control untreated sample;
- In one described aspect, the decrease in the level of Langerin is amount 5%, 10%, 15%, or 20% as compared to the level of Langerin in the first skin sample.
- Again, patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one described aspect, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time. In one described aspect, the sample cells from patient are obtained using a skin biopsy.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.
- Based, in part, on the finding that detectable decrease in certain mRNAs are observed during the psoriasis treatment, the levels of these mRNAs may be used as a biomarker for predicting the sensitivity of a potential psoriasis treatment. The mRNAs include, but are not limited to, mRNAs for Keratin 16, iNOS, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ and/or CXCL9. Each of these biomarkers may be monitored separately, or two or more of the biomarkers may be simultaneously monitored.
- In some embodiments, these biomarkers can be used to predict the effectiveness of a psoriasis treatment in a patient. In one embodiment, the level of the biomarker is measured in a biological sample obtained from a potential patient. Alternatively, the cell markers can also be used as a biomarker for an in vitro assay to predict the success of a psoriasis treatment, by taking a sample of cells from the patient, culturing them in the presence or absence of the treatment compound, and testing the cells for an increase or decrease in the levels of the biomarkers.
- Thus, in one embodiment, provided herein is a method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:
- culturing cells from a skin sample of the patient in the presence or absence of the treatment compound;
- measuring the level of an mRNA selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof; and
- comparing the level of the mRNA in the cells cultured in the presence of the treatment compound to that in cells cultured in the absence of the treatment compound;
- In one embodiment, the level of only one of the mRNA is monitored. In another embodiment, the levels of two or more of the mRNAs are monitored simultaneously.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide.
- In addition to the initial prediction of the likelihood of treatment effectiveness in a patient with psoriasis, the progress of a psoriasis treatment can be followed by monitoring the levels of the mRNAs described above. Thus, in some embodiments, a method of assessing or monitoring the effectiveness of a psoriasis treatment in a patient is provided. A sample is obtained from the patient, and the levels of one or more of the above-described mRNAs are measured to determine whether their levels are increased or decreased compared to the levels prior to the initiation of the treatment.
- The biomarkers can also be used to track and adjust individual patient treatment effectiveness. The biomarkers can be used to gather information needed to make adjustments in a patient's treatment, increasing or decreasing the dose of an agent as needed. For example, a patient receiving a treatment compound can be tested using a biomarker to see if the dosage is becoming effective, or if a more aggressive treatment plan may be needed.
- In one embodiment, provided herein is a method of monitoring patient response to a psoriasis treatment comprising:
- measuring the level of an mRNA selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof, in a first skin sample from the patient,
- measuring the level of an mRNA selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof, in a second skin sample obtained after administering a treatment compound to the patient, and
- comparing the levels of the mRNA obtained from first and second skin samples;
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. In one embodiment, the tests are conducted once in 4 weeks after the treatment and once in 12 weeks after the treatment. By following the levels of these biomarkers, the treatment effectiveness can be monitored over time.
- In one embodiment, the level of only one of the mRNA is monitored. In another embodiment, the levels of two or more of the mRNAs are monitored simultaneously.
- In one embodiment, the level of IL-12/IL-13 p40 mRNA is monitored, and the decrease is about 80%, 85% 90%, or 95% or more as compared to the level of IL-12/IL-13 p40 mRNA in the first skin sample.
- In another described aspect, the level of iNOS mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of iNOS mRNA in the first biological sample.
- In one embodiment, the level of IL-22 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-22 mRNA in the first skin sample.
- In another embodiment, the level of IL-8 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-8 mRNA in the first skin sample.
- In one embodiment, the level of DEFB4 mRNA is monitored, and the decrease is about 45%, 50%, 55%, or 60% or more as compared to the level of DEFB4 mRNA in the first skin sample.
- In another embodiment, the level of MX-1 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of MX-1 mRNA in the first skin sample.
- In one embodiment, the level of Keratin 16 mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of Keratin 16 mRNA in the first skin sample.
- In one embodiment, the level of IL-17A mRNA is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of IL-17A mRNA in the first skin sample.
- In one embodiment, the level of IL-23 p19 mRNA is monitored, and the decrease is about 40% 45%, 50%, or 55% or more as compared to the level of IL-23 p19 mRNA in the first skin sample.
- In one embodiment, the level of IL-10 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-10 mRNA in the first skin sample.
- In one embodiment, the level of IFN-γ mRNA is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of IFN-γ mRNA in the first skin sample.
- In one embodiment, the level of CXCL9 mRNA is monitored, and the decrease is about 20%, 25%, 30%, or 35% or more as compared to the level of CXCL9 mRNA in the first skin sample.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In other embodiments, these biomarkers can additionally be used to track or perform quality control on human research trials or to monitor the patient compliance to a drug regimen by providing a means to confirm that the patient is receiving specific drug treatments. These biomarkers can be used in connection with, for example, the management of patient treatment, clinical trials, and cell-based research.
- In one embodiment, these biomarkers can be used to track patient compliance during individual treatment regimes, or during clinical trials. For example, the levels of biomarkers can be followed at set intervals during a clinical trial to ensure that the patients included in the trial are taking the drugs as instructed. The treatment of individual patients can also be followed using the procedure. For example, when the level of a particular biomarker is measured, an altered level of the biomarker compared to that of an untreated control indicates at least partial patient compliance with the drug treatment protocol. An altered level of the biomarker that is at a similar quantity to that of a positive control indicates the likelihood of full compliance with the treatment protocol.
- Thus, in some embodiments, a method for assessing patient compliance with a drug treatment protocol is provided. A biological sample is obtained from the patient, and the levels of the biomarkers are measured and compared to that of a control untreated sample. An altered levels of biomarkers compared to those of an untreated control sample indicates compliance with the protocol.
- In one embodiment, provided herein is a method for with a drug treatment protocol for psoriasis, comprising:
- measuring the level of an mRNA selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof, in a skin sample from the patient and
- determining if the expression level is decreased in the skin sample compared to the expression level in a control untreated sample;
- Patients can submit the cell sample by any desired means, such as, for example, a skin biopsy. Samples can be taken, for example, every day, once per week, twice per month, once a month, once every two months, quarterly, or yearly, as needed to follow the effectiveness of the treatment. By following the levels of these biomarkers, the patient compliance can be monitored over time.
- In one embodiment, the level of only one of the cell markers is monitored. In another embodiment, the levels of two or more of the cell markers are monitored simultaneously.
- In one embodiment, the level of IL-12/IL-13 p40 mRNA is monitored, and the decrease is about 80%, 85% 90%, or 95% or more as compared to the level of IL-12/IL-13 p40 mRNA in the first skin sample.
- In another described aspect, the level of iNOS mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of iNOS mRNA in the first biological sample.
- In one embodiment, the level of IL-22 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-22 mRNA in the first skin sample.
- In another embodiment, the level of IL-8 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-8 mRNA in the first skin sample.
- In one embodiment, the level of DEFB4 mRNA is monitored, and the decrease is about 45%, 50%, 55%, or 60% or more as compared to the level of DEFB4 mRNA in the first skin sample.
- In another embodiment, the level of MX-1 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of MX-1 mRNA in the first skin sample.
- In one embodiment, the level of Keratin 16 mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of Keratin 16 mRNA in the first skin sample.
- In one embodiment, the level of IL-17A mRNA is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of IL-17A mRNA in the first skin sample.
- In one embodiment, the level of IL-23 p19 mRNA is monitored, and the decrease is about 40% 45%, 50%, or 55% or more as compared to the level of IL-23 p19 mRNA in the first skin sample.
- In one embodiment, the level of IL-10 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-10 mRNA in the first skin sample.
- In one embodiment, the level of IFN-γ mRNA is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of IFN-γ mRNA in the first skin sample.
- In one embodiment, the level of CXCL9 mRNA is monitored, and the decrease is about 20%, 25%, 30%, or 35% or more as compared to the level of CXCL9 mRNA in the first skin sample.
- In one described aspect, the treatment compound is a PDE4 inhibitor provided herein elsewhere. In another described aspect, the treatment compound is (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide. In another embodiment, the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl} -amide.
- In some embodiments, the biomarkers provided herein may be used to predict or monitor the efficacy of treatment for psoriasis by a PDE4 modulator. PDE4 modulators described herein include racemic, stereomerically pure and stereomerically enriched PDE4 modulators, stereomerically and enantiomerically pure compounds that have selective cytokine inhibitory activities, and pharmaceutically acceptable salts, solvates, hydrates, stereoisomers, clathrates, and prodrugs thereof. Certain compounds described herein are known PDE4 modulators of Celgene Corporation, NJ.
- As used herein and unless otherwise indicated, the term "
PDE 4 modulators" encompasses small molecule drugs, e.g., small organic molecules which are not peptides, proteins, nucleic acids, oligosaccharides or other macromolecules. Preferred compounds inhibit TNF-α production. Compounds may also have a modest inhibitory effect on LPS induced IL1β and IL12. More preferably, the compounds provided herein arepotent PDE 4 inhibitors. - Specific examples of
PDE 4 modulators include, but are not limited to, the cyclic imides disclosed inU.S. patent nos. 5,605,914 and5,463,063 ; the cycloalkyl amides and cycloalkyl nitriles ofU.S. patent nos. 5,728,844 ,5,728,845 ,5,968,945 ,6,180,644 and6,518,281 ; the aryl amides (for example N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)-propanamide) ofU.S. patent nos. 5,801,195 ,5,736,570 ,6,046,221 and6,284,780 ; the imide/amide ethers and alcohols (for example, 3-phthalimido-3-(3',4'-dimethoxyphenyl)propan-1-ol) disclosed inU.S. patent no. 5,703,098 ; the succinimides and maleimides (for example methyl 3-(3',4',5'6'-petrahydrophthalimdo)-3-(3",4"-dimethoxyphenyl)propionate) disclosed inU.S. patent no. 5,658,940 ; imido and amido substituted alkanohydroxamic acids disclosed inU.S. patent no. 6,214,857 andWO 99/06041 U.S. patent nos. 6,011,050 and6,020,358 ; fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds disclosed inU.S. patent publication no. 2004/0204448 ; substituted imides (for example, 2-phthalimido-3-(3',4'-dimethoxyphenyl) propane) disclosed inU.S. patent no. 6,429,221 ; substituted 1,3,4-oxadiazoles (for example, 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazole-2-yl)ethyl]-5-methylisoindoline-1,3-dione) disclosed inU.S. patent no. 6,326,388 ; cyano and carboxy derivatives of substituted styrenes (for example, 3,3-bis-(3,4-dimethoxyphenyl) acrylonitrile) disclosed inU.S. patent nos. 5,929,117 ,6,130,226 ,6,262,101 and6,479,554 ; isoindoline-1-one and isoindoline-1,3-dione substituted in the 2-position with an α-(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group disclosed inWO 01/34606 U.S. patent no. 6,667,316 , for example, cyclopropyl-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl} carboxamide, cyclopropyl-N-{2-[1(S)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, and cyclopropyl-N-{2-[1(R)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl} carboxamide; and imido and amido substituted acylhydroxamic acids (for example, (3-(1,3-dioxoisoindoline-2-yl)-3-(3-ethoxy-4-methoxyphenyl) propanoylamino) propanoate disclosed inWO 01/45702 U.S. patent no. 6,699,899 .Other PDE 4 modulators include diphenylethylene compounds disclosed inU.S. patent publication no. 2005/0014727 .Other PDE 4 modulators include isoindoline compounds disclosed inU.S. patent publication nos. 2006/0025457 and2006/0084815 . Otherspecific PDE 4 modulators include 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, and stereoisomers thereof. (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione was disclosed inWO 03/080049 -
Additional PDE 4 modulators belong to a family of synthesized chemical compounds of which typical examples include 3-(1,3-dioxobenzo-[f]isoindol-2-yl)-3-(3-cyclopentyloxy-4-methoxyphenyl)propionamide and 3-(1,3-dioxo-4-azaisoindol-2-yl)-3-(3,4-dimethoxyphenyl)-propionamide. - Various PDE4 modulators described herein contain one or more chiral centers, and can exist as racemic mixtures of enantiomers or mixtures of diastereomers. The methods and compositions herein encompass the use of stereomerically pure forms of such compounds, as well as the use of mixtures of those forms. For example, mixtures comprising unequal amounts of the enantiomers of a particular PDE4 modulator may be used in methods and compositions provided herein. These isomers may be asymmetrically synthesized or resolved using standard techniques such as chiral columns or chiral resolving agents. See, e.g., Jacques, J., et al., Enantiomers, Racemates and Resolutions (Wiley-Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron 33:2725 (1977); Eliel, E. L., Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, S. H., Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN, 1972).
- As used herein, and unless otherwise indicated, the term "optically pure" means a composition that comprises one optical isomer of a compound and is substantially free of other isomers of that compound. For example, an optically pure composition of a compound having one chiral center will be substantially free of the opposite enantiomer of the compound. An optically pure composition of a compound having two chiral centers will be substantially free of other diastereomers of the compound. A typical optically pure compound comprises greater than about 80% by weight of one enantiomer of the compound and less than about 20% by weight of other enantiomers of the compound, greater than about 90% by weight of one enantiomer of the compound and less than about 10% by weight of the other enantiomers of the compound, greater than about 95% by weight of one enantiomer of the compound and less than about 5% by weight of the other enantiomers of the compound, greater than about 97% by weight of one enantiomer of the compound and less than about 3% by weight of the other enantiomers of the compound or greater than about 99% by weight of one enantiomer of the compound and less than about 1% by weight of the other enantiomers of the compound.
- Certain specific PDE4 modulators belong to a class of non-polypeptide cyclic amides disclosed in
U.S. patent nos. 5,698,579 ,5,877,200 ,6,075,041 and6,200,987 , andWO 95/01348 - wherein n has a value of 1, 2, or 3;
- R5 is o-phenylene, unsubstituted or substituted with 1 to 4 substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkyl of 1 to 10 carbon atoms, and halo;
- R7 is (i) phenyl or phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo, (ii) benzyl unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbothoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo, (iii) naphthyl, and (iv) benzyloxy;
- R12 is -OH, alkoxy of 1 to 12 carbon atoms, or
- R8 is hydrogen or alkyl of 1 to 10 carbon atoms; and
- R9 is hydrogen, alkyl of 1 to 10 carbon atoms, -COR10, or -SO2R10, wherein R10 is hydrogen, alkyl of 1 to 10 carbon atoms, or phenyl.
- Specific compounds of this class include, but are not limited to:
- 3-phenyl-2-(1-oxoisoindolin-2-yl)propionic acid;
- 3-phenyl-2-(1-oxoisoindolin-2-yl)propionamide;
- 3-phenyl-3-(1-oxoisoindolin-2-yl)propionic acid;
- 3-phenyl-3-(1-oxoisoindolin-2-yl)propionamide;
- 3-(4-methoxyphenyl)-3-(1-oxisoindolin-yl)propionic acid;
- 3-(4-methoxyphenyl)-3-(1-oxisoindolin-yl)propionamide;
- 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionicacid;
- 3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydroisoindol-2-yl)propionamide;
- 3-(3,4-dimethoxyphenyl)-3-(1-oxisoindolin-2-yl)propionamide;
- 3 -(3,4-diethoxyphenyl)-3 -(1 -oxoisoindolin-yl)propionic acid;
- methyl 3 -(1 -oxoisoindolin-2-yl)-3 -(3 -ethoxy-4-methoxyphenyl)propionate;
- 3-(1-oxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propionic acid;
- 3 -(1 -oxoisoindolin-2-yl)-3 -(3 -propoxy-4-methoxyphenyl)propionic acid;
- 3 -(1 -oxoisoindolin-2-yl)-3 -(3 -butoxy-4-methoxyphenyl)propionic acid;
- 3-(1-oxoisoindolin-2-yl)-3-(3-propoxy-4-methoxyphenyl)propionamide;
- 3-(1-oxoisoindolin-2-yl)-3-(3-butoxy-4-methoxyphenyl)propionamide;
- methyl 3-(1-oxoisoindolin-2-yl)-3-(3-butoxy-4-methoxyphenyl)propionate; and
- methyl 3-(1-oxoisoindolin-2-yl)-3-(3-propoxy-4-methoxyphenyl)propionate.
-
- R1 is the divalent residue of (i) 3,4-pyridine, (ii) pyrrolidine, (iii) imidizole, (iv) naphthalene, (v) thiophene, or (vi) a straight or branched alkane of 2 to 6 carbon atoms, unsubstituted or substituted with phenyl or phenyl substituted with nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, wherein the divalent bonds of said residue are on vicinal ring carbon atoms;
- R2 is -CO - or -SO2 -;
- R3 is (i) phenyl substituted with 1 to 3 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, (ii) pyridyl, (iii) pyrrolyl, (iv) imidazolyl, (iv) naphthyl, (vi) thienyl, (vii) quinolyl, (viii) furyl, or (ix) indolyl;
- R4 is alanyl, arginyl, glycyl, phenylglycyl, histidyl, leucyl, isoleucyl, lysyl, methionyl, prolyl, sarcosyl, seryl, homoseryl, threonyl, thyronyl, tyrosyl, valyl, benzimidol-2-yl, benzoxazol-2-yl, phenylsulfonyl, methylphenylsulfonyl, or phenylcarbamoyl; and
- n has a value of 1, 2, or 3.
-
- R5 is (i) o-phenylene, unsubstituted or substituted with 1 to 4 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, or (ii) the divalent residue of pyridine, pyrrolidine, imidizole, naphthalene, or thiophene, wherein the divalent bonds are on vicinal ring carbon atoms;
- R6 is -CO -, -CH2-, or -SO2-;
- R7 is (i) hydrogen if R6 is -SO2-, (ii) straight, branched, or cyclic alkyl of 1 to 12 carbon atoms, (iii) pyridyl, (iv) phenyl or phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, (v) alkyl of 1 to 10 carbon atoms, (vi) benzyl unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, (vii) naphthyl, (viii) benzyloxy, or (ix) imidazol-4-yl methyl;
- R12 is -OH, alkoxy of 1 to 12 carbon atoms, or
- n has a value of 0, 1, 2, or 3;
- R8' is hydrogen or alkyl of 1 to 10 carbon atoms; and
- R9' is hydrogen, alkyl of 1 to 10 carbon atoms, -COR10, or -SO2 R10 in which R10 is hydrogen, alkyl of 1 to 10 carbon atoms, or phenyl.
-
- R7 is (i) straight, branched, or cyclic alkyl of 1 to 12 carbon atoms, (ii) pyridyl, (iii) phenyl or phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, (iv) benzyl unsubstituted or substituted with one to three substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo, (v) naphthyl, (vi) benzyloxy, or (vii) imidazol-4-ylmethyl;
- R12 is -OH, alkoxy of 1 to 12 carbon atoms, -O-CH2-pyridyl, -O-benzyl or
- R8' is hydrogen or alkyl of 1 to 10 carbon atoms; and
- R9' is hydrogen, alkyl of 1 to 10 carbon atoms, -CH2-pyridyl, benzyl, -COR10, or -SO2R10 in which R10 is hydrogen, alkyl of 1 to 4 carbon atoms, or phenyl.
- Other specific PDE4 modulators include the imido and amido substituted alkanohydroxamic acids disclosed in
WO 99/06041 U.S. patent no. 6,214,857 . Examples of such compound include, but are not limited to: - each of R1 and R2, when taken independently of each other, is hydrogen, lower alkyl, or R1 and R2, when taken together with the depicted carbon atoms to which each is bound, is o-phenylene, o-naphthylene, or cyclohexene-1,2-diyl, unsubstituted or substituted with 1 to 4 substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo;
- R3 is phenyl substituted with from one to four substituents selected from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, alkylthio of 1 to 10 carbon atoms, benzyloxy, cycloalkoxy of 3 to 6 carbon atoms, C4-C6-cycloalkylidenemethyl, C3-C10-alkylidenemethyl, indanyloxy, and halo;
- R4 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, or benzyl;
- R4' is hydrogen or alkyl of 1 to 6 carbon atoms;
- R5 is -CH2-, -CH2-CO-, -SO2-, -S-, or -NHCO-; and
- n has a value of 0, 1, or 2; or
- an acid addition salt of said compounds.
- Additional specific PDE4 modulators provided herein include, but are not limited to:
- 3-(3-ethoxy-4-methoxyphenyl)-N-hydroxy-3-(1-oxoisoindolinyl)propionamide;
- 3 -(3 -ethoxy-4-methoxyphenyl)-N-methoxy-3 -(1 -oxoisoindolinyl)propionamide;
- N-benzyloxy-3-(3-ethoxy-4-methoxyphenyl)-3-phthalimidopropionamide;
- N-benzyloxy-3-(3-ethoxy-4-methoxyphenyl)-3-(3-nitrophthalimido)propionamide;
- N-benzyloxy-3-(3-ethoxy-4-methoxyphenyl)-3-(1-oxoisoindolinyl)propionamide;
- 3-(3-ethoxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide;
- N-hydroxy-3-(3,4-dimethoxyphenyl)-3-phthalimidopropionamide;
- 3-(3-ethoxy-4-methoxyphenyl)-N-hydroxy-3-(3-nitrophthalimido)propionamide;
- N-hydroxy-3-(3,4-dimethoxyphenyl)-3-(1-oxoisoindolinyl)propionamide;
- 3-(3-ethoxy-4-methoxyphenyl)-N-hydroxy-3-(4-methyl-phthalimido)propionamide;
- 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-phthalimidopropionamide;
- 3-(3-ethoxy-4-methoxyphenyl)-N-hydroxy-3-(1,3-dioxo-2,3-dihydro-1H-benzo[f]isoindol-2-yl)propionamide;
- N-hydroxy-3-{3-(2-propoxy)-4-methoxyphenyl}-3-phthalimidopropionamide;
- 3-(3-ethoxy-4-methoxyphenyl)-3-(3,6-difluorophthalimido)-N-hydroxypropionamide;
- 3 -(4-aminophthalimido)-3 -(3 -ethoxy-4-methoxyphenyl)-N-hydroxypropionamide;
- 3 -(3 -aminophthalimido)-3 -(3 -ethoxy-4-methoxyphenyl)-N-hydroxypropionamide;
- 3 -(3 -acetoamidophthalimido)-3 -(3 -ethoxy-4-methoxyphenyl)-N-hydroxypropionamide;
- N-hydroxy-3-(3,4-dimethoxyphenyl)-3-(1-oxoisoindolinyl)propionamide;
- 3-(3-cyclopentyloxy-4-methoxyphenyl)-N-hydroxy-3-(1-oxoisoindolinyl) propionamide; and
- N-benzyloxy-3-(3-ethoxy-4-methoxyphenyl)-3-(3-nitrophthalimido)propionamide.
-
Additional PDE 4 modulators provided herein include the phenethylsulfones substituted on the phenethyl group with a oxoisoindoline group. Examples of such compounds include, but are not limited to, those disclosed inU.S. patent no. 6,020,358 , which include the following: - Y is C=O, CH2, SO2, or CH2C=O; each of R1, R2, R3, and R4, independently of the others, is hydrogen, halo, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, hydroxy, or -NR8R9; or any two of R1, R2, R3, and R4 on adjacent carbon atoms, together with the depicted phenylene ring are naphthylidene;
- each of R5 and R6, independently of the other, is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, or cycloalkoxy of up to 18 carbon atoms;
- R7 is hydroxy, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, or NR8'R9';
- each of R8 and R9 taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R8 and R9 is hydrogen and the other is - COR10 or -SO2R10, or R8 and R9 taken together are tetramethylene, pentamethylene, hexamethylene, or -CH2CH2X1CH2CH2- in which X1 is -O-, -S- or -NH-; and
- each of R8' and R9' taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R8' and R9' is hydrogen and the other is - COR10' or -SO2R10', or R8' and R9' taken together are tetramethylene, pentamethylene, hexamethylene, or -CH2CH2X2CH2CH2- in which X2 is -O-, -S-, or -NH-.
- It will be appreciated that while for convenience the above compounds are identified as phenethylsulfones, they include sulfonamides when R7 is NR8'R9'.
- Specific groups of such compounds are those in which Y is C=O or CH2.
- A further specific group of such compounds are those in which each of R1, R2, R3, and R4 independently of the others, is hydrogen, halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or -NR8R9 in which each of R8 and R9 taken independently of the other is hydrogen or methyl or one of R8 and R9 is hydrogen and the other is -COCH3.
- Particular compounds are those in which one of R1, R2, R3, and R4 is -NH2 and the remaining of R1, R2, R3, and R4 are hydrogen.
- Particular compounds are those in which one of R1, R2, R3, and R4 is-NHCOCH3 and the remaining of R1, R2, R3, and R4 are hydrogen.
- Particular compounds are those in which one of R1, R2, R3, and R4 is-N(CH3)2 and the remaining of R1, R2, R3, and R4 are hydrogen.
- A further preferred group of such compounds are those in which one of R1, R2, R3, and R4 is methyl and the remaining of R1, R2, R3, and R4 are hydrogen.
- Particular compounds are those in which one of R1, R2, R3, and R4 is fluoro and the remaining of R1, R2, R3, and R4 are hydrogen.
- Particular compounds are those in which each of R5 and R6, independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.
- Particular compounds are those in which R5 is methoxy and R6 is monocycloalkoxy, polycycloalkoxy, and benzocycloalkoxy.
- Particular compounds are those in which R5 is methoxy and R6 is ethoxy.
- Particular compounds are those in which R7 is hydroxy, methyl, ethyl, phenyl, benzyl, or NR8'R9' in which each of R8' and R9' taken independently of the other is hydrogen or methyl.
- Particular compounds are those in which R7 is methyl, ethyl, phenyl, benzyl or NR8'R9' in which each of R8' and R9' taken independently of the other is hydrogen or methyl.
- Particular compounds are those in which R7 is methyl.
- Particular compounds are those in which R7 is NR8'R9' in which each of R8' and R9' taken independently of the other is hydrogen or methyl.
- Additional PDE4 modulators include fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds disclosed in
U.S. patent publication no. 2004/0204448 . Representative compounds are of formula: - Y is -C(O)-, -CH2, -CH2C(O)-, -C(O)CH2-, or SO2;
- Z is -H, -C(O)R3, -(C0-1-alkyl)-SO2-(C1-4-alkyl), -C1-8-alkyl, -CH2OH, CH2(O)(C1-8alkyl) or -CN;
- R1 and R2 are each independently -CHF2, -C1-8-alkyl, -C3-18-cycloalkyl, or -(C1-10-alkyl)(C3-18-cycloalkyl), and at least one of R1 and R2 is CHF2;
- R3 is -NR4R5, -alkyl, -OH, -O-alkyl, phenyl, benzyl, substituted phenyl, or substituted benzyl;
- R4 and R5 are each independently -H, -C1-8-alkyl, -OH, -OC(O)R6;
- R6 is -C1-8-alkyl, -amino(C1-8-alkyl), -phenyl, -benzyl, or -aryl;
- X1, X2, X3, and X4 are each independently -H, -halogen, -nitro, -NH2, -CF3, -C1-6-alkyl, -(C0-4-alkyl)-(C3-6-cycloalkyl), (C0-4-alkyl)-NR7R8, (C0-4-alkyl)-N(H)C(O)-(R8), (C0-4-alkyl)-N(H)C(O)N(R7R8), (C0-4-alkyl)-N(H)C(O)O(R7R8), (C0-4-alkyl)-OR8, (C0-4-alkyl)-imidazolyl, (C0-4-alkyl)-pyrrolyl, (C0-4-alkyl)-oxadiazolyl, or (C0-4-alkyl)-triazolyl, or two of X1, X2, X3, and X4 may be joined together to form a cycloalkyl or heterocycloalkyl ring, (e.g., X1 and X2, X2 and X3, X3 and X4, X1 and X3, X2 and X4, or X1 and X4 may form a 3, 4, 5, 6, or 7 membered ring which may be aromatic, thereby forming a bicyclic system with the isoindolyl ring); and
- R7 and R8 are each independently H, C1-9-alkyl, C3-6-cycloalkyl, (C1-6-alkyl)-(C3-6-cycloalkyl), (C1-6-alkyl)-N(R7R8), (C1-6-alkyl)-OR8, phenyl, benzyl, or aryl; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
- Additional PDE4 modulators include the enantiomerically pure compounds disclosed in
U.S. patent publication nos. 2003/0187052 ,2004/0167199 , and2005/0014727 and international patent publication nos.WO 2003/080048 andWO 2003.080049 . In one described aspect, the compound is an enantiomer of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and an enantiomer of 3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide. - In some embodiments, PDE4 modulator is cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide, available from Celgene Corp., Warren, NJ. 3-(3,4-Dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide has the following chemical structure:
- Other PDE4 modulators include, but are not limited to, the cycloalkyl amides and cycloalkyl nitriles disclosed in
U.S. patent nos. 5,728,844 ,5,728,845 ,5,968,945 ,6,180,644 and6,518,281 , andWO 97/08143 WO 97/23457 - one of R1 and R2 is R3-X- and the other is hydrogen, nitro, cyano, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo, or R3-X-;
- R3 is monocycloalkyl, bicycloalkyl, or benzocycloalkyl of up to 18 carbon atoms;
- X is a carbon-carbon bond, -CH2-, or -O-;
- R5 is (i) o-phenylene, unsubstituted or substituted with 1 to 3 substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbo(lower)alkoxy, acetyl, or carbamoyl, unsubstituted or substituted with lower alkyl, acetoxy, carboxy, hydroxy, amino, lower alkylamino, lower acylamino, or lower alkoxy; (ii) a vicinally divalent residue of pyridine, pyrrolidine, imidazole, naphthalene, or thiophene, wherein the divalent bonds are on vicinal ring carbon atoms; (iii) a vicinally divalent cycloalkyl or cycloalkenyl of 4-10 carbon atoms, unsubstituted or substituted with 1 to 3 substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkylamino, lower alkyl, lower alkoxy, or phenyl; (iv) vinylene disubstituted with lower alkyl; or (v) ethylene, unsubstituted or monosubstituted or disubstituted with lower alkyl;
- R6 is -CO-, -CH2-, or -CH2CO-;
- Y is -COZ, -C= N, -OR8, lower alkyl, or aryl;
- Z is -NH2, -OH, -NHR, -R9, or -OR9
- R8 is hydrogen or lower alkyl;
- R9 is lower alkyl or benzyl; and,
- n has a value of 0, 1, 2, or 3.
- In one described aspect, one of R1 and R2 is R3-X- and the other is hydrogen, nitro, cyano, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo, or R3-X-;
R3 is monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms;
X is -CH2-, or -O-;
R5 is (i) the vicinally divalent residue of pyridine, pyrrolidine, imidazole, naphthalene, or thiophene, wherein the two bonds of the divalent residue are on vicinal ring carbon atoms; - (ii) a vicinally divalent cycloalkyl of 4-10 carbon atoms, unsubstituted or substituted with 1 to 3 substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl;
- (iii) di-substituted vinylene, substituted with nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo;
- (iv) ethylene, unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo;
- In another described aspect, one of R1 and R2 is R3-X- and the other is hydrogen, nitro, cyano, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkyl, lower alkoxy, halo, HF2CO, F3CO, or R3-X-;
R3 is monocycloalkyl, bicycloalkyl, benzocyclo alkyl of up to 18 carbon atoms, tetrahydropyran, or tetrahydrofuran;
X is a carbon-carbon bond, -CH2-, -O-, or -N=;
R5 is (i) o-phenylene, unsubstituted or substituted with 1 to 3 substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbo(lower)alkoxy, acetyl, or carbamoyl, unsubstituted or substituted with lower alkyl, acetoxy, carboxy, hydroxy, amino, lower alkylamino, lower acylamino, or lower alkoxy; (ii) a vicinally divalent residue of pyridine, pyrrolidine, imidazole, naphthalene, or thiophene, wherein the divalent bonds are on vicinal ring carbon atoms; (iii) a vicinally divalent cycloalkyl or cycloalkenyl of 4-10 carbon atoms, unsubstituted or substituted with 1 or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbo(lower)alkoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, lower alkylamino, lower alkyl, lower alkoxy, or phenyl; (iv) vinylene di-substituted with lower alkyl; or (v) ethylene, unsubstituted or monosubstituted or disubstituted with lower alkyl;
R6 is -CO-, -CH2-, or -CH2CO-;
Y is -COX, -C≡N, -OR8, alkyl of 1 to 5 carbon atoms, or aryl;
X is -NH2, -OH, -NHR, -R9, -OR9, or alkyl of 1 to 5 carbon atoms;
R8 is hydrogen or lower alkyl;
R9 is alkyl or benzyl; and,
n has a value of 0, 1, 2, or 3. -
- Y is -C≡N or CO(CH2)mCH3;
- m is 0, 1, 2, or 3;
- R5 is (i) o-phenylene, unsubstituted or substituted with 1 to 3 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo; (ii) the divalent residue of pyridine, pyrrolidine, imidizole, naphthalene, or thiophene, wherein the divalent bonds are on vicinal ring carbon atoms; (iii) a divalent cycloalkyl of 4-10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl or halo; (iv) di-substituted vinylene, substituted with nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo; or (v) ethylene, unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo;
- R6 is -CO-, -CH2-, -CH2CO-, or -SO2-;
- R7 is (i) straight or branched alkyl of 1 to 12 carbon atoms; (ii) cyclic or bicyclic alkyl of 1 to 12 carbon atoms; (iii) pyridyl; (iv) phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, straight, branched, cyclic, or bicyclic alkyl of 1 to 10 carbon atoms, straight, branched, cyclic, or bicyclic alkoxy of 1 to 10 carbon atoms, CH2R where R is a cyclic or bicyclic alkyl of 1 to 10 carbon atoms, or halo; (v) benzyl substituted with one to three substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo; (vi) naphthyl; or (vii) benzyloxy; and
- n has a value of 0, 1, 2, or 3.
-
- R5 is (i) the divalent residue of pyridine, pyrrolidine, imidizole, naphthalene, or thiophene, wherein the divalent bonds are on vicinal ring carbon atoms; (ii) a divalent cycloalkyl of 4-10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl or halo; (iii) di-substituted vinylene, substituted with nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo; or (iv) ethylene, unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with and alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 3 carbon atoms, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo;
- R6 is -CO-, -CH2-, -CH2CO-, or -SO2-;
- R7 is (i) cyclic or bicyclic alkyl of 4 to 12 carbon atoms; (ii) pyridyl; (iii) phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, straight, branched, cyclic, or bicyclic alkyl of 1 to 10 carbon atoms, straight, branched, cyclic, or bicyclic alkoxy of 1 to 10 carbon atoms, CH2R where R is a cyclic or bicyclic alkyl of 1 to 10 carbon atoms, or halo; (iv) benzyl substituted with one to three substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo; (v) naphthyl; or (vi) benzyloxy; and
- Y is COX, -C≡N, OR8, alkyl of 1 to 5 carbon atoms, or aryl;
- X is -NH2, -OH, -NHR, -R9, -OR9, or alkyl of 1 to 5 carbon atoms;
- R8 is hydrogen or lower alkyl;
- R9 is alkyl or benzyl; and
- n has a value of 0, 1, 2, or 3.
-
Other PDE 4 modulators include, but are not limited to, the aryl amides (for example, an example being N-benzoyl-3-amino-3-(3',4'-dimethoxyphenyl)-propanamide) disclosed inU.S. patent nos. 5,801,195 ,5,736,570 ,6,046,221 and6,284,780 . Representative compounds are of formula: - Ar is (i) straight, branched, or cyclic, unsubstituted alkyl of 1 to 12 carbon atoms; (ii) straight, branched, or cyclic, substituted alkyl of 1 to 12 carbon atoms; (iii) phenyl; (iv) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo; (v) heterocycle; or (vi) heterocycle substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo;
- R is -H, alkyl of 1 to 10 carbon atoms, CH2OH, CH2CH2OH, or CH2COZ where Z is alkoxy of 1 to 10 carbon atoms, benzyloxy, or NHR1 where R1 is H or alkyl of 1 to 10 carbon atoms; and
- Y is i) a phenyl or heterocyclic ring, unsubstituted or substituted one or more substituents each selected independently one from the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo or ii) naphthyl. Specific examples of the compounds are of formula:
- Ar is 3,4-disubstituted phenyl where each substituent is selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo;
- Z is alkoxy of 1 to 10 carbon atoms, benzyloxy, amino, or alkylamino of 1 to 10 carbon atoms; and
- Y is (i) a phenyl, unsubstituted or substituted with one or more substituents each selected, independently one from the other, from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, and halo, or (ii) naphthyl.
-
Other PDE 4 modulators include, but are not limited to, the imide/amide ethers and alcohols (for example, 3-phthalimido-3-(3',4'-dimethoxyphenyl) propan-1-ol) disclosed inU.S. patent no. 5,703,098 . Representative compounds have the formula: - R1 is (i) straight, branched, or cyclic, unsubstituted alkyl of 1 to 12 carbon atoms; (ii) straight, branched, or cyclic, substituted alkyl of 1 to 12 carbon atoms; (iii) phenyl; or (iv) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, acylamino, alkylamino, di(alkyl) amino, alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, bicycloalkyl of 5 to 12 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkoxy of 3 to 10 carbon atoms, bicycloalkoxy of 5 to 12 carbon atoms, and halo;
- R2 is hydrogen, alkyl of 1 to 8 carbon atoms, benzyl, pyridylmethyl, or alkoxymethyl;
- R3 is (i) ethylene, (ii) vinylene, (iii) a branched alkylene of 3 to 10 carbon atoms, (iv) a branched alkenylene of 3 to 10 carbon atoms, (v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, amino substituted with alkyl of 1 to 6 carbon atoms, amino substituted with acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, and halo, (vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, amino substituted with alkyl of 1 to 6 carbon atoms, amino substituted with acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, and halo, (vii) o-phenylene unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, amino substituted with alkyl of 1 to 6 carbon atoms, amino substituted with acyl of 1 to 6 carbon atoms, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 12 carbon atoms, and halo, (viii) naphthyl, or (ix) pyridyl;
- R4 is -CX-, -CH2- or -CH2CX-;
- X is O or S; and
- n is 0, 1, 2, or 3.
-
Other PDE 4 modulators include, but are not limited to, the succinimides and maleimides (for example methyl 3-(3',4',5'6'-petrahydrophthalimdo)-3-(3",4"-dimethoxyphenyl)propionate) disclosed inU.S. patent no. 5,658,940 . Representative compounds are of formula: - R1 is -CH2-, -CH2CO-, or -CO-;
- R2 and R3 taken together are (i) ethylene unsubstituted or substituted with alkyl of 1-10 carbon atoms or phenyl, (ii) vinylene substituted with two substituents each selected, independently of the other, from the group consisting of alkyl of 1-10 carbon atoms and phenyl, or (iii) a divalent cycloalkyl of 5-10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl unsubstituted or substituted with alkyl of 1-3 carbon atoms, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, norbornyl, phenyl or halo;
- R4 is (i) straight or branched unsubstituted alkyl of 4 to 8 carbon atoms, (ii) cycloalkyl or bicycloalkyl of 5-10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, branched, straight or cyclic alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl or halo, (iii) phenyl substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, cycloalkyl or bicyctoalkyl of 3 to 10 carbon atoms, cycloalkoxy or bicycloalkoxy of 3 to 10 carbon atoms, phenyl or halo, (iv) pyridine or pyrrolidine, unsubstituted or substituted with one or more substituents each selected independently of the other from the group consisting of nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl or halo; and,
- R5 is -COX, -CN, -CH2COX, alkyl of 1 to 5 carbon atoms, aryl, -CH2OR, -CH2 aryl, or -CH2OH,
- where X is NH2, OH, NHR, or OR6,
- where R is lower alkyl; and
- where R6 is alkyl or benzyl.
-
Other PDE 4 modulators include, but are not limited to, substituted imides (for example, 2-phthalimido-3-(3',4'-dimethoxyphenyl) propane) disclosed inU.S. patent no. 6,429,221 . Representative compounds have the formula: - R1 is (i) straight, branched, or cyclic alkyl of 1 to 12 carbon atoms, (ii) phenyl or phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, straight or branched alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, (iii) benzyl or benzyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo, or (iv) -Y-Ph where Y is a straight, branched, or cyclic alkyl of 1 to 12 carbon atoms and Ph is phenyl or phenyl substituted with one or more substituents each selected independently of the other from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or halo;
- R2 is -H, a branched or unbranched alkyl of 1 to 10 carbon atoms, phenyl, pyridyl, heterocycle, -CH2-aryl, or -CH2-heterocycle;
- R3 is i) ethylene, ii) vinylene, iii) a branched alkylene of 3 to 10 carbon atoms, iv) a branched alkenylene of 3 to 10 carbon atoms, v) cycloalkylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo, vi) cycloalkenylene of 4 to 9 carbon atoms unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, or halo, or vii) o-phenylene unsubstituted or substituted with 1 to 2 substituents each selected independently from nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 4 carbon atoms, alkoxy 1 to 4 carbon atoms, or halo; and,
- R4 is -CX, or -CH2-;
- X is O or S.
- Other PDE4 modulators include, but are not limited to, substituted 1,3,4-oxadiazoles (for example, 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-(1,3,4-oxadiazole-2-yl)ethyl]-5-methylisoindoline-1,3-dione) disclosed in
U.S. patent no. 6,326,388 . Representative compounds are of formula: - the carbon atom designated* constitutes a center of chirality;
- Y is C=O, CH2, SO2 or CH2C=O;
- X is hydrogen, or alkyl of 1 to 4 carbon atoms;
- each of R1, R2, R3, and R4, independently of the others, is hydrogen, halo, trifluoromethyl, acetyl, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, hydroxy, -CH2NR8R9, -(CH2)2NR8R9, or -NR8R9 or
- any two of R1, R2, R3, and R4 on adjacent carbon atoms, together with the depicted benzene ring are naphthylidene, quinoline, quinoxaline, benzimidazole, benzodioxole or 2-hydroxybenzimidazole;
- each of R5 and R6, independently of the other, is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 6 carbon atoms, cyano, benzocycloalkoxy, cycloalkoxy of up to 18 carbon atoms, bicyloalkoxy of up to 18 carbon atoms, tricylcoalkoxy of up to 18 carbon atoms, or cycloalkylalkoxy of up to 18 carbon atoms;
- each of R8 and R9, taken independently of the other is hydrogen, straight or branched alkyl of 1 to 8 carbon atoms, phenyl, benzyl, pyridyl, pyridylmethyl, or one of R8 and R9 is hydrogen and the other is -COR10, or -SO2R10, or R8 and R9 taken together are tetramethylene, pentamethylene, hexamethylene, -CH=NCH=CH-, or-CH2CH2X1CH2CH2- in which X1 is -O-, -S-, or -NH-,
- R10 is hydrogen, alkyl of 1 to 8 carbon atoms, cycloalkyl, cycloalkylmethyl of up to 6 carbon atoms, phenyl, pyridyl, benzyl, imidazolylmethyl, pyridylmethyl, NR11R12, CH2R14R15, or NR11R12,
- wherein R14 and R15, independently of each other, are hydrogen, methyl, ethyl, or propyl, and
- wherein R11 and R12, independently of each other, are hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl; and
- the acid addition salts of said compounds which contain a nitrogen atom susceptible of protonation.
-
- the carbon atom designated* constitutes a center of chirality;
- Y is C=O, CH2, SO2 or CH2C=O;
- X is hydrogen, or alkyl of 1 to 4 carbon atoms;
- (i) each of R1, R2, R3, and R4, independently of the others, is hydrogen, halo, trifluoromethyl, acetyl, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, hydroxy, -CH2NR8R9, -(CH2)2NR8R9, or -NR8R9 or
- (ii) any two of R1, R2, R3, and R4 on adjacent carbon atoms, together with the depicted benzene ring to which they are bound are naphthylidene, quinoline, quinoxaline, benzimidazole, benzodioxole or 2-hydroxybenzimidazole;
- each of R5 and R6, independently of the other, is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 6 carbon atoms, cyano, benzocycloalkoxy, cycloalkoxy of up to 18 carbon atoms, bicyloalkoxy of up to 18 carbon atoms, tricylcoalkoxy of up to 18 carbon atoms, or cycloalkylalkoxy of up to 18 carbon atoms;
- (i) each of R8 and R9, independently of the other, is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, pyridyl, pyridylmethyl, or
- (ii) one of R8 and R9 is hydrogen and the other is -COR10, or -SO2R10, in which R10 is hydrogen, alkyl of 1 to 8 carbon atoms, cycloalkyl, cycloalkylmethyl of up to 6 carbon atoms, phenyl, pyridyl, benzyl, imidazolylmethyl, pyridylmethyl, NR11R12, or CH2NR14R15, wherein R11 and R12, independently of each other, are hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl and R14 and R15, independently of each other, are hydrogen, methyl, ethyl, or propyl; or
- (iii) R8 and R9 taken together are tetramethylene, pentamethylene, hexamethylene, -CH=NCH=CH-, or -CH2CH2X1CH2CH2- in which X1 is -O-, -S-, or -NH-.
- Other specific PDE4 modulators include, but are not limited to, cyano and carboxy derivatives of substituted styrenes (for example, 3,3-bis-(3,4-dimethoxyphenyl) acrylonitrile) disclosed in
U.S. patent nos. 5,929,117 ,6,130,226 ,6,262,101 and6,479,551 . Representative compounds are of formula: - (a) X is -O- or -(CnH2n)- in which n has a value of 0, 1, 2, or 3, and R1 is alkyl of one to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
- (b) X is -CH= and R1 is alkylidene of up to 10 carbon atoms, monocycloalkylidene of up to 10 carbon atoms, or bicycloalkylidene of up to 10 carbon atoms;
-
- (a) X is -O- or -(CnH2n)- in which n has a value of 0, 1, 2, or 3, and R1 is alkyl of one to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
- (b) X is -CH= and R1 is alkylidene of up to 10 carbon atoms, monocycloalkylidene of up to 10 carbon atoms, or bicycloalkylidene of up to 10 carbon atoms;
-
- (a) X is -O- or -(CnH2n)- in which n has a value of 0, 1, 2, or 3, and R1 is alkyl of up to 10 carbon atoms, monocycloalkyl of up to 10 carbon atoms, polycycloalkyl of up to 10 carbon atoms, or benzocyclic alkyl of up to 10 carbon atoms, or
- (b) X is -CH=, and R1 is alkylidene of up to 10 carbon atoms or monocycloalkylidene of up to 10 carbon atoms;
-
- Other PDE4 modulators include, but are not limited to, isoindoline-1-one and isoindoline-1,3-dione substituted in the 2-position with an α-(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group disclosed in
WO 01/34606 U.S. patent no. 6,667,316 . Representative compounds are of formula:
wherein: - one of X and X' is =C=O or =SO2, and the other of X and X' is =C=O, =CH2, =SO2 or =CH2C=O;
- n is 1, 2 or 3;
- R1 and R2 are each independently (C1-C4)alkyl, (C1-C4)alkoxy, cyano, (C3-C18)cycloalkyl, (C3-C18)cycloalkoxy or (C3-C18)cycloalkyl-methoxy;
- R3 is SO2-Y, COZ, CN or (C1-C6)hydroxyalkyl, wherein:
- Y is (C1-C6)alkyl, benzyl or phenyl;
- Z is -NR6R7, (C1-C6)alkyl, benzyl or phenyl;
- R6 is H, (C1-C4)alkyl, (C3-C18)cycloalkyl, (C2-C5)alkanoyl, benzyl or phenyl, each of which can be optionally substituted with halo, amino or (C1-C4)alkyl-amino;
- R7 is H or (C1-C4)alkyl;
- R4 and R5 are taken together to provide -NH-CH2-R8-, NH-CO-R8-, or -N=CH-R8-, wherein:
- R8 is CH2, O, NH, CH=CH, CH=N, or N=CH; or
- one of R4 and R5 is H, and the other of R4 and R5 is imidazoyl, pyrrolyl, oxadiazolyl, triazolyl, or a structure of formula (A),
- z is 0 or 1;
- R9 is: H; (C1-C4)alkyl, (C3-C18)cycloalkyl, (C2-C5)alkanoyl, or (C4-C6)cycloalkanoyl, optionally substituted with halo, amino, (C1-C4)alkyl-amino, or (C1-C4)dialkyl-amino; phenyl; benzyl; benzoyl; (C2-C5)alkoxycarbonyl; (C3-C5)alkoxyalkylcarbonyl; N-morpholinocarbonyl; carbamoyl; N-substituted carbamoyl substituted with (C1-C4)alkyl; or methylsulfonyl; and
- R10 is H, (C1-C4)alkyl, methylsulfonyl, or (C3-C5)alkoxyalkylcarbonyl; or
- R9 and R10 are taken together to provide -CH=CH-CH=CH-, -CH=CH-N=CH-, or (C1-C2)alkylidene, optionally substituted with amino, (C1-C4)alkyl-amino, or (C1-C4)dialkyl-amino; or
- R4 and R5 are both structures of formula (A).
- In one described aspect, z is not 0 when (i) R3 is -SO2-Y, -COZ, or -CN and (ii) one of R4 or R5 is hydrogen. In another described aspect, R9 and R10, taken together, is-CH=CH-CH=CH-, -CH=CH-N=CH-, or (C1-C2)alkylidene substituted by amino, (C1-C4)alkyl-amino, or (C1-C4)dialkyl-amino. In another described aspect, R4 and R5 are both structures of formula (A).
Exemplary compounds are of formula: - Further examples include, but are not limited to: 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-dinitroisoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-diaminoisoindoline-1,3-dione; 7-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3 -pyrrolino [3,4-e]benzimidazole-6,8-dione; 7-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]hydro-3-pyrrolino[3,4-e]benzimidazole-2,6,8-trione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-3-pyrrolino[3,4-f]quinoxaline-1,3-dione; Cyclopropyl-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl}carboxamide; 2-Chloro-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl}acetamide; 2-Amino-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl}acetamide; 2-N,N-Dimethylamino-N-{2-[-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl} acetamide; N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl}-2,2,2-trifluoroacetamide; N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-1,3-dioxoisoindolin-4-yl}methoxycarboxamide; 4-[1-Aza-2-(dimethylamino)vinyl]-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3-dione; 4-[1-Aza-2-(dimethylamino)prop-1-enyl]-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(5-methyl-1,3,4-oxadiazol-2-yl)isoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-pyrrolylisoindoline-1,3-dione; 4-(Aminomethyl)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-isoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-(pyrrolylmethyl)isoindoline-1,3-dione; N-{2-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisoindolin-4-yl} acetamide; N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl}acetamide; N-{2-[1R-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisoindolin-4-yl}acetamide; N-{2-[1R-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl} acetamide; N-{2-[1S-(3-Ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisoindolin-4-yl}acetamide; N-{2-[1S-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl}acetamide; 4-Amino-2-[1-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutylisoindoline-1,3-dione; 4-Amino-2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]isoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-3-oxobutyl]-4-pyrrolylisoindoline-1,3-dione; 2-Chloro-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindol-4-yl}acetamide; 2-(Dimethylamino)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl}acetamide; 4-Amino-2-[1R-(3-ethoxy-4-methoxyphenyl)-3-hydroxybutyl]isoindoline-1,3-dione; 4-Amino-2-[1R-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]isoindoline-1,3-dione; 2-[1R-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-4-pyrrolylisoindoline-1,3-dione; 2-(Dimethylamino)-N-{2-[1R-(3-ethoxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl}acetamide; Cyclopentyl-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}carboxamide; 3-(Dimethylamino)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}propanamide; 2-(Dimethylamino)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}propanamide; N-{2-[(1R)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}-2-(dimethylamino)acetamide; N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}-2-(dimethylamino)acetamide; 4-{3-[(Dimethylamino)methyl]pyrrolyl}-2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]isoindoline-1,3-dione; Cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}carboxamide; 2-[1-(3,4-dimethoxyphenyl)-2-(methylsulfonyl)ethyl]-4-pyrrolylisoindoline-1,3-dione; N-{2-[1-(3,4-dimethoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}-2-(dimethylamino)acetamide; Cyclopropyl-N-{2-[1-(3,4-dimethoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}carboxamide; Cyclopropyl-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide; 2-(Dimethylamino)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}acetamide; Cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide; Cyclopropyl-N-{2-[(1R)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide; (3R)-3-[7-(Acetylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylpropanamide; (3R)-3-[7-(Cyclopropylcarbonylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylpropanamide; 3-{4-[2-(Dimethylamino)acetylamino]-1,3-dioxoisoindolin-2-yl}-3-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylpropanamide; (3R)-3-[7-(2-Chloroacetylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxy-phenyl)-N,N-dimethylpropanamide; (3R)-3-{4-[2-(dimethylamino)acetylamino]-1,3-dioxoisoindolin-2-yl}-3-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylpropanamide; 3-(1,3-Dioxo-4-pyrrolylisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylpropanamide; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4-(imidazolyl-methyl)isoindoline-1,3-dione; N-({2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}methyl)acetamide; 2-Chloro-N-({2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}methyl)acetamide; 2-(Dimethylamino)-N-({2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxoisoindolin-4-yl}methyl)acetamide; 4-[Bis(methylsulfonyl)amino]-2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]isoindoline-1,3-dione; 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-4-[(methylsulfonyl)amino]isoindoline-1,3-dione; N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-3-hydroxypentyl]-1,3-dioxoisoindolin-4-yl}acetamide; N- {2-[1-(3-Ethoxy-4-methoxyphenyl)-3-oxopentyl]1,3-dioxoisoindolin-4-yl}acetamide; 2-[(1R)-1-(3-Ethoxy-4-methoxyphenyl)-3-hydroxybutyl]-4-(pyrrolylmethyl)isoindoline-1,3-dione; 2-[(1R)-1-(3-Ethoxy-4-methoxyphenyl)-3-oxobutyl]-4-(pyrrolylmethyl)isoindoline-1 ,3-dione; N-{2-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-3-hydroxybutyl]-1,3-dioxoisomdolin-4-yl}acetamide; N-{2-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-3-oxobutyl]-1,3-dioxoisoindolin-4-yl}acetamide; 2-[1-(3-Cyclopentyloxy-4-methoxyphenyl)-3-oxobutyl]-4-pyrrolylisoindoline-1,3-dione; 2-[1-(3,4-Dimethoxyphenyl)-3-oxobutyl]-4-[bis(methylsulfonyl)amino]isoindoline-1,3-dione; and pharmaceutically acceptable salts, solvates, and stereoisomers thereof.
- Still
other PDE 4 modulators include, but are not limited to, imido and amido substituted acylhydroxamic acids (for example, (3-(1,3-dioxoisoindoline-2-yl)-3-(3-ethoxy-4-methoxyphenyl) propanoylamino) propanoate disclosed inWO 01/45702 U.S. patent no. 6,699,899 . Representative compounds are of formula: - the carbon atom designated * constitutes a center of chirality,
- R4 is hydrogen or -(C=O)-R12,
- each of R1 and R12, independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl methyl, pyridyl, imidazoyl, imidazolyl methyl, or
- CHR*(CH2)nNR*R0,
- wherein R* and R0, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl methyl, pyridyl, imidazoyl or imidazolylmethyl, and n = 0, 1, or 2;
- R5 is C=O, CH2, CH2-CO-, or SO2;
- each of R6 and R7, independently of the other, is nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, halo, bicycloalkyl of up to 18 carbon atoms, tricycloalkoxy of up to 18 carbon atoms, 1-indanyloxy, 2-indanyloxy, C4-C8-cycloalkylidenemethyl, or C3-C10-alkylidenemethyl;
- each of R8, R9, R10, and R11, independently of the others, is
- (i) hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halo, or
- (ii) one of R8, R9, R10, and R11 is acylamino comprising a lower alkyl, and the remaining of R8, R9, R10, and R11 are hydrogen, or
- (iii) hydrogen if R8 and R9 taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (iv) hydrogen if R10 and R11, taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (v) hydrogen if R9 and R10 taken together are benzo.
-
Other PDE 4 modulators include, but are not limited to, 7-amido-isoindolyl compounds disclosed inU.S. patent publication no. 2004/0254214 . Representative compounds are of formula: - Y is -C(O)-, -CH2, -CH2C(O)- or SO2;
- X is H;
- Z is (C0-4-alkyl)-C(O)R3, C1-4-alkyl, (C0-4-alkyl)-OH, (C1-4-alkyl)-O(C1-4-alkyl), (C1-4-alkyl)-SO2(C1-4-alkyl), (C0-4-alkyl)-SO(C1-4-alkyl), (C0-4-alkyl)-NH2, (C0-4-alkyl)-N(C1-8akyl)2, (C0-4-alkyl)-N(H)(OH), or CH2NSO2(C1-4-alkyl);
- R1 and R2 are independently C1-8-alkyl, cycloalkyl, or (C1-4-alkyl)cycloalkyl;
- R3 is, NR4 R5, OH, or O-(C1-8-alkyl);
- R4 is H;
- R5 is -OH, or -OC(O)R6;
- R6 is C1-8-alkyl, amino-(C1-8-alkyl), (C1-8-alkyl)-(C3-6-cycloalkyl), C3-6-cycloalkyl, phenyl, benzyl, or aryl;
- or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof; or formula:
- Y is -C(O)-, -CH2, -CH2C(O)-, or SO2;
- X is halogen, -CN, -NR7R8, -NO2, or -CF3;
- Z is (C0-4alkyl)-SO2(C1-4-alkyl), -(C0-4-alkyl)-CN, -(C0-4-alkyl)-C(O)R3, C1-4-alkyl, (C0-4-alkyl)OH, (C0-4-alkyl)O(C1-4-alkyl), (C0-4-alkyl)SO(C1-4-alkyl), (C0-4-alkyl)NH2, (C0-4-alkyl)N(C1-8-alkyl)2, (C0-4-alkyl) N(H)(OH), (C0-4-alkyl)-dichloropyridine or (C0-4-alkyl)NSO2(C1-4-alkyl);
- W is -C3-6-cycloalkyl, -(C1-8-alkyl)-(C3-6-cycloalkyl), -(C0-8-alkyl)-(C3-6-cycloalkyl)NR7R8, (C0-8-alkyl)-NR7R8, (C0-4alkyl)-CHR9-(C0-4alkyl)-NR7R8;
- R1 and R2 are independently C1-8-alkyl, cycloalkyl, or (C1-4-alkyl)cycloalkyl;
- R3 is C1-8-alkyl, NR4R5, OH, or O-(C1-8-alkyl);
- R4 and R5 are independently H, C1-8-alkyl, (C0-8-alkyl)-(C3-6-cycloalkyl), OH, or -OC(O)R6;
- R6 is C1-8-alkyl, (C0-8-alkyl)-(C3-6-cycloalkyl), amino-(C1-8-alkyl), phenyl, benzyl, or aryl;
- R7 and R8 are each independently H, C1-8-alkyl, (C0-8-alkyl)-(C3-6-cycloalkyl), phenyl, benzyl, aryl, or can be taken together with the atom connecting them to form a 3 to 7 membered heterocycloalkyl or heteroaryl ring;
- R9 is C1-4 alkyl, (C0-4alkyl)aryl, (C0-4alkyl)-(C3-6-cycloalkyl), (C0-4alkyl)-heterocylcle; or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
-
-
-
Other PDE 4 modulators include, but are not limited to, isoindoline compounds disclosed inU.S. patent publication no. 2006/0025457 . Representative compounds are listed in Table 1 below, for which pharmaceutically acceptable prodrugs, salts, solvates, and stereoisomers thereof are also encompassed:Table 1. No. Structure No. Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 - In another described aspect, also discussed are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-dinitroisoindoline-1,3-dione and its acid addition salts. In another described aspect, a hydrochloride salt of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4,5-dinitroisoindoline-1,3-dione is also provided.
-
Other PDE 4 modulators include, but are not limited to, isoindoline compounds disclosed inU.S. patent publication no. 2006/0084815 . Representative compounds are cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-[1,3,4]oxadiazol-2-yl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide, which has the following chemical structure, and pharmaceutically acceptable salts, solvates, prodrugs, and stereoisomers thereof: -
Other PDE 4 modulators include, but are not limited to, N-alkyl-hydroxamic acid-isoindolyl compounds disclosed inU.S. patent publication no. 2004/0259873 . Representative compounds are of formula: - Y is -C(O)-, -CH2, -CH2C(O)- or SO2;
- R1 and R2 are independently C1-8-alkyl, CF2H, CF3, CH2CHF2, cycloalkyl, or (C1-8-alkyl)cycloalkyl;
- Z1 is H, C1-6-alkyl, -NH2 -NR3R4 or OR5;
- Z2 is H or C(O)R5;
- X1, X2, X3 and X4 are each independent H, halogen, NO2, OR3, CF3, C1-6-alkyl, (C0-4-alkyl)-(C3-6-cycloalkyl), (C0-4-alkyl)-N-(R8R9), (C0-4-alkyl)-NHC(O)-(R8), (C0-4-alkyl)-NHC(O)CH(R8)(R9), (C0-4-alkyl)-NHC(O)N(R8R9), (C0-4-alkyl)-NHC(O)O(R8), (C0-4-alkyl)-O-R8, (C0-4-alkyl)-imidazolyl, (C0-4-alkyl)-pyrrolyl, (C0-4-alkyl) oxadiazolyl, (C0-4-alkyl)-triazolyl or (C0-4-alkyl)-heterocycle;
- R3, R4, and R5 are each independently H, C1-6-alkyl, O-C1-6-alkyl, phenyl, benzyl, or aryl;
- R6 and R7 are independently H or C1-6-alkyl;
- R8 and R9 are each independently H, C1-9-alkyl, C3-6-cycloalkyl, (C1-6-alkyl)-(C3-6cycloalkyl), (C0-6-alkyl)-N(R4R5), (C1-6-alkyl)-OR5, phenyl, benzyl, aryl, piperidinyl, piperizinyl, pyrolidinyl, morpholino, or C3-7-heterocycloalkyl;
- or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.
-
Other PDE 4 modulators include, but are not limited to, diphenylethylene compounds disclosed inU.S. patent publication no. 2005/0014727 . Representative compounds are of formula:
wherein: - R1 is -CN, lower alkyl, -COOH, -C(O)-N(R9)2, -C(O)-lower alkyl, -C(O)-benzyl, -C(O)O-lower alkyl, -C(O)O-benzyl;
- R4 is -H, -NO2, cyano, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, halogen, -OH, -C(O)(R10)2, -COOH, -NH2, -OC(O)-N(R10)2;
- R5 is substituted or unsubstituted lower alkyl, substituted or unsubstituted alkoxy, or substituted or unsubstituted alkenyl;
- X is substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, substituted or unsubstituted pyrrolidine, substituted or unsubstituted imidizole, substituted or unsubstituted naphthalene, substituted or unsubstituted thiophene, or substituted or unsubstituted cycloalkyl;
- each occurrence of R9 is independently -H or substituted or unsubstituted lower alkyl; and
- each occurrence of R10 is independently -H or substituted or unsubstituted lower alkyl.
-
- R1 and R2 are independently -H, -CN, substituted or unsubstituted lower alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, -COOH,-C(O)-lower alkyl, -C(O)O-lower alkyl, -C(O)-N(R9)2, substituted or unsubstituted aryl, or substituted or unsubstituted heterocycle;
- each occurrence of Ra, Rb, Rc and Rd is independently -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2;
- R3 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2, or R3 with either Ra or with R4, together form -O-C(R16R17)-O- or -O-(C(R16R17))2-O-;
- R4 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2;
- R5 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2,-OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2;
- R6 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2;
- R7 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2;
- R8 is -H, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocycle, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkoxy, halogen, cyano, -NO2, -OH, -OPO(OH)2, -N(R9)2, -OC(O)-R10, -OC(O)-R10-N(R10)2, -C(O)N(R10)2, -NHC(O)-R10, -NHS(O)2-R10, -S(O)2-R10, -NHC(O)NH-R10, -NHC(O)N(R10)2, -NHC(O)NHSO2-R10, -NHC(O)-R10-N(R10)2, -NHC(O)CH(R10)(N(R9)2) or -NHC(O)-R10-NH2, or R8 with either Rc or with R7, together form -O-C(R16R17)-O- or -O-(C(R16R17))2-O-;
- each occurrence of R9 is independently -H, substituted or unsubstituted lower alkyl, or substituted or unsubstituted cycloalkyl;
- each occurrence of R10 is independently substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted lower hydroxyalkyl, or R10 and a nitrogen to which it is attached form a substituted or unsubstituted heterocycle, or R10 is -H where appropriate; and
- each occurrence of R16 and R17 is independently -H or halogen.
- In one described aspect, compounds provided herein are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and cyclopropyl-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, which respectively have the following structures:
- All of the compounds described can either be commercially purchased or prepared according to the methods described in the patents or patent publications disclosed herein. Further, optically pure compounds can be asymmetrically synthesized or resolved using known resolving agents or chiral columns as well as other standard synthetic organic chemistry techniques.
- Compounds used herein may be small organic molecules having a molecular weight less than about 1,000 g/mol, and are not proteins, peptides, oligonucleotides, oligosaccharides or other macromolecules.
-
-
- It should be noted that if there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.
- Any suitable method of detecting differences the levels of mRNA or protein biomarkers can be used. In some embodiments, the biomarker to be detected is an mRNA molecule. In other embodiments, the method of measuring gene or protein expression can involve methods such as cDNA hybridization, flow cytometry, immunofluorescence, immunoblots, ELISAs or microspotted-antibody immunofluorescence assays, an antibody-based dipstick assay, cytometric bead arrays, or other common mRNA or protein detecting methods.
- Several methods of detecting or quantitating mRNA levels are known in the art. Exemplary methods include but are not limited to northern blots, ribonuclease protection assays, PCR-based methods, and the like. When the biomarker is an mRNA molecule, the mRNA sequence, or a fragment thereof, can be used to prepare a probe that is at least partially complementary. The probe can then be used to detect the mRNA sequence in a sample, using any suitable assay, such as PCR-based methods, Northern blotting, a dipstick assay, and the like.
- In other embodiments, a nucleic acid assay for testing for immunomodulatory activity in a biological sample can be prepared. An assay typically contains a solid support and at least one nucleic acid contacting the support, where the nucleic acid corresponds to at least a portion of an mRNA that has altered expression during an immunomodulatory treatment in a patient. The assay can also have a means for detecting the altered expression of the mRNA in the sample.
- The assay method can be varied depending on the type of mRNA information desired. Exemplary methods include but are not limited to Northern blots and PCR-based methods (e.g., qRT-PCR). Methods such as qRT-PCR can also accurately quantitate the amount of the mRNA in a sample.
- Any suitable assay platform can be used to determine the presence of the mRNA in a sample. For example, an assay may be in the form of a dipstick, a membrane, a chip, a disk, a test strip, a filter, a microsphere, a slide, a multiwell plate, or an optical fiber. An assay system may have a solid support on which a nucleic acid corresponding to the mRNA is attached. The solid support may comprise, for example, a plastic, silicon, a metal, a resin, glass, a membrane, a particle, a precipitate, a gel, a polymer, a sheet, a sphere, a polysaccharide, a capillary, a film a plate, or a slide. The assay components can be prepared and packaged together as a kit for detecting an mRNA.
- The nucleic acid can be labeled, if desired, to make a population of labeled mRNAs. In general, a sample can be labeled using methods that are well known in the art (e.g., using DNA ligase, terminal transferase, or by labeling the RNA backbone, etc.; see, e.g., Ausubel, et al., Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons 1995 and Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, 2001 Cold Spring Harbor, N.Y.). In some embodiments, the sample is labeled with fluorescent label. Exemplary fluorescent dyes include but are not limited to xanthene dyes, fluorescein dyes, rhodamine dyes, fluorescein isothiocyanate (FITC), 6 carboxyfluorescein (FAM), 6 carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6 carboxy 4', 5' dichloro 2', 7' dimethoxyfluorescein (JOE or J), N,N,N',N' tetramethyl 6 carboxyrhodamine (TAMRA or T), 6 carboxy X rhodamine (ROX or R), 5 carboxyrhodamine 6G (R6G5 or G5), 6 carboxyrhodamine 6G (R6G6 or G6), and rhodamine 110; cyanine dyes, e.g. Cy3, Cy5 and Cy7 dyes; Alexa dyes, e.g. Alexa-fluor-555; coumarin, Diethylaminocoumarin, umbelliferone; benzimide dyes, e.g. Hoechst 33258; phenanthridine dyes, e.g. Texas Red; ethidium dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethine dyes, BODIPY dyes, quinoline dyes, Pyrene, Fluorescein Chlorotriazinyl, R110, Eosin, JOE, R6G, Tetramethylrhodamine, Lissamine, ROX, Napthofluorescein, and the like.
- The nucleic acids may be present in specific, addressable locations on a solid support; each corresponding to at least a portion of mRNA sequences that are differentially expressed upon treatment of an immunomodulatory compound in a cell or a patient.
- A typical mRNA assay method can contain the steps of 1) obtaining surface-bound subject probes; 2) hybridization of a population of mRNAs to the surface-bound probes under conditions sufficient to provide for specific binding (3) post-hybridization washes to remove nucleic acids not bound in the hybridization; and (4) detection of the hybridized mRNAs. The reagents used in each of these steps and their conditions for use may vary depending on the particular application.
- Hybridization can be carried out under suitable hybridization conditions, which may vary in stringency as desired. Typical conditions are sufficient to produce probe/target complexes on a solid surface between complementary binding members, i.e., between surface-bound subject probes and complementary mRNAs in a sample. In certain embodiments, stringent hybridization conditions may be employed.
- Hybridization is typically performed under stringent hybridization conditions. Standard hybridization techniques (e.g. under conditions sufficient to provide for specific binding of target mRNAs in the sample to the probes) are described in Kallioniemi et al., Science 258:818-821 (1992) and
WO 93/18186 - Those of ordinary skill will readily recognize that alternative but comparable hybridization and wash conditions can be utilized to provide conditions of similar stringency.
- After the mRNA hybridization procedure, the surface bound polynucleotides are typically washed to remove unbound nucleic acids. Washing may be performed using any convenient washing protocol, where the washing conditions are typically stringent, as described above. The hybridization of the target mRNAs to the probes is then detected using standard techniques.
- Other methods, such as PCR-based methods, can also be used to follow the expression of the mRNA biomarkers. Examples of PCR methods can be found in the literature. Examples of PCR assays can be found in
U.S. Patent No. 6,927,024 . Examples of RT-PCR methods can be found inU.S. Patent No. 7,122,799 . A method of fluorescent in situ PCR is described inU.S. Patent No. 7,186,507 . - In some embodiments, Real-Time Reverse Transcription-PCR (qRT-PCR) can be used for both the detection and quantification of RNA targets (Bustin, et al., 2005, Clin. Sci., 109:365-379). Quantitative results obtained by qRT-PCR are generally more informative than qualitative data. Thus, in some embodiments, qRT-PCR-based assays can be useful to measure mRNA levels during cell-based assays. The qRT-PCR method is also useful to monitor patient therapy. Examples of qRT-PCR-based methods can be found, for example, in
U.S. Patent No. 7,101,663 . - In contrast to regular reverse transcriptase-PCR and analysis by agarose gels, real-time PCR gives quantitative results. An additional advantage of real-time PCR is the relative ease and convenience of use. Instruments for real-time PCR, such as the Applied Biosystems 7500, are available commercially, as are the reagents, such as TaqMan Sequence Detection chemistry. For example, TaqMan® Gene Expression Assays can be used, following the manufacturer's instructions. These kits are pre-formulated gene expression assays for rapid, reliable detection and quantification of human, mouse and rat mRNA transcripts. An exemplary PCR program, for example, is 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, then 60°C for 1 minute.
- To determine the cycle number at which the fluorescence signal associated with a particular amplicon accumulation crosses the threshold (referred to as the CT), the data can be analyzed, for example, using a 7500 Real-Time PCR System Sequence Detection software v1.3 using the comparative CT relative quantification calculation method. Using this method, the output is expressed as a fold-change of expression levels. In some embodiments, the threshold level can be selected to be automatically determined by the software. In some embodiments, the threshold level is set to be above the baseline but sufficiently low to be within the exponential growth region of an amplification curve.
- When the biomarker is a protein, several protein detection and quantitation methods can be used to measure the presence of the biomarker. Any suitable protein quantitation method can be used. In some embodiments, antibody-based methods are used. Exemplary methods that can be used include but are not limited to immunoblotting (western blot), enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, cytometric bead array, mass spectroscopy, and the like. Several types of ELISA are commonly used, including direct ELISA, indirect ELISA, and sandwich ELISA.
- In some described aspects, a kit for detecting the mRNA biomarkers can be prepared. The kits can include, for example, a probe or probe set comprising oligonucleotides that can bind to the mRNA biomarker(s) of interest for psoriasis. Washing solutions, reagents for performing a hybridization assay, mRNA isolation or purification means, detection means, as well as positive and negative controls can also be included. The kit can also include instructions for using the components of the kit. The kit can be tailored for in-home use, clinical use, or research use.
- In some described aspects, a kit for detecting protein levels can be prepared. The kits can include, for example, a dipstick coated with an antibody that recognizes the protein, washing solutions, reagents for performing the assay, protein isolation or purification means, detection means, as well as positive and negative controls. The kit can also include instructions for using the components of the kit. The kit can be tailored for in-home use, clinical use, or research use.
- The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are intended to be merely illustrative.
- Skin biopsies were evaluated on 20 patients in a clinical trial, where 20 mg of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide was administered b.i.d. to patients with psoriasis. Skin biopsies were done 4 weeks and 12 weeks post-treatment.
- The biopsies were subjected to a histological analysis in which response was assessed in H&E stained sections of skin biopsies and after staining frozen sections of skin biopsies with antibodies to keratin 16, CD3, CD11c, ICAM-1, Langerin, CD56, Foxp3, and HLA-DR. This analysis thus included an assessment of epidermal growth/differentiation, skin infiltration by T-cells and DC subsets, presence of regulatory T-cells, and presence of inflammation-regulating molecules in skin lesions.
- Of the 20 cases analyzed, 19 showed good or active psoriasis lesions in baseline biopsies. One had minimally reactive epidermis in the baseline lesional biopsy and thus did not meet histologic criteria for active psoriasis vulgaris in the baseline biopsy. At day 29, 10 cases showed improvement in psoriasis, based on a reduction in epidermal hyperplasia and/or a reduction in keratin 16 staining. Using all measured values of thickness, there was a 23% reduction in epidermal thickness at week 4 (p = 0.07 or approaching statistical significance in a 2-sided test). Nine cases showed disease improvement in day 85 biopsies, with 5 cases showing absence of keratin 16 staining. At this timepoint, the median reduction in epidermal thickness was 34% (p-value 0.049). Hence, the quantitative reduction in epidermal thickness was significant for the group as a whole. It is very unusual that psoriasis shows spontaneous improvement, so the 5 cases where epidermis became K16- (keratin 16 negative) are highly significant in qualitative terms.
- As to the infiltrating leukocytes in these biopsies, T-cell reductions were measured in day 29 and day 85 biopsies, but the heterogeneity of the response did not lead to statistical significance of the overall reductions. CD11c marks myeloid dendritic cells in human skin. Normally, there is a resident population of CD11c+ cells in the dermis, but psoriasis shows both an increase in dermal CD11c+ DCs and inappropriate migration of CD11c+ cells into the epidermis of skin lesions. Dermal CD11c+ DCs were reduced in
week 4 andweek 12 biopsies, and the 45% median reduction inweek 4 biopsies was highly significant (p = 0.001). Epidermal CD11c+ infiltrates were even more strongly reduced (73-84%) atweeks week 4 andweek 12. A small increase in epidermal Langerhan's cells was noted in day 85 biopsies, consistent with normalization of this cell population with effective therapy. - The expression of inflammation-associated molecules ICAM-1 and HLA-DR was reduced in parallel with disease improvement reflected by epidermal thickness or K16 staining. These were qualitative markers of inflammation, so the change has not been quantified and subjected to statistical analysis. However, one case showed a good example of progressive reductions in ICAM-1 and HLA-DR staining in parallel with reductions in epidermal hyperplasia.
- The presence of Foxp3+ cells in the dermis of skin lesions was reduced over time in parallel with reductions in T-cells. One case showed a good example of this outcome. This suggests that the mechanism of action is more related to suppression of active inflammation, rather than suppression of inflammation through an increased Treg T-cell population.
- The results observed in certain histological analysis are summarized below:
Table 2 Histologic Measurement Week 4 Week 12Median % change from baseline P Median % change from baseline P CD11c myeloid DC in Dermis -45.8 0.001 -54.6 0.363 CD11c myeloid DC in Epidermis -73.1 0.001 -88.6 >0.001 CD3 T cells in Dermis -24.5 0.82 -62.0 0.255 CD3 T cells in Epidermis -35.0 0.286 -47.4 0.136 CD56 NK cells in Dermis -27.6 0.544 -12.5 0.656 CD56 NK cells in Epidermis -75.6 0.004 -73.3 0.499 Langerin in Dermis -50.0 0.456 -57.9 0.474 Langerin in Epidermis 9.5 0.082 17.1 0.026 Epidermal Thickness -22.9 0.070 -34.3 0.049 - mRNA abundance for a variety of inflammatory molecules was measured by real-time RT-PCR and expression was normalized to the house-keeping gene HARP (human acidic ribosomal protein). Inflammatory markers assessed by mRNA levels included the chemokine CXCL9, beta-defensin (DEFB4), interferon-gamma, IL-10, IL-17a, IL-22, IL-8, keratin 16, MX-1, IL-12/23 p40, IL-23 p19, iNOS and TNF. These are inflammatory molecules produced by activated DC populations, Th1, Th17, Th22 T-cells, and response genes to interferon (MX-1, CXCL9) or IL-17 (defensin). Keratin 16 was also measured by mRNA levels to assess the epidermal response by an alternate means.
- At
week 12, there was a median reduction in K16 mRNA by 78% (p = 0.045), which confirms the overall improvement of psoriasis as assessed by epidermal thickness measures at this same time-point. The reduction in K16 mRNA was of higher magnitude than the reduction in epidermal thickness, as this keratin is produced only in reactive (hyperplastic) epidermis. Normal epidermis has a thickness value, so the maximal case for a thickness reduction is to normal values. - From the histologic analysis, CD11c+ myeloid leukocytes showed more consistent reductions than T-cells in lesions. From the genomic standpoint, iNOS, p40, and p19 genes are products of inflammatory (CD11c+) DCs. Normalized iNOS mRNA expression was reduced by 61% at week 4 (p=0.015) and by 100% at week 12 (p=0.005). This is consistent with the core drug mechanism of reducing bioactive TNF in inflammatory skin lesions.
- Another TNF-induced gene in CD11c+ DCs is the IL-12/23 p40 gene. One p40 custom probe set showed significant reductions in
week 4 andweek 12 biopsies. Without being limited by a particular theory, the prediction of this reduction is that levels of IL-12 and/or IL-23 would be reduced, with subsequent reductions in Th1, Th17, and Th22 T-cell activation, followed by reductions in downstream genes of IL-17 or interferon signaling. Normalized IL-17A mRNA levels were reduced by 49% at week 12 (p=0.023), and normalized IL-22 mRNA levels were reduced by 100% at week 12 (p=0.001). - DEFB4 is a defensin induced in keratinocytes by IL-17. Normalized expression of DEFB4 was reduced by 47% at week 4 (p=0.036) and by 45% in
week 12 biopsies (p=0.011). IL-8 is also induced in keratinocytes by IL-17. Normalized expression of this inflammatory chemokine was reduced by 76% inweek 4 biopsies (p=0.001) and by 66% inweek 12 biopsies (p=0.017). Without being limited by a particular theory, the larger magnitude reduction in IL-8 (as compared to DEFB4), probably reflects the co-regulation of IL-8 by TNF and the fact that TNF signaling is probably reduced by the study drug. - Reduction in normalized MX-1 mRNA in biopsies was also consistently observed: median reduction of 51% at week 4 (p=0.005) and a reduction of 52% at week 12 (p<0.001). This most likely reflects a reduction in other interferons (Type 1 interferons) that were not directly measured by genomic probes.
- The results are summarized in the following table:
Table 3 mRNA Week 4 Week 12Median % change from baseline (normalized to hARP) P Median % change from baseline (normalized to hARP) P IL-12/IL-23 p40 -100 0.003 -86.7 0.023 iNOS -61.0 0.015 -100 0.005 IL-22 -74.4 0.900 -100 0.001 IL-8 -76.4 0.001 -66.5 0.017 DEFB4 -55.4 0.032 -82.3 0.002 MX-1 -51.1 0.005 -52.6 <0.001 K-16 -62.0 0.143 -78.6 0.045 IL-17A -72.5 0.091 -49.4 0.023 IL-23p19 -53.4 0.333 -68.3 0.257 IL-10 -49.1 0.871 -26.5 0.912 IFN-g -38.2 0.221 -37.6 0.812 CXCL9 (MIG) -30.7 0.701 -36.4 0.538 - The pharmacodynamic effects of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide were studied in skin biopsies from subjects treated with the compound in a
phase 2, multi-center, open-label study evaluating the safety, tolerability, and efficacy of the compound in recalcitrant psoriasis vulgaris. Skin biopsies were taken from uninvolved and involved skin at baseline, and from involved skin after treatment with (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide 20 mg BID after 4 and 12 weeks. - Skin biopsies were evaluated on 20 patients in this trial. The biopsies were analyzed by immunohistochemistry for a set of cellular markers (keratin 16, CD3, CD11c, ICAM-1, Langerin, CD56, Foxp3, and HLA-DR) to assess epidermal growth/differentiation, skin infiltration by T-cells and dendritic cells (DC), presence of regulatory T-cells, and the presence of inflammation-regulating molecules in skin lesions.
- Antibody staining for ICAM-1, Foxp3, and HLA-DR was qualitative and no major changes were noted for these markers. Overall, there was a major reduction in inflammatory myeloid CD11c+ DCs, also called TIP-DCs (TNF- and iNOS-producing DCs) in both the epidermis (
FIG. 1 ) and dermis (FIG. 3 ) at bothweek 4 andweek 12. In particular, as shown inFIG. 1 , pathologic infiltration of psoriatic epidermis by the myeloid DC was inhibited most strongly. There were also significant reductions in CD3+ T cells in the epidermis and dermis, and in CD56+ NK cells in the epidermis. - Additionally, the reductions observed from biopsies were evaluated separately in responders and non-responders. In general, reductions in cellular infiltrates in epidermis (
FIG. 2 ) and dermis (FIG. 4 ) were greater among responders (those with a change in PASI of 75% or more at week 12) than among non-responders. Langerin, a marker of Langerhans cells (LC), was slightly elevated in the epidermis (FIG. 1 ) but not the dermis (FIG. 3 ), though this effect was not statistically significant, it was attributable mostly to the increase in LC in the epidermis among non-responders (FIG. 2 ). - The expression of proinflammatory gene products known to be involved in the pathogenesis of psoriasis was measured by real-time polymerase chain reaction (RT-PCR). With regard to gene expression, there were reductions in iNOS and IL-12/IL-23 p40 mRNAs, along with reductions in IL-17A and IL-22 mRNAs, indicating inhibition of the Th1, Th17, and Th22 pathways (
FIG. 5 ). The IL-12/23 p40 mRNA levels showed significant reductions inweek 4 andweek 12 biopsies. Normalized IL-17A mRNA levels were reduced by 49% atweek 12 and normalized IL-22 mRNA levels were reduced by 100% atweek 12. DEFB4, a defensin induced in keratinocytes by IL-17, was reduced by 55% inweek 4 biopsies and by 82% inweek 12 biopsies. IL-8, which is induced in keratinocytes by IL-17, was reduced by 76% inweek 4 biopsies and by 66% inweek 12 biopsies. - Additionally, the reduction of gene expression was evaluated separately in responders and non-responders. In general, inhibition of gene expression was greater among responders than non-responders (
FIG. 6 ). The results of this analysis strongly support the biological activity of (S)-N-(2-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide in psoriasis vulgaris by a mechanism involving inhibition of myeloid dendritic cells, and suppression of genes contributing to the Th1, Th17, and Th17 pro-inflammatory pathways. - To identify changes in cellular infiltration or gene expression that correlate with changes in PASI score, a correlation analysis was performed using the Spearman rank-order correlation method. As shown in Table 4, a significant correlation was observed between the decrease in CD56+ NK cells in the epidermis and the decrease in the PASI score at week 4 (p=0.009). A strong trend was observed between the decrease in CD11c+ myeloid DC in the epidermis the decrease in PASI score at week 4 (p=0.052).
Table 4. Correlation of Percent Changes from Baseline (week 0) in PASI Score and the Associated Skin Biopsy Parameters Test Week No. * PSAI Median Change (%) Biopsy Parameters Median Change (%) Spearman Rank-order Correlation Coefficient p-value** CD3 in Dermis 4 19 -29.0 -24.5 -0.143 0.559 12 15 -48.0 -63.1 0.211 0.451 CD3 in Epidermis 4 19 -29.0 -35.0 0.044 0.858 12 15 -48.0 -56.1 0.304 0.271 CD11c in Dermis 4 20 -32.0 -45.8 0.302 0.196 12 14 -52.5 -56.0 0.073 0.805 CD11c in Epidermis 4 18 -26.5 -73.1 0.465 0.052 12 13 -45.0 -97.5 0.448 0.125 CD56 in Dermis 4 20 -32.0 -27.6 0.232 0.326 12 15 -48.0 -18.2 0.432 0.108 CD56 in Epidermis 4 16 -15.0 -75.6 0.631 0.009 12 12 -42.5 -77.6 0.189 0.557 Langerin in Dermis 4 17 -18.0 -50.0 0.465 0.06 12 12 -54.0 -67.0 0.416 0.178 Langerin in Epidermis 4 20 -32.0 9.49 0.336 0.148 12 15 -48.0 41.67 0.289 0.296 Thickness 4 19 -29.0 -22.9 0.051 0.836 12 14 -46.5 -34.8 0.341 0.233 * Subjects with values for both PASI % change and biopsy parameters % change were included
** p-value is for testing no correlation in rank-order % changes - As shown below in Table 5, among the changes in gene expression and PASI change at
week 4, there was a significant correlation for DEFB4 (p=0.005), MX-1 (p=0.008) and IL-12/IL-23p40 (p=0.033). Atweek 12, there was a significant correlation between the drop in PASI score and the drop in expression DEFB4 (p=0.009), IL-17A (p=0.03), K16 (p=0.001), and iNOS (p=0.033). Atweek 12, there was also a strong trend was also observed for the decrease in PASI score and the expression of IL-8 week (p=0.051) (Table 14.2.20.4).Table 5. Correlation of Percent Changes from Baseline (week 0) in PASI Score and Gene Expression of the Associated Inflammatory Biomarkers Test Week No.* PSAI Median Change (%) Gene Expression Median Change (%) Spearman Rank-order Correlation Coefficient p-value** CD83/hARP 4 15 -18.0 -12.4 -0.097 0.732 12 11 -48.0 27.39 0 1 CXCL9/hARP 4 17 -29.0 -30.7 0.286 0.266 12 11 -48.0 -15.8 0.182 0.593 DEFB4/hARP 4 16 -23.5 -55.4 0.669 0.005 12 10 -46.5 -82.0 0.769 0.009 IPNγ/hARP 4 15 -35.0 -38.2 0.448 0.094 12 12 -54.0 -15.3 -0.376 0.185 IL-10/hARP 4 18 -32.0 -49.1 -0.018 0.945 12 14 -54.0 -15.3 -0.376 0.185 IL-17A/hARP 4 16 -23.5 -72.5 0.424 0.102 12 10 -46.5 -46.7 0.681 0.03 IL-2/hARP 4 12 -32.0 3.33 -0.358 0.253 12 10 -54.0 -25.0 0.091 0.802 IL-22/hARP 4 10 -18.5 -74.4 0.323 0.363 12 6 -46.5 -100 0.135 0.798 IL-8/hARP 4 18 -32.0 -76.4 0.076 0.763 12 14 -54.0 -79.2 0.53 0.051 K16/hARP 4 18 -32.0 -62.0 0.419 0.084 12 14 -54.0 -82.5 0.798 0.001 MX1/hARP 4 17 -29.0 -51.1 0.62 0.008 12 11 -48.0 -51.5 0.018 0.958 p40/hARP 4 13 -29.0 -100 0.593 0.033 12 7 -48.0 -51.5 0.018 0.958 TNFα/hARP 4 17 -29.0 -13.0 -0.307 0.231 12 13 -60.0 -41.3 -0.049 0.873 iNOS/hARP 4 15 -35.0 -61.0 0.465 0.067 12 11 -48.0 -100 0.642 0.033 p19/hARP 4 18 -32.0 -53.4 0.182 0.47 12 14 -54.0 -67.9 0.411 0.144 * Subjects with values for both PASI % change and biopsy parameters % change were included
** p-value is for testing no correlation in rank-order % changes - Additionally, in order to identify specific changes in cellular infiltration or gene expression at
week 4 that might predict eventual clinical response as defined by a PASI-75 or greater atweek 12, a Spearman rank-order correlation analysis was performed. For example, if the IFN-γ /hARP ratio decreases by -70% to -100% atWeek 4, it was predicted that the subject will have PASI-75 response; otherwise non PASI-75 response. From this analysis, a significant correlation was found between the change in IFN-γ expression atweek 4 and a later change in PASI score at week 12 (p=0.04) (FIG. 7 ). As shown inFIG. 7 , among four subjects who had PASI-75 response atweek 12, three showed IFNγ change between -70% to -100% atweek 4, indicating a 75% accuracy in this prediction model. Indeed, the three subjects who attained a PASI-75 or better atweek 12 showed a 100% reduction in IFN-γ gene expression in the skin atweek 4. In addition, all of the eight subjects who had non PASI-75 response atweek 12 showed IFNγ change was less than 70% decrease, indicating a 100% accuracy. - Alternatively, the analysis may be set to designate PASI-75 response to be change in IFNγ expression between -60% and -100%. When this analysis was conducted, the prediction accuracies were about 75% for PASI-75 response and 80% for non PASI-75 response, respectively. Therefore, monitoring a subject for a decrease in IFN-γ expression in the skin or peripheral blood may provide a method of early prediction for eventual attainment of a beneficial clinical response.
- Another useful predictive marker may be the reduction in the amount of Langerin (a marker of Langerhans cells, or LC) in the dermis at
week 4. Similar to the IFNγ analysis, if the Langerin staining in the dermis is decreased by -70% to -100% atWeek 4, it was predicted that the subject will have PASI-75 response; otherwise non PASI-75 response. As shown inFIG. 8 , among four subjects who had PASI-75 response atweek 12, three showed Langerin change between -70% to -100% atweek 4, indicating a 75% accuracy in this prediction model. In addition, nine out of the ten subjects who had non PASI-75 response atweek 12 showed Langerin change less than 70% decrease, indicating a 90% accuracy.
Y is -COX, -C≡N, -OR8, alkyl of 1 to 5 carbon atoms, or aryl;
X is -NH2, -OH, -NHR, -R9, -OR9, or alkyl of 1 to 5 carbon atoms;
R8 is hydrogen or lower alkyl;
R9 is alkyl or benzyl; and,
n has a value of 0, 1, 2, or 3.
R3 is (i) phenyl, unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkyl of up to 10 carbon atoms, cycloalkyl of up to 10 carbon atoms, alkoxy of up to 10 carbon atoms, cycloalkoxy of up to 10 carbon atoms, alkylidenemethyl of up to 10 carbon atoms, cycloalkylidenemethyl of up to 10 carbon atoms, phenyl, or methylenedioxy; (ii) pyridine, substituted pyridine, pyrrolidine, imidizole, naphthalene, or thiophene; (iii) cycloalkyl of 4-10 carbon atoms, unsubstituted or substituted with 1 or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, phenyl;
each of R4 and R5 taken individually is hydrogen or R4 and R5 taken together are a carbon-carbon bond;
Y is -COZ, -C≡N, or lower alkyl of 1 to 5 carbon atoms;
Z is -OH, -NR6R6, -R7, or -OR7; R6 is hydrogen or lower alkyl; and R7 is alkyl or benzyl.
R3 is pyrrolidine, imidazole or thiophene unsubstituted or substituted with 1 or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl;
each of R4 and R5 taken individually is hydrogen or R4 and R5 taken together are a carbon-carbon bond;
Y is -COZ, -C≡N, or lower alkyl of 1 to 5 carbon atoms;
Z is -OH, -NR6R6, -R7, or -OR7; R6 is hydrogen or lower alkyl; and R7 is alkyl or benzyl.
R3 is (i) phenyl or naphthyl, unsubstituted or substituted with 1 or more substituents each selected independently from nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, or carbamoyl substituted with alkyl of 1 to 3 carbon atoms, acetoxy, carboxy, hydroxy, amino, amino substituted with an alkyl of 1 to 5 carbon atoms, alkoxy or cycloalkoxy of 1 to 10 carbon atoms; or (ii) cycloalkyl of 4 to 10 carbon atoms, unsubstituted or substituted with one or more substituents each selected independently from the group consisting of nitro, cyano, halo, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, substituted amino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, or phenyl.
Claims (10)
- A method of predicting whether a patient will be responsive to a treatment for psoriasis comprising:culturing cells from a skin sample of the patient in the presence or absence of the treatment compound;measuring the level of a cell marker or mRNA; andcomparing the level of the cell marker or mRNA in the cells cultured in the presence of the treatment compound to that in cells cultured in the absence of the treatment compound,wherein the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide, and
wherein a decreased level of the cell marker or mRNA in the presence of the treatment compound indicates the likelihood of an effective patient response to the treatment compound,
wherein the cell marker is selected from CD3, CD56, Foxp3, Langerin and a combination thereof or
wherein the mRNA is selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof. - The method of claim 1, wherein (i) the level of only one of the cell markers or mRNAs is monitored, or (ii) the levels of two or more of the cell markers or mRNAs are monitored simultaneously.
- A method of monitoring patient response to a psoriasis treatment comprising:measuring the level of a cell marker or mRNA in a first skin sample from the patient;measuring the level of the same cell marker or mRNA in a second skin sample obtained after administering a treatment compound to the patient; andcomparing the levels of the cell marker or mRNA obtained from first and second skin samples,wherein the treatment compound is cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide, and
wherein a decreased level of the cell marker in the second skin sample indicates an effective response,
wherein the cell marker is selected from CD3, CD56, Foxp3, Langerin and a combination thereof, or
wherein the mRNA is selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof. - The method of claim 3, wherein the level of CD3 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD3 in the first skin sample.
- The method of claim 3, wherein the level of CD3 obtained from the epidermis region is monitored, and the decrease is about 25%, 30%, 35%, or 40% or more as compared to the level of CD3 in the first skin sample.
- The method of claim 3, wherein the level of CD56 obtained from the dermis region is monitored, and the decrease is about 15%, 20%, 25%, or 30% or more as compared to the level of CD56 in the first skin sample.
- The method of claim 3, wherein the level of CD56 obtained from the epidermis region is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of CD56 in the first skin sample.
- The method of claim 3, wherein the level of Langerin obtained from the dermis region is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of Langerin in the first skin sample.
- A method for monitoring patient compliance with a drug treatment protocol for psoriasis comprising:measuring the level of a cell marker or mRNA in a skin sample from the patient; anddetermining if the expression level is decreased in the skin sample compared to the expression level in a control untreated sample,wherein the drug treatment protocol comprises administering cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide to the patient, and
wherein a decreased expression indicates patient compliance with said drug treatment protocol
wherein the cell marker is selected from CD3, CD56, Foxp3, Langerin and a combination thereof, or
wherein the mRNA is selected from mRNA for Keratin 16, IL-12/IL-23 p40, IL-23 p19, IL-17A, IL-22, DEFB4, IL-8, MX-1, IL-10, IFN-γ, CXCL9 and a combination thereof. - The method of claim 3 or 9, wherein(i) the level of IL-12/IL-13 p40 mRNA is monitored, and the decrease is about 80%, 85%, 90%, or 95% or more as compared to the level of IL-12/IL-13 p40 mRNA in the first skin sample;(ii) the level of IL-22 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-22 mRNA in the first skin sample;(iii) the level of IL-8 mRNA is monitored, and the decrease is about 65%, 70%, 75%, or 80% or more as compared to the level of IL-8 mRNA in the first skin sample;(iv) the level of DEFB4 mRNA is monitored, and the decrease is about 45%, 50%, 55%, or 60% or more as compared to the level of DEFB4 mRNAin the first skin sample;(v) the level of MX-1 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of MX-1 mRNA in the first skin sample;(vi) the level of Keratin 16 mRNA is monitored, and the decrease is about 50%, 55%, 60%, or 65% or more as compared to the level of Keratin 16 mRNA in the first skin sample;(vii) the level of IL-17A mRNA is monitored, and the decrease is about 60%, 65%, 70%, or 75% or more as compared to the level of IL-17A mRNA in the first skin sample;(viii) the level of IL-23 p19 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-23 p19 mRNA in the first skin sample;(ix) the level of IL-10 mRNA is monitored, and the decrease is about 40%, 45%, 50%, or 55% or more as compared to the level of IL-10 mRNA in the first skin sample;(x) the level of IFN-γ mRNA is monitored, and the decrease is about 30%, 35%, 40%, or 45% or more as compared to the level of IFN-γ mRNA in the first skin sample; or(xi) the level of CXCL9 mRNA is monitored, and the decrease is about 20%, 25%, 30%, or 35% or more as compared to the level of CXCL9 mRNA in the first skin sample.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35511610P | 2010-06-15 | 2010-06-15 | |
US201161454916P | 2011-03-21 | 2011-03-21 | |
PCT/US2011/040430 WO2011159750A1 (en) | 2010-06-15 | 2011-06-15 | Biomarkers for the treatment of psoriasis |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2583098A1 EP2583098A1 (en) | 2013-04-24 |
EP2583098B1 true EP2583098B1 (en) | 2018-08-08 |
Family
ID=44279738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11726315.2A Active EP2583098B1 (en) | 2010-06-15 | 2011-06-15 | Biomarkers for the treatment of psoriasis |
Country Status (13)
Country | Link |
---|---|
US (1) | US20110318741A1 (en) |
EP (1) | EP2583098B1 (en) |
JP (3) | JP2013531499A (en) |
KR (1) | KR101913868B1 (en) |
CN (1) | CN103026229B (en) |
AU (1) | AU2011268450B2 (en) |
BR (1) | BR112012032217A2 (en) |
CA (1) | CA2798742A1 (en) |
ES (1) | ES2692152T3 (en) |
IL (1) | IL222844A (en) |
MX (1) | MX341896B (en) |
NZ (1) | NZ603375A (en) |
WO (1) | WO2011159750A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019000046A (en) | 2010-11-04 | 2023-10-05 | Boehringer Ingelheim Int | Anti-il-23 antibodies. |
CA2871985C (en) | 2012-05-03 | 2023-10-10 | Boehringer Ingelheim International Gmbh | Anti-il-23p19 antibodies |
WO2014178715A1 (en) * | 2013-05-02 | 2014-11-06 | Stichting Katholieke Universiteit | Personalised medicine |
WO2015173792A1 (en) | 2014-05-11 | 2015-11-19 | Mapi Pharma Ltd. | Amorphous form of apremilast |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
UA123624C2 (en) | 2014-09-03 | 2021-05-05 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Compound targeting il-23a and tnf-alpha and uses thereof |
EP3380074A4 (en) * | 2015-11-23 | 2019-04-24 | Sirbal Ltd. | Identification of biomarkers in serum samples collected from clinical trials by multiplex technology |
CN107860830A (en) * | 2017-10-10 | 2018-03-30 | 暨南大学 | Application of the biomarker in its targeted drug in a kind of psoriasis vulgaris blood plasma |
EP4182691A2 (en) * | 2020-07-17 | 2023-05-24 | Icahn School of Medicine at Mount Sinai | Biomarkers and classifier of psoriasis and methods of treatment |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090239926A1 (en) * | 2008-03-24 | 2009-09-24 | Schafer Peter H | Methods for the treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-carboxamide |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
JP3645903B2 (en) | 1992-03-04 | 2005-05-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Comparative genomic hybridization (CGH) |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5605914A (en) | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US5703098A (en) | 1994-12-30 | 1997-12-30 | Celgene Corporation | Immunotherapeutic imides/amides |
US5801195A (en) | 1994-12-30 | 1998-09-01 | Celgene Corporation | Immunotherapeutic aryl amides |
US6518281B2 (en) | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5728845A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
US5658940A (en) | 1995-10-06 | 1997-08-19 | Celgene Corporation | Succinimide and maleimide cytokine inhibitors |
CZ299810B6 (en) | 1996-08-12 | 2008-12-03 | Celgene Corporation | Substituted aromatic compound and use thereof in the reduction of cytokine level |
CZ299873B6 (en) | 1997-07-31 | 2008-12-17 | Celgene Corporation | Hydroxamic acid derivative and pharmaceutical composition in which the derivative is comprised |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
US6087112A (en) * | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US6667316B1 (en) | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7186507B2 (en) | 1999-12-09 | 2007-03-06 | Indiana University Research And Technology Corporation | Fluorescent in situ RT-PCR |
US6326388B1 (en) | 1999-12-21 | 2001-12-04 | Celgene Corporation | Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level |
US6699899B1 (en) | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US7101663B2 (en) | 2001-03-02 | 2006-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | PCR method |
US7893101B2 (en) * | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
WO2003080048A1 (en) | 2002-03-20 | 2003-10-02 | Celgene Corporation | (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
BR0316256A (en) | 2002-11-18 | 2005-10-04 | Celgene Corp | Methods of inhibiting tnf-alpha production and pde4 activity, treating or preventing a disease or disorder, controlling camp levels in a cell and producing a compound, pharmaceutical composition and compound |
CA2511843C (en) | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
KR20050117533A (en) | 2003-03-05 | 2005-12-14 | 셀진 코포레이션 | Diphenylethylene compounds and uses thereof |
WO2004080422A2 (en) | 2003-03-12 | 2004-09-23 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
NZ542671A (en) | 2003-03-12 | 2008-12-24 | Celgene Corp | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
AU2006330410A1 (en) * | 2005-12-28 | 2007-07-05 | Centocor, Inc. | Markers and methods for assessing and treating psoriasis and related disorders |
US8575190B2 (en) * | 2007-11-14 | 2013-11-05 | Mitsubishi Gas Chemical Company, Inc. | Method of preventing or ameliorating psoriasis using pyrroloquinoline quinone compounds |
EP2695616A1 (en) * | 2008-03-27 | 2014-02-12 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
EP2337799A2 (en) * | 2008-08-28 | 2011-06-29 | Wyeth LLC | Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases |
-
2011
- 2011-06-15 MX MX2012013803A patent/MX341896B/en active IP Right Grant
- 2011-06-15 CA CA2798742A patent/CA2798742A1/en not_active Abandoned
- 2011-06-15 US US13/161,201 patent/US20110318741A1/en not_active Abandoned
- 2011-06-15 KR KR1020127032791A patent/KR101913868B1/en active IP Right Grant
- 2011-06-15 ES ES11726315.2T patent/ES2692152T3/en active Active
- 2011-06-15 CN CN201180029695.0A patent/CN103026229B/en active Active
- 2011-06-15 BR BR112012032217A patent/BR112012032217A2/en not_active Application Discontinuation
- 2011-06-15 AU AU2011268450A patent/AU2011268450B2/en active Active
- 2011-06-15 EP EP11726315.2A patent/EP2583098B1/en active Active
- 2011-06-15 WO PCT/US2011/040430 patent/WO2011159750A1/en active Application Filing
- 2011-06-15 NZ NZ603375A patent/NZ603375A/en unknown
- 2011-06-15 JP JP2013515465A patent/JP2013531499A/en active Pending
-
2012
- 2012-11-04 IL IL222844A patent/IL222844A/en active IP Right Grant
-
2016
- 2016-05-20 JP JP2016101189A patent/JP2016185151A/en active Pending
-
2018
- 2018-06-27 JP JP2018121550A patent/JP2018183146A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090239926A1 (en) * | 2008-03-24 | 2009-09-24 | Schafer Peter H | Methods for the treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-carboxamide |
Non-Patent Citations (2)
Title |
---|
ANAND B S ET AL: "NOVEL DIPEPTIDE PRODRUGS OF ACYCLOVIR FOR OCULAR HERPES INFECTIONS: BIOREVERSION, ANTIVIRAL ACTIVITY AND TRANSPORT ACROSS RABBIT CORNEA", CURRENT EYE RESEARCH, IRL PRESS, OXFORD, GB, vol. 26, no. 3-04, 1 March 2003 (2003-03-01), pages 151 - 163, XP009036464, ISSN: 0271-3683, DOI: 10.1076/CEYR.26.3.151.14893 * |
DE MEIJERE ARMIN: "BONDING PROPERTIES OF CYCLOPROPANE AND THEIR CHEMICAL CONSEQUENCES.", ANGEWANDTE CHEMIE - INTERNATIONAL EDITION IN ENGLISH 1979 NOV, vol. 18, no. 11, November 1979 (1979-11-01), pages 809 - 826 * |
Also Published As
Publication number | Publication date |
---|---|
MX2012013803A (en) | 2012-12-17 |
JP2018183146A (en) | 2018-11-22 |
IL222844A0 (en) | 2012-12-31 |
MX341896B (en) | 2016-09-07 |
EP2583098A1 (en) | 2013-04-24 |
US20110318741A1 (en) | 2011-12-29 |
JP2013531499A (en) | 2013-08-08 |
BR112012032217A2 (en) | 2016-10-25 |
KR101913868B1 (en) | 2018-12-28 |
CN103026229B (en) | 2016-03-30 |
JP2016185151A (en) | 2016-10-27 |
CA2798742A1 (en) | 2011-12-22 |
AU2011268450B2 (en) | 2015-07-16 |
NZ603375A (en) | 2014-10-31 |
KR20130085953A (en) | 2013-07-30 |
ES2692152T3 (en) | 2018-11-30 |
CN103026229A (en) | 2013-04-03 |
WO2011159750A1 (en) | 2011-12-22 |
IL222844A (en) | 2016-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2583098B1 (en) | Biomarkers for the treatment of psoriasis | |
AU2011268450A1 (en) | Biomarkers for the treatment of psoriasis | |
Stannard et al. | Lupus skin is primed for IL-6 inflammatory responses through a keratinocyte-mediated autocrine type I interferon loop | |
Koczan et al. | Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules | |
Garcia–Rodriguez et al. | Increased gene expression of Toll‐like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis | |
US20160153998A1 (en) | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma | |
Hügle et al. | Tumor necrosis factor–costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts | |
Li et al. | CXCL16 upregulates RANKL expression in rheumatoid arthritis synovial fibroblasts through the JAK2/STAT3 and p38/MAPK signaling pathway | |
JP2011509676A (en) | Selective differentiation, identification and regulation of human Th17 cells | |
Cai et al. | BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti‐PD‐1/PD‐L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity | |
CA2871535A1 (en) | Biomarkers for the treatment of hepatocellular carcinoma | |
Blokland et al. | Decreased circulating CXCR3+ CCR9+ T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren’s syndrome to facilitate their concerted migration | |
Shah et al. | Behind the scenes with basophils: an emerging therapeutic target | |
AU2021292323A1 (en) | IRAK degraders and uses thereof | |
Yuan | IL-33 in autoimmunity; possible therapeutic target | |
KR20220025115A (en) | Methods and compositions for modulating th-gm cell function | |
Laurent et al. | Interleukin‐1β–Activated Microvascular Endothelial Cells Promote DC‐SIGN–Positive Alternatively Activated Macrophages as a Mechanism of Skin Fibrosis in Systemic Sclerosis | |
Ide et al. | Angiotensin II increases expression of IP-10 and the renin-angiotensin system in endothelial cells | |
Kaur et al. | Interleukin‐18, IL‐18 binding protein and IL‐18 receptor expression in asthma: a hypothesis showing IL‐18 promotes epithelial cell differentiation | |
Weber et al. | NLRP3 inhibition leads to impaired mucosal fibroblast function in patients with inflammatory bowel diseases | |
Winkler et al. | The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial | |
JP2014517915A (en) | Biomarkers for the treatment of multiple myeloma | |
US20230003719A1 (en) | Materials and methods for inflammatory molecular markers | |
Siegel | The Role of Extracellular Sulfatase-2 in the Pathogenesis of Rheumatoid Arthritis | |
Sigurðardóttir | Studies of the Systemic Inflammation in Psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130920 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1184536 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180220 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LIN, YONG Inventor name: SUTHERLAND, DONNA Inventor name: SCHAFER, PETER, H. |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1027603 Country of ref document: AT Kind code of ref document: T Effective date: 20180815 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011050806 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2692152 Country of ref document: ES Kind code of ref document: T3 Effective date: 20181130 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1027603 Country of ref document: AT Kind code of ref document: T Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181108 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181109 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181208 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181108 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011050806 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20190509 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602011050806 Country of ref document: DE Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KIRKER AND CIE S.A., CH Ref country code: CH Ref legal event code: PUE Owner name: AMGEN (EUROPE) GMBH, CH Free format text: FORMER OWNER: CELGENE CORPORATION, US |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602011050806 Country of ref document: DE Representative=s name: MUELLER-BORE & PARTNER PATENTANWAELTE PARTG MB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602011050806 Country of ref document: DE Owner name: AMGEN (EUROPE) GMBH, CH Free format text: FORMER OWNER: CELGENE CORPORATION, SUMMIT, N.J., US |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190630 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181208 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: AMGEN (EUROPE) GMBH Effective date: 20200716 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20200806 AND 20200812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180808 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230529 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230703 Year of fee payment: 13 Ref country code: CH Payment date: 20230702 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240521 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240521 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20240522 Year of fee payment: 14 Ref country code: FR Payment date: 20240522 Year of fee payment: 14 |